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ABSTRACT 
 
Purpose: A prolonged time to diagnosis (TTD) for cancer patients has been 
highlighted as a factor potentially contributing to worse outcomes. The 
majority of early diagnosis research in childhood and young adult (CYA) 
cancer has focused on primary care. This population-based study aimed to 
investigate TTD in secondary care services for CYAs diagnosed with cancer 
and its effect on survival in Yorkshire, UK.   
Method: 1098 cases of cancer aged between 0-24 years were identified 
from the Yorkshire Specialist Registry of Cancer in Children and Young 
People over a 6 year period. ICD-10 codes contained within the in-patient 
HES episodes were reviewed against accepted UK CYA cancer awareness 
campaigns in order to identify alert signs and symptoms preceding the date 
of definitive diagnosis. The cohort was analysed in terms of the time spent in 
hospital care, number of alert and non-alert code containing events and 1 
and 3-year survival, the latter modelled using Cox regression. 
Results: 457 (41.6%) cases had no identifiable alert code containing 
episodes preceding their date of diagnosis. In two thirds of the remaining 
cases (437/641) the alert codes only occurred within the month preceding 
diagnosis. Cases with alert codes present within the month prior to diagnosis 
had a significantly poorer survival compared to patients with no alert code 
containing episodes (hazard ratio=1.67, p=0.003). For cases with a more 
prolonged TTD, there was a significantly poorer survival for 15-24 year olds 
(hazard ratio = 2.48, p=0.001) but not for 0-14 year olds (hazard ratio=0.98, 
p=0.964). 
Conclusions: In Yorkshire, secondary care services appear to be organised 
effectively to deal with timely diagnosis of CYA cancers. This research 
supports the current focus of early diagnosis research at primary care for 
childhood cancer but indicates the need for further investigation of TTD in 
secondary care particularly in the TYA population. 
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Chapter 1 Introduction 
1.1 Motivation 
1.1.1 Why childhood and young adult cancer? 
Although cancer is a rare occurrence in children and young adults (CYA), it 
has profound implications for patients and the people close to them. The 
diagnosis of cancer is devastating at any age, however life years lost in 
those who die and the disability experienced due to the disease and its 
treatment by those who survive is of particular concern in the CYA 
population.  
The incidence of CYA cancers in the UK is increasing and so is the number 
and proportion surviving their cancer (1). Survival rates for cancer in CYA 
vary by diagnosis, age and between countries (2, 3). The improvements in 
the survival rates for teenagers and young adults have been more modest 
than those seen in younger children (2, 4). Advances in cancer treatments, 
improvements in supportive care, increased awareness of CYA cancers, 
advances in diagnostic investigations, centralisation of cancer specific 
services and the recruitment of more patients into national and international 
trials are all potentially contributing to improving survival.  
Despite the reduction in mortality in the UK, survival in CYA patients treated 
in England lags behind our European counterparts (5, 6). This worrying 
observation was highlighted in the EUROCARE-4 study published in 2009, a 
study that analysed survival and survival time trends in young Europeans 
covering 83 cancer registries in 23 countries from 1995-2002 (5). The 5-year 
survival for CYA in England was below the European average for both age 
groups (5). 
CYA cancers need special consideration for a number of reasons: they are 
the leading cause of natural death within the CYA age-range (7), and the 
pattern of increasing incidence and falling mortality is leading to an ever 
increasing cohort of survivors (4). In 2011 it was estimated that there were 
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40,000 survivors of childhood cancer alive in the UK of whom 60% would 
experience at least one adverse late effect of their treatment as well as 
being at an increased risk of a second malignancy (8). Those providing care 
for CYA cancer patients must aim to continue to improve survival while 
reducing the burden of the treatment. It has been suggested that reducing 
the time to diagnosis (TTD) for cancer in CYA in the UK is one way of 
reducing the burden of disease and treatment and improving survival and 
survivorship.  
 
1.1.2 Why early diagnosis of cancer?  
The NHS Cancer Plan (2000) gave cancer a high priority within the NHS (9). 
The aim was to reduce death rates, improve prospects for survival and 
quality of life through improvements in early detection and effective 
screening and address healthcare inequalities (9). The Cancer Reform 
Strategy (2007) built on this and set out a five year plan, which identified 
earlier diagnosis of cancer as a key area for improving cancer care within 
the UK (6). In 2005 the National Institute for Health and Clinical Excellence 
(NICE) published updated guidance that specifically aimed to improve 
clinical outcomes and the experience of cancer for CYA and their families 
(10). The Yorkshire and Humber Children and Young People‟s Cancer 
Network (YHCYPCN) emerged from the recommendations made within the 
2005 NICE guidance, and through work with the National Cancer Action 
Team (NCAT), has implemented the cancer strategy reforms to provide the 
best care for young cancer users in the region. 
NICE published referral guidance for suspected cancer for GPs in 2005 
containing a childhood cancer section (see Appendix 1). The pre-diagnostic 
period has been further highlighted in the recent Department of Health (DH) 
Improving Outcomes: A Strategy for Cancer 2011 (11). Charities, non-NHS 
and non-government organisations are also working to improve the TTD for 
CYA. For example, the Headsmart campaign launched in 2011 aims to 
improve patient and professional awareness of CYA brain tumours. 
Headsmart is a partnership between the Children‟s Brain Tumour Research 
Centre in Nottingham, Royal College of Paediatrics and Child Health and 
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Brain Tumour Research (previously the Samantha Dickson Brain Tumour 
Trust) (12).   
Since 2009 research into early diagnosis in the UK has been coordinated 
and supported by the National Awareness and Early Diagnosis Initiative 
(NAEDI), which primarily focuses on adult cancers in the primary care 
setting. To date the majority of guidance and research on early diagnosis 
has been primarily focused on patient awareness, improving access to 
primary care and referral pathways. This project will therefore provide a 
novel approach to an under-researched area of healthcare in which the 
importance of early diagnosis is poorly understood. 
 
1.1.3 Why secondary care and childhood and young adult 
cancer? 
Healthcare within the UK is based around a hierarchical structure consisting 
of primary, secondary, tertiary and quaternary levels of healthcare. The initial 
point of healthcare engagement can vary across the age spectrum, but is 
predominantly focused at the primary healthcare setting with primary care 
physicians often referred to as having a “gate-keeper” role. However, 
focusing on childhood healthcare engagement reveals an increased 
involvement of emergency care and outpatient care situated in the 
secondary care environment. This point was highlighted in an article by Gill 
et al published in 2013, who showed a year-on-year increase in emergency 
admission rates in under 15s between 2003 to 2010 in a population based 
study of Hospital Episodes Statistics (HES) data (13). This publication 
contained data on a number of common illnesses of childhood and did not 
include data specifically on cancer-related admissions. Nonetheless it 
demonstrates the important role secondary care services play at the point of 
contact for childhood illness.   
The prominence of emergency admission at diagnosis for cancer patients 
under 25 years of age is highlighted in the National Cancer Intelligence 
Network (NCIN) Routes to Diagnosis publication in 2010 (14, 15). This work 
used HES data linked to cancer registration information to map the routes to 
diagnosis for cancer across all ages within England in 2007 (14). The 
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authors identified 269 distinct routes of admission and highlighted that 
patients aged less than 25 are most likely to present within the routes 
defined as an emergency (15). This work mainly focused on adult cancers 
and didn‟t provide any insight into the specific challenges to diagnosis faced 
by CYA with cancer.  
In a similar manner to the NCIN routes to diagnosis work, the National Audit 
of Cancer Diagnosis in Primary Care 2011 provided an insight into current 
practice in primary care cancer diagnosis, which encompasses the entire 
cancer population (16). This work focused partly on those aged under 25: 
25% of cases diagnosed with cancer in the under 25s were referred on from 
primary care via the two week referral for suspected cancer pathway; 40% of 
males and 45% of females were referred on from primary care via 
emergency routes; 65-70% of cases had only 1 or 2 GP attendances prior to 
referral for suspected cancer (16).   
All this information gives an indication of the important role of secondary 
care services in the initial contact and diagnosis of cancer in those aged 
under 25 years. However, to date there is no body of work that focuses 
specifically on this area of healthcare in this age group. This thesis aims to 
provide a unique insight into the role of secondary care services in the 
diagnosis of cancer among those aged 0-24 years through the use of a 
population-based study which links registry to electronic health-records data.          
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1.2 Aims & Objectives 
1.2.1.1 Aims 
 Describe the pattern of variation of TTD for CYA within secondary 
care services in the Yorkshire and Humber region and highlight the 
major factors that influence TTD for this population.  
 Assess how variations in TTD within secondary care services affect 
the outcome for CYA patients and construct recommendations for 
healthcare providers to aid early diagnosis of CYA cancers.      
 
1.2.1.2 Objectives  
 
 To assess variations in the time interval from the point at which a 
case presents to secondary care with a sign or symptom that 
potentially identifies their cancer to the definitive diagnosis, using 
population based cancer registry data linked to HES data. 
 To examine whether correlation exists between the TTD and 
outcomes such as stage at diagnosis and survival. If correlation is 
found, the data will be analysed further to determine whether these 
effects are attributable to specific cancer subtypes, ages or other 
population characteristics. 
 Assess how reliable and accurate HES data are in the analysis of a 
patient‟s TTD and survival. 
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1.3 Outline of thesis 
The purpose of this project is to develop our understanding of the time spent 
in hospital preceding a diagnosis of cancer in CYA and to investigate how 
variations in this time period affect outcomes for CYA in Yorkshire. The 
current knowledge base will be explored and described through in-depth 
analysis of cancer registry data linked to HES data. This project will aim to 
provide new information and develop recommendations for secondary care 
services to aid early diagnosis of cancer in CYA in secondary care. 
Chapter 2 will provide background that further supports the motivation for 
this research as outlined in Chapter 1 as well as providing the reader with 
important information regarding the complex nature of cancer among 0-24 
year olds in the UK. The chapter will cover two main areas: the first 
introduces some of the main considerations for early diagnosis research; the 
second discusses major challenges for early diagnosis research in CYAs, 
highlighting the unique and complex nature of the disease that affects the 
TTD. 
Chapter 3 will review the latest literature on early diagnosis in CYA and will 
pull out key factors that influence TTD as well as highlighting what is known 
of the association between TTD and specific outcomes for CYA. This section 
will inform the development of the methodology for this study. 
Chapter 4 will provide an overview of the research methods, including 
information regarding the Yorkshire Specialist Registry of Cancer in Children 
and Young People (YSRCCYP), HES data and cross-validation with clinical 
notes. The chapter will outline common awareness campaigns and early 
diagnosis guidance for CYA cancer used to define alert symptoms and 
signs. The method of defining and flagging the alert episodes within the HES 
linked patient records and the subsequent survival analysis of patients with 
and without alert signs will be presented. A brief description of the process of 
validating the HES record with a small but representative sample of medical 
case notes will conclude this chapter. 
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Chapter 5 will present the results describing TTD within secondary care 
services for a population based cohort of CYA diagnosed with cancer 
between 2004 and 2009 in Yorkshire.  
Chapters 6 will discuss the findings and outline recommendations for 
secondary care services and early diagnosis research in CYA, with the aim 
of improving TTD. These sections will also discuss the unique perspective 
on TTD provided by this study into secondary care and outline future work. 
At the end of this chapter the conclusions will bring together the main points 
from the preceding chapters to give an overview of the project.  
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Chapter 2 Time to Diagnosis 
This chapter will provide the background that underpins and supports the 
work throughout this thesis. General considerations needed to construct a 
robust method for early diagnosis research are discussed in the initial 
section of this chapter; including the important time periods that contribute to 
the overall TTD for cancer. The second section discusses factors that 
influence the TTD in CYA cancers. The final section of this chapter will bring 
all the key issues raised together in a conclusive summary.  
  
2.1 Early diagnosis research 
Survival for cancer in the UK has been shown to be inferior to many of our 
European counterparts (5). A number of areas within UK cancer care have 
been highlighted as potentially contributing to poorer survival. The Cancer 
Reform Strategy highlighted the early diagnosis of cancer as a key area for 
improvement in the UK cancer care and subsequently the TTD has come 
under increasing scrutiny (6). The theory that prolonging the time spent prior 
to receiving the diagnosis of cancer results in more advanced disease at 
diagnosis and therefore a worse outcome has been widely accepted within 
UK healthcare research. Significance has been placed upon delays within 
the diagnostic process and how these may negatively impact on survival. 
National research initiatives, awareness campaigns and healthcare policy 
documents have set out plans to improve the TTD for cancer across the 
age-spectrum, some of which are specifically aimed at childhood and young 
adult cancer (12, 17).  
A field of research is developing that focuses on the time patients spend in 
the pre-diagnosis and treatment period of disease. Early diagnosis research 
focuses on the pre-diagnosis symptomatic period of the patient pathway, this 
period is complex and can be divided in a number of different ways 
depending on the focus of the research. In order for the methods applied in 
early diagnosis studies to be robust and reproducible it is important that 
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clear definitions for the time periods being studied are present at the outset 
of any early diagnosis research project. Figure 2.1 illustrates the time period 
from first symptom until start of treatment, indicating specific events that 
define the boundaries for various time intervals and potential variable routes 
to diagnosis (18). This section will discuss the time interval that make up the 
pre-diagnosis period up to and including the date of diagnosis. The focus of 
this study is the period of time spent in secondary care by CYA‟s with 
cancer, which is part of the diagnostic interval identified in Figure 2.1. The 
date of definitive diagnosis is taken as the end point for the period being 
studied and the point of entry into secondary care as the initiating time point 
for the interval being studied. The rationale for the focus of this study will be 
discussed further in Chapter 4 (Methods).  
 
Figure 2.1 Outline of milestones and time intervals in the route to 
diagnosis and treatment (Olesen, 2009) 
 
 
The majority of this research has, so far, lacked clear structure and the 
methodology and terminology applied along with the definitions for intervals 
being studied often vary widely as do the outcomes measured (19). This has 
resulted in debatable conclusions being drawn, especially regarding the 
association of a prolonged TTD of cancer with overall outcome. In response 
to the absence of a clear direction in early diagnosis research an 
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international consensus group published guidance for the early diagnosis 
researcher in 2012, under the title - “The Aarhus statement: improving 
design and reporting of studies on early cancer diagnosis” (19). The 
systematic review included within the Aarhus statement identified all studies 
of symptomatic cancer patients presenting to primary care, the group 
concluded: 
“There is little consistency in the definitions and measurement 
of key time points and intervals; 
 There is little guidance for researchers in designing 
studies that require the measurement of diagnostic 
time points and intervals;  
 Little work in this field explicitly uses a theoretical 
framework to underpin definitions and measurement of 
diagnostic intervals; 
 There is a lack of transparency and precision over the 
methods and instruments in early diagnosis 
research….”(19) 
The paper identifies Walters model of pathways to treatment as a clear 
theoretical framework that should underpin future early diagnosis research, 
see Figure 2.2 (20). They also discuss definitions of key time points and 
highlights the Olesen et al 2009 illustration of milestones and time intervals 
as a good guide to outline of terminology, see Figure 2.1 (18, 19). Defining 
the time-points that divide the intervals being studied is not straight forward. 
There may be a number of different time points that potentially define a 
particular event in the pathway to diagnosis. The exact timing of an event 
may also vary depending on the perspective from which it is being viewed, 
either patient or healthcare professional.   
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Figure 2.2 Model of pathways to treatment (Walter, 2012) 
 
The Aarhus statement was the first of its kind and is an indispensable tool 
for early diagnosis research, whilst the publication doesn‟t specifically deal 
with cancer in children and young adults the issues raised are common 
across all age groups. Due to the rare nature of cancer in children and 
young adults the difficulties faced by early diagnosis researchers within 
these age-groups are heightened. Walter‟s model presents the “Events”, 
“Intervals”, “Contributing factors” and “Processes” involved in a person 
receiving a diagnosis and subsequent treatment for cancer. It is important to 
recognise that the “Processes” don‟t run in a linear fashion, as suggested in 
Figure 2.1, at any point a “Contributing factor” can result in reappraisal and 
rescheduling of the whole process (20). This model applies to all types of 
cancer and across the spectrum of ages; as such it will be referred to 
throughout this thesis as the theoretical framework from which the study 
methods have developed. The literature review chapter will in part explore 
the extent to which such theoretical models have been applied in early 
diagnosis research in children and young people to date. 
 
2.1.1 Symptom recognition 
Figure 2.1 highlights the first symptom as the initiating event for the TTD and 
treatment. As a cancer develops there is a point in time where the person or 
carer realises a change in the function or feeling within their body, which 
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subsequently triggers concern and eventually manifests a desire to engage 
with a healthcare professional. This event and the subsequent trigger to 
contact a healthcare professional may take time, the length of which will be 
determined by such factors as a person‟s awareness of their own body, 
knowledge of health and desire to act upon their concerns. The first 
theoretical model dealing with the process a patient goes through to receive 
a diagnosis of cancer was developed by Safer et al 1979, this separates the 
time between symptom recognition and healthcare engagement into 3 
intervals (21). Anderson adapted Safer‟s model in 1995 and conceptualised 
a number of delay intervals punctuated by decision-making processes(22). 
The Anderson model of total patient delay was further refined by Walter in 
2012 to produce a model of pathways to treatment, Figure 2.2, this model is 
now widely accepted amongst early diagnosis researchers (20). 
A prospective study of the interval between symptom recognition and 
healthcare engagement would be ethically challenging. Therefore, 
identification of the point of first symptom recognition has to rely on patient 
recall, either at the point of data collection or as recorded by a healthcare 
professional in the medical records at the point of contact or diagnosis. How 
a patient recalls a symptom and what they confer to the health professional 
may be influenced by a number of factors, three groups of contributing 
factors are identified in Figure 2.2; patient factors, healthcare factors and 
disease factors. The factors that affect CYA‟s with cancer and the 
challenges faced by early diagnosis researchers will be discussed in later in 
this chapter and the present literature explored in more depth in Chapter 3. 
  
2.1.2 Healthcare engagement 
All patients require some degree of healthcare engagement prior to their 
cancer diagnosis. The route to diagnosis through the healthcare system will 
be influenced by the structure of the healthcare system, the initial point of 
contact and the patients attitudes towards healthcare. Defining the point of 
initial engagement can vary depending whether it is being viewed from the 
patient or healthcare professionals perspective. A professional may not view 
a symptom as indicative of cancer at the point of contact and therefore not 
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act to investigate or refer, an alternative view maybe taken by the patient 
when recalling the events leading to their diagnosis. It is therefore important 
that the early diagnosis researcher set out a clear definition for the time of 
initial healthcare engagement and Weller et al considers this as „the point at 
which, given the presenting signs, symptoms, history and other risk factors, 
it would be at least possible for the clinician seeing the patient to have 
started investigation or referral for possible important pathology, including 
cancer‟ (19).  Defining the point of healthcare engagement is also influenced 
by the collection method and data sources used by the early diagnosis 
researcher, for example, retrospective healthcare records review for the date 
of initial engagement will be influenced by the completeness of information 
at the point of recording and interpretation of the point a significant event 
occurs, such as presentation with a symptom potentially indicating cancer. 
The early diagnosis researcher should therefore identify criteria for defining 
the point of engagement taking into account the limitations of the data being 
used.  
It is also important to consider when and where a patient is referred for 
investigation or opinion as there may be several referrals made prior to the 
eventual successful diagnosis. The patterns of referral and complexity of the 
diagnostic route can influence the time spent prior to diagnosis and 
understanding how routes to diagnosis vary within a population is vital to the 
development of effective interventions for improving the TTD. Healthcare 
factors that influence the time taken to receive a diagnosis of cancer for 
CYA‟s in the UK will be discussed further within this chapter.    
   
2.1.3  Date of diagnosis 
The date of diagnosis of cancer is a key time point for this project, however 
there are several events that potentially identify this point, for examples: 
 The date the doctors tells the patient they have cancer. 
 The date a scan defines a mass likely to be cancer. 
 The date a biopsy is taken which confirms a cancer. 
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 The date the pathologist signs and communicates the report to the 
treating physician. 
In order for early diagnosis research to be robust and reproducible there 
must be a clear hierarchy of events accepted as defining the date of 
diagnosis. A hierarchy is important as the process of receiving the diagnosis 
of cancer can involve a number of steps and not all cancers are diagnosed 
using the same investigations. A point highlighted in the varied approaches 
to the diagnosis of central nervous system tumours, for many tumour types a 
biopsy is required and a histological diagnosis is made, however in cases of 
diffuse pontine glioma a radiological diagnosis is often made upon MRI scan 
findings and biopsies are rarely attempted due to the perceived dangers 
associated with surgery in the pons (23).  
Weller et al suggests the use of the European Network of Cancer Registries: 
Hierarchy for Defining the Date of Diagnosis (24), and this is outlined below: 
In the order of declining priority: 
1. Date of first histological or cytological confirmation of this 
malignancy (with the exception of histology or cytology at 
autopsy). This date should be, in the following order: 
(a) date when the specimen was taken (biopsy) 
(b) date of receipt by the pathologist 
(c) date of the pathology report 
2. Date of admission to the hospital because of this 
malignancy. 
3. When evaluated at an outpatient clinic only: date of first 
consultation at the outpatient clinic because of this 
malignancy. 
4. Date of diagnosis, other than 1, 2 or 3. 
5. Date of death, if no information is available other than the 
fact that the patient has died because of a malignancy. 
6. Date of death, if the malignancy is discovered at autopsy.  
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2.2 Challenges facing early diagnosis research in childhood 
and young adults with cancer 
CYA cancers are rare and only contributes 1% of new cancer cases in the 
UK each year, the incidence of cancer increases with age into adulthood, 
another reason for the predominant focus of early diagnosis research on 
adult cancers (25). The rare nature of cancer in childhood and young adults 
often leads to the grouping of these populations together into the 0 to 24 age 
boundary for research purposes, as seen in the NCIN routes to diagnosis 
work and the National Audit of Cancer Diagnosis in Primary Care (14, 16). 
Our American counterparts consider young adults as up to 30 years of age 
(26, 27). However the overall age-range for childhood and young adult 
cancers is generally agreed as 0 to 24 years inclusive in the UK and across 
Europe (28, 29).   
Within this complex population it is difficult to establish clear subdivisions 
within UK health services and health services research, this is most evident 
in the varied boundaries used to define the teenage and young adult 
population. The age boundaries used to define childhood and young adult 
populations often varies between population-based cancer registries 
depending on the country or individual researcher. The UK defines childhood 
cancer as occurring from birth up to the age of 14-years (inclusive) (3). 
Teenage and young adult cancer services include patients from 13 to 24 
years inclusive (25), however within population-based registries TYA age 
boundaries are also defined as 15 to 24 years inclusive (30). The divisions 
made between cancer care services for children, teenagers, young adults 
and older adults in the NHS are founded in the variations in disease profiles 
with age as well as the recognition of the spectrum of physical and 
psychological development that occurs across the 0-24 year‟s age range. 
Companionship of peers and age appropriate surroundings can have a 
profound influence on the overall experience of disease and treatment (25).  
The processes that define the onset of adulthood such as physical growth, 
maturation of personality and development of a sense of independence 
occur over variable periods in the lives of young people. All these factors will 
influence awareness of illness and healthcare engagement in CYA‟s and 
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potentially the TTD. For the purposes of health research the splitting of the 
CYA population by smaller age boundaries results in smaller populations for 
analysis and often reduces the researchers ability to conduct timely studies 
and may limit conclusions drawn. The issue of grouping or splitting the CYA 
cancer population for ease of analysis will be further highlighted throughout 
the subsequent sections of this chapter. 
 
2.2.1 Disease related factors 
The type of cancer has a fundamental influence on the time taken to receive 
a diagnosis; the primary site, the growth rate and the way a tumour spreads 
can influence. The population of cancers that affect CYA‟s are multiple and 
varied, they behave differently between and within diagnostic groups. The 
majority of tumours in children originate from embryological cell lines unlike 
the epithelial origins of carcinomatous cancers which predominate in adults 
(31). The cancers seen in teenagers and young adults are a mixture of those 
seen in childhood and adulthood, but they often have unique patterns of 
behaviour. This section will initially explore some of the variations in 
incidence and survival between CYA tumours, and will go on to discuss 
disease factors implicated within the literature as potentially influencing the 
TTD such as the form of the tumour, presenting symptoms, site of the 
tumour development, rates of growth, size of tumour and how these affect 
survival outcome.  
An established classification system should be applied in order to describe 
cancers across a population. A number of international classification 
systems for cancer have been developed to allow international comparison 
of incidence and survival (32). The main focus of any classification system 
should reflect the predominant nature of the disease within the study 
population. It should represent the numerically important groups as well as 
rarer population specific tumours (33).  
The International Classification of Childhood Cancers (ICCC) is an 
adaptation of the International Classification of Diseases for Oncology and is 
designed to allow comparison of cancer in the paediatric population. ICCC is 
in its 3rd edition, published in 2005 and classifies cancer primarily by 
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morphology. This type of classification is most appropriate in the childhood 
population due to the often disseminated nature of these cancers‟ at 
presentation (33). The ICCC-3 system has a hierarchical structure based 
around 3 levels:  
 12 broad diagnostic groups  
 47 diagnostic sub-groups   
 Optional “Extended Classification” which comprises 2-11 divisions for 
selected diagnostic subgroups 
Within the teenage and young adult population the occurrence of both adult 
and childhood cancer‟s alongside unique tumour types has lead to the 
production of a specific classification system; the Birch et al system. This is 
similar to the ICCC system in that it is primarily based on morphology but is 
designed to reflect the predominant cancers of teenagers and young adults 
(34). Within this project a number of different classification systems are 
encountered. However, to ensure consistency throughout this project the 
ICCC system will be applied within the 0-24 year age range. 
It is important that early diagnosis researchers understand variations in 
cancer incidence rates and survival for a study population, in order for them 
to identify the predominant and significant population within the study cohort.   
The most reliable and up to date incidence figures for CYA cancers are 
commonly presented for two subpopulations; childhood cancers and 
teenage and young adult cancers. The next paragraphs will explore the 
variations in incidence of childhood cancer and then variations in teenage 
and young adult cancers by diagnosis. 
The average number of new cases of cancer in children from 2005 to 2007 
within the UK was 1490 per year, accounting for around 0.5% of all new 
cases of cancer each year across all ages (3). For all childhood cancers 
leukaemia‟s constitute around 30%, CNS tumours 25%, lymphoma 10%, 
soft-tissue sarcoma, sympathetic nervous system tumours and renal 
tumours between 6-7% each, carcinoma, germ cell tumours and 
retinoblastoma 3% each, hepatic and other or unspecified tumours around 
1% each (3). The UK has a below average incidence rate compared to the 
rest of Europe, 134 versus 141 age-standardised incidence rates (per 
- 18 - 
 
 
million) (35). There is a general trend to an increasing incidence of childhood 
cancer in recent years that can only partly be attributed to changes in 
diagnosis and registration of cancer in childhood. Other factors considered 
as contributing to this increasing incidence include life-style choices or 
changes in exposure to carcinogenic agents both to the child and the 
parents (35).  
Cancer in the 15 to 24 year age-range accounts for around 0.5% of all new 
cancers each year in the UK. The distribution of cancers within teenage and 
young adults in the UK is different to that in children. Nonetheless, the 
increasing incidence of cancer in children in recent decades is mirrored in 
the older population. Leukaemia contributes to a lesser extent in 15-24 year 
olds and there is a higher proportion of lymphoma, germ-cell tumours, 
carcinoma and bone sarcoma (36). CNS tumours are still common but 
contribute a smaller proportion of overall cases of cancer compared to the 
childhood population, neuroblastoma, retinoblastoma and renal tumours are 
very rare in the 15 to 24 year age group (4, 36, 37).   
The outcome for a population with cancer is an important consideration for 
the early diagnosis researcher, not only when comparing results but also for 
targeting of effective interventions. Survival is the most commonly 
investigated outcome in cancer research as discussed in the Methods 
(Chapter 4). The next two paragraphs will consider survival for CYA cancers.  
The five-year survival rates for all childhood cancers have increased over 
the last 40 years from under 30% in the late 1960‟s to under 80% by 2005 
(3). Survival rates are not equal across all types of childhood cancer (3, 5) 
Retinoblastoma has almost 100% survival at five-years, such favourable 
survival has been related to a number of factors, some of which are listed: 
 Screening of new-borns and infants identified at high-risk of 
retinoblastoma due to the high proportion of heritable disease with 
known autosomal dominant inheritance pattern.  
 Neonatal screening for sporadic cases.  
 Improved treatment in specialist retinoblastoma centres within the UK.  
Acute Lymphoblastic Leukaemia is the most common cancer in childhood 
and the survival rate in the UK is around 88%, this has improved greatly over 
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the last 40 years, the success relates to identification of effective anti-
neoplastic agents and progressive refinement of treatment protocols through 
ongoing clinical trials. The most recent trial, UKALL2011, has focused on 
reducing the burden of treatment whilst maintaining survival through risk 
stratification and modifications of therapeutic regimes. The success of ALL 
has not been realised in all childhood tumour types; osteosarcoma has seen 
little improvement in five-year survival since the early 1980‟s and survival 
rates in the UK remain static in children at <55% (38). Survival figures for 
CNS tumours (ICCC group 3) have improved from 40% five-year survival in 
the late 1960‟s to 70% by 2005, however there are gaps in survival within 
the population of CNS tumours (39). For some tumours the outcome 
remains dismal, for instance in cases of diffuse intrinsic pontine glioma more 
than 90% of children will not survive beyond two years post diagnosis (23). 
Alternatively the five-year survival for astrocytoma in childhood is around 
80% (3). Shifting patterns in survival are not confined to inter-diagnosis 
variation, survival rates can vary within a specific diagnostic group, for 
example, neuroblastoma has a highly favourable outcome if diagnosed 
below the age of 18 months compared to all other ages (40). This pattern of 
variable survival with age is seen in Wilms‟ tumours where five-year survival 
in one to four year-olds is up to 86% compared to 70% five-year survival if 
diagnosed between 10-14 years (41).  
The improving trends in survival over time seen in childhood cancer are 
reflected to a lesser degree in teenagers and young adults. In the England 
five-year overall survival between 1979-1984 stood at 63% this rose to 74% 
between 1996-2001(29). Survival patterns vary within this population, the 
younger end of this age range have better survival rates for Leukaemia and 
CNS, whereas older patients with GCTs‟ fare better (29, 30). Unfortunately 
survival has remained relatively static for certain tumour types such as high-
grade glioma, bone sarcoma or soft-tissue sarcoma (29). As with most 
paediatric cancers females do better than males, the exception being germ 
cell tumours.  
The age boundaries used to define the teenage and young adult cancer 
within health research are not as well defined as those for childhood cancer. 
The publications by Birch and Alston on survival and incidence of cancer in 
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teenagers and young adults in England published in 2008 defined the age 
boundaries for the population as 13-24 years inclusive (29, 36). Croucher 
published a paper on trends in incidence and survival in teenagers and 
young adults in the south-east of England using different age boundaries 15-
24 inclusive (30). Arora published a paper looking at contrasting incidence 
rates for cancer in young people across England and India and identified the 
study age boundaries at 15 to 29, Birch and Alston were also authors on this 
paper (42). There are differing age groups within the boundaries set by 
these authors. Birch and Alston define three sub-groups (13-16, 17-20, 21-
24) (29, 36) compared to two groups in Croucher (15-19, 20-24) (30). The 
narrow age-ranges used by Birch and Alston in the 2008 paper allow clear 
representation of changing patterns in incidence and survival by diagnosis 
and sexes across the teenage and young adult population. However, the 
five-year population boundaries used by Croucher reflect the predominant 
divisions used across childhood, teenage and young adult research. The use 
of five year age bands has been advocated in a recent publication from the 
child and young people‟s health outcomes forum in response to the 
challenges set out in „Getting it right for children and young people‟ 
published in 2010 (43). The independent forum indicates the use of five year 
bands will improve local, national and international of data on incidence and 
outcomes of general health in children and young people (44). Within this 
publication they also recommend several outcome indicators for child health, 
one of which is “time from NHS presentation to diagnosis or start of 
treatment” (44).   
The previously highlighted variations in incidence and survival allude to the 
heterogeneity of this population of tumours. Figure 2.2 identifies several 
disease related factors that may influence the TTD. This section will discuss 
some disease related factors that have been implicated within the literature 
as potentially influencing the TTD for CYA cancers, these include:  
 The form of the tumour 
 The presenting symptoms 
 The site tumour development 
 The growth rate of a tumour 
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 The size of the tumour  
CYA cancers can be described by their form, as either solid tumours, such 
as renal or CNS tumours or alternatively as liquid cancers such as 
leukaemia. The form of the tumour can influence the presentation of the 
tumour and the TTD. The most common liquid tumour seen in CYA‟s in the 
UK is acute lymphoblastic leukaemia (ALL), this is a neoplasm of 
lymphoblasts that occurs following dysregulation of normal haemopoetic 
stem cells (45). ALL presents most frequently with disseminated disease 
including signs of bone marrow infiltration often manifesting as clinical signs 
of anaemia, thrombocytopenia or neutropenia (45). There are multiple 
organs that can manifest signs of ALL, for instance the central nervous 
system, testicles, mediastinum, bones, joints and eyes, but no primary site of 
disease. ALL can therefore present in a variety of guises, mimicking a 
number of more common presentations such as infections or inflammatory 
disease and may not necessarily be the primary differential diagnosis. There 
are no clear staging criteria for ALL as patients present with widespread 
disease. Therefore a risk stratification system for the disease has developed 
based upon other factors such as age at diagnosis, cytogenetics and white 
cell count at presentation. 
In contrast to ALL, Nephroblastoma is a solid tumour also known as Wilms‟ 
Tumour and is the predominant renal tumour in childhood, it accounts for 6-
8% of all childhood malignancies and less that 1% of TYA malignancies (46). 
Wilms‟ tumour commonly presents with a painless mass in the abdomen that 
may be found incidentally on abdominal examination or brought to a 
healthcare professional‟s attention due to increasing abdominal distension. 
Haematuria, pain, weight loss, persistent urinary tract infections and 
constipation can all be the presenting symptom in this tumour as well as 
other more unusual complaints such as hypertension, coagulopathy due to 
acquired von Wilebrands disease or as an emergency presentation with an 
intra-abdominal haemorrhage (45). Only around 10% of patients have 
metastatic disease at presentation and the lungs are the most common site 
of metastatic spread (45). Overall survival is high, reaching 80-90% five-year 
survival (41). Survival for Wilms‟ tumours varies widely by the extent of the 
disease which is defined by the stage at diagnosis; stage IV, metastatic 
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disease at presentation is associated with a poor survival just above 50% 
(31). Earlier diagnosis in Wilms‟ tumours before stage IV disease has 
developed would theoretically improve the outcome. 
The site of tumour development in solid tumours can influence the TTD. 
Certain tumour sites in the body such as the abdomen may predispose to a 
more insidious onset of disease meaning more extensive disease at 
presentation, as discussed in Wilms‟ tumour above. Neuroblastoma also 
primarily presents in the abdomen, 60% of cases have a primary tumour in 
the abdomen with 30 to 50% located in the adrenal gland, other common 
places are the pelvis and cervical region (45). This is the most common solid 
tumour of infancy and the second most common extra-cranial malignant 
tumour of childhood with the peak incidence at 18-23 months, 80% of 
neuroblastoma cases occurs below the age of four years-old (31). 
Approximately 50% of patients will present with metastatic disease, the 
common sites are liver, lymph nodes, bone, bone marrow and skin (31, 33). 
Stage of disease at diagnosis is a factor that contributes significantly to the 
risk stratification of this neuroblastoma with higher stage disease indicating 
higher risk of a poor outcome, however other factors such as age and 
cytogenetic markers also influence risk stratification. Within the UK evidence 
has suggested neuroblastoma is generally diagnosed at a later stage than 
Germany and France and the UK appears to have a worse outcome (47). 
From this evidence it has been suggested that reducing the TTD and 
diagnosing the disease at an early stage could impact on outcome (47). 
Nationwide mass screening programmes of infants for neuroblastoma were 
introduced in Japan in 1985, this was done by measuring urine 
catecholamines at 6 months of age (48, 49). The programme identified 
tumours with mostly favourable biological markers, however in the few 
tumours with less favourable biology there appeared to be a benefit from an 
early diagnosis (48, 49). Trials have also been conducted in Austria, 
Germany and Canada, which all identified an increase in the incidence of 
tumours but no impact on overall survival (50-52). This finding is felt to be 
due to the identification of asymptomatic tumours that naturally regress (51, 
52). However, in light of the failed screening programmes and significant 
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influence of tumour biology in the risk stratification of  neuroblastoma the link 
between TTD and outcome remains unclear.  
In rhabdomyosarcoma (RMS) the primary site of disease has a major 
influence on how the disease presents. This is the most common soft-tissue 
sarcoma of childhood, this solid tumour accounts for around 60% of STS in 
the 0-14 year age range, the median age is five years with a peak incidence 
of two years of age (53). RMS can present in a number of anatomical sites, 
with head and neck RMS making up 40% of childhood RMS followed by 
25% genitourinary, 20% in the extremities, 10% trunk walls and 10% other 
sites. The outcome for a patient with RMS is influenced by a number of 
factors, including; the site of primary disease, as well as age at diagnosis, 
size of primary tumour, extent of disease at diagnosis, histological sub-type 
and prediction of treatment sequalae. The site of the disease will alter the 
symptoms with which it presents, certain symptoms may cause more alarm, 
prompting the patient to seek help quickly and triggering rapid investigation 
and referral by healthcare professionals. 
The rate a tumour progresses varies between and within diagnostic groups. 
Variations in the rate of tumour progression can be examined across the 
lymphoma population. The doubling time of a tumour indicates the time 
taken for a group of cells to double in size and indicates the speed of 
proliferation. The clinical behaviour of lymphomas varies widely and there 
are multiple discrete entities within this broad diagnostic group, the doubling 
time has been reported for a number of types of lymphoma affecting all 
ages: Burkitt‟s lymphoma predominantly seen in children and young adults 
has a very short doubling time, 24 to 48 hours, compared to follicular 
lymphoma, nearly always seen in older adults, which can have a doubling 
time of up to 1 year (54, 55). The speed at which the clinical features of 
lymphoma progress can indicate the specific diagnosis. It is generally 
accepted within CYA lymphoma‟s that Non Hodgkin‟s lymphoma has a more 
rapid progression and presentation than Hodgkin‟s lymphoma (45).  Morley-
Jacob published an update on lymphoma in children and young adults in 
2011 and highlighted early referral of suspected cases for biopsy as a key 
learning point, presumably with the aim of improving stage at diagnosis and 
reducing treatment burden(56). Theoretically improving the TTD within the 
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lymphoma population has the potential to impact on disease and treatment 
related morbidity rather than improving overall high rates of survival. 
The rate of tumour development can indicated the aggressiveness of a 
tumour. Within CNS tumour group the highly varied biological behaviour has 
necessitated the assignment of a “malignancy scale” to accompany the 
morphological diagnosis. This scale predicts the biological behaviour of the 
tumour, giving an indication of how aggressive a tumour is and how rapidly it 
will progress, which in turn influences the choice of treatment (57). The 
WHO grading system is applied internationally and are four grades applied 
within this system; grade one reflects lesions with a low proliferation index 
with most tumours amenable to surgical resection and more favourable cure 
rates, with the exception of some brainstem and optic pathways tumours; 
grade two tumours have a more infiltrative nature and a greater tendency to 
recur and progress to a higher malignant grade; grade three tumours have 
histological evidence of malignancy and require adjuvant radiotherapy 
and/or chemotherapy to give the best chance of cure; grade four tumours 
are highly malignant, rapidly progressing tumours that are generally 
associated with less favourable outcomes (57). The grading of tumour is 
important and guides treatment, prognosis and late-effects of treatment. 
CNS tumours are the second most common tumour of childhood accounting 
for around 25% of tumours in this age group, their incidence reduces in 
teenagers and young adults to a nadir between 15-20 years of age, overall 
CNS tumours account for 9% of tumours in teenagers and young adults (4, 
58). These tumours are the leading cause of cancer related deaths under 
the age of 25, and for those who survive around 60% will have a significant 
neurocognitive deficit.  
Astrocytoma is the predominant CNS tumour across the CYA population, 
these tumours fall within the histopathological diagnosis of glioma tumours 
which arise from glial cells (59). Astrocytomas account for around 40% of 
childhood CNS tumours and a higher proportion of CNS tumours in the 15-
24 years age group (3, 4). The morphological diagnosis of astrocytoma, 
ICCC diagnostic sub-group IIIb, identifies a group of tumours with highly 
varied patterns of behaviour that range from pilocytic astrocytomas that are 
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benign in nature with excellent survival rates to anaplastic astrocytomas an 
aggressive neoplasm with a poor outcome. 
Low-grade gliomas generally have a very good prognosis, 95% five-years 
overall survival and comparatively low treatment burden compared to high 
grade gliomas, with most successfully treated by surgery alone. High-grade 
gliomas are highly malignant aggressive tumours that are defined by site 
and histological phenotype they usually occur between the ages of 5 to 10 
years-old in otherwise healthy children (60). Important predictors of outcome 
in high-grade glioma are the degree of surgical clearance, the use of 
radiotherapy to the resected tumour bed and more recently the addition of 
high-dose chemotherapy have led to improvements in survival for high-grade 
tumours (61). Despite these precautions the often highly aggressive and 
invasive treatment required in brain tumours results in significant 
neurocognitive deficits and disability in long-term survivors (62).  
The size of the tumour at presentation is an important prognostic factor for 
certain bone sarcomas and soft-tissue sarcomas, a point previously 
discussed in relation to rhabdomyosarcoma. Malignant bone tumours 
account for around 4% of childhood cancers and 7-8% of teenage and 
young adult cancers in the UK (1, 3, 38). Osteosarcoma accounts for 50% of 
bone sarcomas in the CYA populations, Ewing‟s sarcomas account for 40% 
of bone sarcomas in childhood and 30% of bone sarcomas in teenagers and 
young adults. The survival from bone sarcoma is poor compared to most 
other tumours within this population; they are the fourth most common 
tumour of teenagers and young adult but the second leading cause of 
mortality. Five-year survival for osteosarcoma is similar in childhood cancer 
(~55-60%) and young adult cancer (~50%), there is a wider survival gap 
seen in Ewing‟s sarcoma by age with children (~60%) having a more 
favourable outcome than young adults (~30 to 40%) (2, 38). In 
osteosarcoma a poor prognosis is associated with a large tumour volume, 
incomplete tumour resection, a poor response to chemotherapy, the 
presence of metastases at diagnosis, axial site of tumour, age over 40 years 
and higher grades of tumour (63). Factors associated with a poor outcome 
for Ewing‟s sarcoma are primary tumour volume greater than 200ml, age 
greater than 14 years, bone metastases, bone marrow involvement and lung 
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metastases, these factors have been combined to produce a scoring system 
for Ewing‟s sarcoma (64).  
The size of tumour at diagnosis is associated with a worse outcome in 
Ewing‟s sarcoma with a specific cut off of 200ml volume however such a 
threshold has not been established for osteosarcoma. In adult studies of 
bone sarcoma links have been shown between the time taken to receive a 
diagnosis and outcome for Ewing‟s sarcoma but not osteosarcoma, this may 
reflect the influence of variable tumour grade in osteosarcoma. The higher 
the grade of tumour the more aggressive the malignancy and the faster 
tumour growth, therefore rapid changes in size of mass will be noted by 
patients and highlighted to healthcare professionals. Due to the rarity of 
these tumours the numbers of patients available to study in the childhood 
and young adult cancer population are small.     
 
2.2.2 Patient related factors 
Walter identifies several patient factors that contribute to determine the TTD 
(Figure 2.2). The type of cancers affecting CYAs varies by the patient 
demographics such as the age and the sex. Across Europe the incidence of 
childhood cancer is highest in the 0-4 year age-range in both males and 
females, males have a higher incidence of cancer most notably in the 5-9 
age range (65). There are variations in incidence between the 15-19 and 20-
24 year age ranges with the latter having a higher incidence of cancer (30). 
Cancer incidence varies between the sexes and different incidence profiles 
are seen for cancers between males and females in the UK in the 15-24 
year-old group. Testicular cancer is the most common cancer type in the 
male group 15-24 making up 27% of the total cancers for this age group (1), 
however in females of the same age malignant melanoma and lymphomas 
both provide around 17% of the overall cancers for this age group (1). The 
approach to healthcare is different between the sexes, in a study by Fern et 
al of young people with potential cancer symptoms the females attended 
more frequently than males and older females attended more frequently than 
younger females (66).  
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The age and sex of a patient can also have an effect on healthcare 
engagement. The age of a patient has a significant influence their pre-
diagnosis experience, young children cannot access healthcare 
independently and rely on their parents or carers to recognise illness and act 
for them. Therefore the experiences and beliefs of the parents can dictate 
the time spent prior to diagnosis. TYAs face a number of potential hurdles 
when engaging with healthcare services; reduced parental surveillance 
combined with developing an understanding of their bodies and their health 
may result in a prolonged patient interval as they struggle to understand 
changes within their body that are manifestations of disease. This age group 
also face a number of major life events as they transition into adult life, 
including leaving home, starting higher education, getting a job or starting a 
family all of which can be stressful and impact on health and well-being.  
Where a person is born and lives may impact on the chance of developing 
cancer, the incidence of cancer varies across Europe with the highest rates 
in North Europe (67). The incidences rates for CYA cancer vary across the 
UK, most notably in teenage and young adult cancers where there appear to 
be a clear north south divide (28).  
 
2.2.3 Healthcare related factors 
The point of access and route taken through a healthcare system to reach a 
definitive diagnosis of cancer will depend on the availability, structure and 
delivery of healthcare within a country or region. As discussed in the 
introduction the routes to diagnosis for cancer in England has been studied 
at the primary care level (Primary care audit) (16) and throughout secondary 
care (NCIN routes to diagnosis) (14, 15). The NCIN routes to diagnosis 
document identifies 269 distinct routes to diagnosis for cancer and divided 
these into 8 groups of routes to diagnosis, these are listed below (14): 
 Screen detected 
 Two week wait – urgent GP referrals with suspected cancer 
 GP/outpatient – Routine or urgent referrals but not part of the two 
week wait referral route 
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 Other Outpatient 
 Inpatient Elective 
 Emergency presentations 
 Diagnosed on death certificate 
 Unknown 
Both the NCIN and Primary care documents suggest that the 0-24 year age 
group of patients diagnosed with cancer access healthcare in a different 
manner to the majority of their adult counterparts, with larger proportion 
accessing specialist care through emergency routes. These two documents 
provide an insight into the routes to diagnosis for 0 to 24 year olds with 
cancer but they do not focus on the specific challenges faced by this age 
group. There are suggestions in the literature that the referral pathways for 
CYA cancers may vary from adults, the role of the 2 week urgent referral 
pathway in childhood cancer has been questioned. Bragonier & Kenyon 
2012 published a retrospective review of 312 two week referrals, highlighting 
the extremely low pick up rate of the 2 week referral pathway in childhood 
cancer (68). The vast majority of cancers in this population being diagnosed 
via alternative referral routes (69). The profile of admissions within 
secondary care services will be explored within this study. Access to health 
care is influenced by geography across the globe and even within the UK 
there are variations in healthcare provision that impact on outcome for 
CYA‟s in the general and not just those with cancer (70). The socio-
economic status of a person can impact on their access to healthcare, even 
in the UK with a free to all at point of access healthcare system. The NCIN 
routes to cancer diagnosis publication in 2010 identified more affluent 
patients as less likely to present with cancer through an emergency 
admission (71). 
The diagnosis of cancer in CYAs is a rare event and the symptoms they 
present with are often common to other more prevalent diagnoses, for this 
reason many healthcare professionals don‟t consider cancer in young 
patients (72). This can result in a protracted and negative experience within 
the healthcare system prior to diagnosis.  
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2.3 Conclusions  
Based on the evidence presented within this chapter it is clear that there are 
many challenges facing all early diagnosis researchers, particularly in 
relation to CYA cancer. Low incidence rates of cancer within 0-24 year age 
range results in a limited sample for study. Highly variable patterns of 
incidence by age, sex and diagnosis coupled with variable focus points for 
cancer classification systems and different age boundaries for study 
populations act as impediments to clear comparisons between studies in 0 
to 24 year age group.  
The site, size, pattern of spread and speed of tumour proliferation can all 
influence the presentation and progression of the disease and therefore the 
TTD. Variations in behaviour of tumours between and within diagnostic 
groups makes intra-population comparisons difficult and leads to uncertainty 
regarding conclusions drawn in relation to the time taken to reach a definitive 
diagnosis across CYA cancer as a whole.  
Every advance in the fields of paediatric, teenage and young adult oncology 
results in a constant shift in the screening, diagnosis, treatments and follow-
up for cancer patients. The resultant changes in incidence and survival must 
be carefully interpreted by epidemiologists and health providers in order to 
inform future advances in the field.  
Early diagnosis research in any age group should be underpinned by a 
theoretical framework and accompanied by clear definitions of significant 
milestones that outline the study intervals being scrutinised. The Aarhus 
statement provides such guidance. The systematic review that makes up the 
next chapter will add to the information gathered relating to early diagnosis 
thus far and explore the literature relevant to TTD in CYA cancers, 
assessing the strengths and limitations of CYA early diagnosis research to 
date.  
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Chapter 3 Systematic Review 
3.1 Introduction 
Improving the early diagnosis of cancer in all ages has been identified as a 
key factor to address in cancer care within the NHS (6, 11). Delays to the 
diagnosis of cancer have been implicated as contributing to poorer survival 
outcomes for both adults and CYA with cancer in the UK compared to many 
of our European counterparts. This systematic review will identify early 
diagnosis research that focuses on delayed diagnosis and TTD for cancer in 
CYA populations across the globe. The quality of methods used and the 
terminology applied to the field of early diagnosis research in CYA will be 
explored. A particular focus will be placed upon the application of the term 
“delay”, a term that carries negative connotations and is synonymous with 
early diagnosis research to date. The review will seek to investigate how 
TTD varies within the CYA population, identify factors that contribute to a 
prolonged TTD and explore the association of TTD with outcome in CYA 
cancers. Finally pulling all this together to inform the development of a 
robust reproducible method for the study of TTD in secondary care services 
within Yorkshire. 
      
3.1.1 Early diagnosis research within the adult cancer population 
Chapter 2 identifies several reasons for the predominant focus on adult 
cancers in early diagnosis research to date, especially in the UK. It is 
therefore important to consider the findings of major adult systematic 
reviews. Improving TTD for adult cancer patients has been repeatedly 
highlighted as a key area for improvement of cancer care within the NHS (6, 
9, 11), however the impact of the time taken to achieve a diagnosis of 
cancer on patient outcomes is unclear (73).  
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Systematic reviews relating to delayed diagnosis in breast, upper gastro-
intestinal tract, and colorectal cancer have been identified (74-77). These 
look at the association between delayed diagnosis and outcome, the factors 
that influence pre-hospital delay and delayed presentation amongst a 
number of other aims (74-77). The systematic review by Richards et al 1999 
of the “…influence of delay on survival in breast cancer patients…” linked 
delays to diagnosis of 3-6 months with a lower survival in breast cancer 
patients (77). This review highlights the scope of adult early diagnosis to 
include large study populations, included are 87 studies published between 
1907 and 1996 involving over 101 945 patients(77). The extensive study 
population and the author‟s attempts to deal with bias in the construct of the 
review add validity to the conclusions. However the methodology didn‟t 
discuss what constitutes a “delay” to diagnosis, with this term relating to the 
entire time a patient spends prior to their diagnosis. In such studies the term 
“delay” carries negative connotations, inferring undue prolongation of the 
time prior to the receiving of a diagnosis of cancer.  
The results of these studies have been used by healthcare planners, 
government departments, cancer charities and those organisations involved 
in research planning as fuel to focus efforts on reducing delays in diagnosis 
within UK healthcare.  
 
3.1.2 Previous systematic reviews of delayed diagnosis in 
childhood and young adult cancer 
To date two reviews have focused on TTD for childhood and young adult 
cancer. In 2007 Dang-Tan et al published a review of 23 epidemiological 
papers, including study populations under the age of 30 (78). The authors 
identify the early diagnosis of CYA cancer as “…a fundamental goal of 
oncology..” citing the opportunity of timely treatment in early stage disease 
(78). This review provides an analysis of the factors associated with delay to 
diagnosis in childhood and young adult cancer grouping factors as patient, 
cancer or healthcare-related (78). The authors identify diagnostic delays as 
being longer than patient or parent delay. The main factors relating to delays 
in diagnosis are patient‟s age, parental education, presenting symptoms, 
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tumour site, stage at diagnosis and initial point of medical contact (78). The 
authors touch on the challenges of early diagnosis research, in particular 
they discuss the varied terminology applied within the field and outline a set 
of milestones within the cancer care pathway. Unfortunately they continue to 
use the term delay to refer to the entirety of the time-intervals being studied 
and the limitations in the methodology used within the reviewed studies are 
not explored (78).  
The second review published by Brasme et al in 2012 is more extensive and 
identified 98 papers relating to the “distribution, determinants and 
consequences” of TTD of paediatric cancers (79). Papers containing adults 
were included if at least 70% of the study population was paediatric. This 
review again provides an extensive analysis of the factors associated with 
delay, identifying and discussing some of the medico-legal issues 
surrounding delayed diagnosis in childhood cancers (79). The authors 
identify several factors associated with prolonged delays to diagnosis 
including older age, level of qualification of the medical professional at initial 
contact, the tumour site and histology and presentation with non-specific 
symptoms (79). They also conclude that delayed diagnosis is associated 
with a poor outcome in retinoblastoma and possibly leukaemia, 
nephroblastoma and rhabdomyosarcoma but no association was shown for 
CNS tumours, osteosarcoma and Ewings sarcoma (79).  
Caution must be taken in relation to the conclusions drawn from the Brasme 
paper. The statistical methods of weighted means of the median and mean 
TTD are of debatable efficacy, an issue that will be further explored later 
within this chapter. Brasme et al provide little insight into the intrinsic 
limitations of the applied methodologies within early diagnosis research in 
children and young adults, nor is there any proposed solution to the issue of 
how we interpret delay and TTD (79). 
There are also a number of systematic reviews focusing on the presentation 
of cancer in CYA, such as Wilne et al 2007 that draws together CYA 
literature to identify patterns in clinical presentation of CNS tumours in 
childhood (80). The systematic review by Wilne et al developed a guideline 
to assist in the identification and referral for childhood CNS tumours. 
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Subsequently this has evolved into the national campaign, known as 
HeadSmart, aimed at raising awareness of the symptoms and signs of brain 
tumours children and teenagers, in both patients, carers and health-
professionals (80). 
 
3.2 Methods and materials 
3.2.1 Data search 
A literature search from 1948 to May 2012 was undertaken, using a 
predefined search protocol in: Medline, EMBASE, EMBASE Classic, CRD 
databases, Cochrane Library, Medline in-Process & Other Non-Indexed 
Citations. Citations searches, reference lists and colleague 
recommendations were also reviewed. One reviewer (CL) screened each 
title and abstract for inclusion, and a second independent reviewer (MvL) 
checked a random sample of potential citations (20%). Concordance 
between reviewers was high, and differences of opinion resolved by 
discussion. 
 
3.2.1.1 Inclusion criteria 
Primary research studies published in English were considered if they: 
 Focused on children and young adults (0 to 30 years), the upper age 
limit was extended to 30 to include US studies involving young adults.  
 Quantified the time between onset of symptoms and definitive 
diagnosis of cancer for at least 15 cases.   
 Used diagnostic groups similar to the International Classification of 
Childhood Cancer (ICCC) (33).  
Papers were excluded if they focused only on melanoma, due to the 
inconsistency of classification and registration of skin cancers within this 
study population.  
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3.2.1.2 Quality assessment  
Methodological quality of the papers was assessed by the scoring systems 
outlined in Macdonald et al, 2006 (81) and against the Aarhus checklist (19).  
A scoring system for descriptive studies as used to assess general 
methodological quality due to the majority of the studies having a cross-
sectional retrospective design. This system assessed studies by: 
 The presence of a hypothesis or research question 
 Whether the source of the cases was identified  
 Whether inclusion/exclusion criteria were defined 
 Whether the sample size stated 
 Whether there was a discussion of bias 
 Whether the analytical method was described 
Each of the 6 criteria was scored on a present (1) or not present basis (0) 
basis, and an overall score out of 6 generated. Studies with robust well 
constructed methods have higher scores and poor quality methods score 
lower.  
As previously discussed in Chapter 2 the Aarhus statement published in 
2012 provided specific guidance for the early diagnosis researcher (19). This 
publication included a checklist to aid the design of consistent and 
transparent methods in early diagnosis research. This checklist consists of 
20 items; 7 relating to “definitions of time points and intervals”; 13 relate to 
“measurement” of which 3 address the context, relevance to definitions and 
acknowledgement of theoretical framework, 8 relate to questionnaires or 
interview and 2 to clinical notes review and databases (19). This scoring 
system was used to generate a score out of 20 to reflect the methodological 
quality of the studies specifically relating to early diagnosis.  
 
3.2.1.3 Data extraction 
Data extracted included: study type and period, published year, country, 
cancer type, explanatory factors, sample size and numbers excluded. 
Descriptive statistics extracted included: range, inter-quartile range, median, 
mean and standard deviation of TTD along with summary data for patient 
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and professional intervals.  We also recorded authors‟ defined study time 
period. 
 
3.2.1.4 Included studies 
Of the initial 1665 abstracts, 65 full text articles were assessed, and 32 
papers met the inclusion criteria and were reviewed. The studies varied; by 
country of publication, with papers predominantly published in Europe and 
North America; by diagnostic group, 11 papers studying multiple diagnostic 
groups, the rest focusing in on one single broad diagnostic group; and by 
age of study population though the majority focused upon children and 
young teenagers.  The studies included sample sizes ranging from 29 to 
2896, the median sample size was 139 cases and the mean 344, and these 
results highlight the predominantly small study populations. The limited 
number of large samples size studies may reflect the rare nature of CYA 
cancer and the limited availability of large regional or national CYA cancer 
registries across the globe. Table 3.1 outlines the summary information and 
data presented for each study. 
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Table 3.1 Summary data presented within the papers reviewed 
 
 
 
Author/Year/Country Cancer
Sample 
size
Age-Range 
(Years)
Median (days) Mean 
(days)
Standard 
Deviation
Range 
(Days)TTD PI DI
Brasme 2011 France Medulloblastoma 166 <15 65 3-457
Klitbo 2011 Denmark Brain Tumours 46 0-17 51 6 3 0-365
Shay 2011 Israel Brain Tumours 330 0-18 234 3-3283
Wilne 2011 UK Brain Tumours 139 <17 100 0-2520
Hayashi 2009 Japan Brain Tumours 54 0-15 20.5
Kukal 2009 Swiss Brain Tumours 315 0-16 60 14 14 0-3480
Reulecke 2008 Germany Brain Tumours 245 <20 24 59 0-795
Mehta 2002 Canada Brain Tumours 104 ≤17 91 222
Halperin 2001 US Medulloblastoma 122 0->17* 100 ±149.8
Edgeworth 1996 UK Brain Tumours 74 0-16 140 203.7 0-910
Bai 2011 China Retinoblastoma 572 0-14 61 125 ±179.4 3-1094
Wallach 2006 Swiss Retinoblastoma 139 Children* 114
Rodrigues 2004 Brazil Retinoblastoma 327 ≤12 91 176 200.6 3-1459
Wirix 2002 Belgium Retinoblastoma 33 0-7 97 61-365
Goddard 1999 UK Retinoblastoma 100 <9* 56 18 14 7-672
Chotel 2008 UK STS (Synovial) 35 3-16 686^ 2-2548
Ferrari 2010 Italy STS 575 ≤21 61 7-1824
Goyal 2004 UK Bone tumours 115 4-22 116 30-1398
Yang 2009 Hong Kong Osteosarcoma 51 3-20 61 30 21 4-361
Crawford 2007 US CNSGCT∞ 30 6-17 255
LaQuaglia 1992 US Adenocarcinoma 29 ≤21 61 12-547
Loh 2012 Singapore Multiple 390 0-18 37 21 8 1-1982
Cecen 2011 Turkey Multiple 329 0-19 53 3 28 0-2520
Stefan 2011 S.Africa Multiple 194 0-15 34 5 20 2-1826
Haimi 2010 Israel Multiple 315 0-20 49 7 28 110 188.9 0-1456
James 2010 Nigeria Multiple 64 1-14 92 14 62 169 196 15-1098
Dang-Tan 2008 Canada Multiple 2896 0-19 30 9 8 13-69ø
Martin 2007 US Multiple 235 15-29 75 24.4
Thulesius 2000 Sweden Multiple 64 0-16 63+ 35+ 21+ 1-1393+
Saha 1993 UK Multiple 184 0-15 28~
Pollock 1992 US Multiple 2665 0-29 (50)*1
Flores 1986 US Multiple 79 <20 (77)*2
 * Age ranges not clearly defined, however all refer to the study of children 
^Chotel – Paper reports mean PI as 301 days (0-1092) and mean DI as 350 days (0-2534)     TTD – Time to Diagnosis 
øDang-Tan – The interquartile range is represented       PI – Patient Interval 
∞CNSGCT – Central Nervous System Germ Cell Tumours       DI – Doctor Interval 
+Thulesius – Reported values for brain tumour patients, paper also reports Leukaemia TTD 21, PI 1, DI 0 
~Saha – Median TTD 28 days (7-364 days) for 101 males and 28 days (7-504 days) for 83 females 
*1Pollock – This is a combined mean from the mean for each cancer group, included to display paper in review results 
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3.2.1.5 Quality of studies, applied methods and summary statistics 
All included papers were observational studies and data collection was 
predominantly retrospective using patient interviews or case note/cancer 
registry review. The majority of studies were cross-sectional focusing on an 
institution or clinic, the others population-based retrospective cohort studies.  
Very few studies offered a clear hypothesis and most cross-sectional studies 
lacked clearly defined inclusion criteria and did not deal with bias in their 
construct (82-86). All papers scored moderate to low scores when applying 
the descriptive study assessment tool, and a similar outcome was seen 
when applying the Aarhus checklist (19). Only 1 study set out a clear set of 
milestones (87). The circumstances in which a delay to diagnosis became 
unacceptable were clearly defined by Shay et al 2011, if the patient 
encountered any of the 6 defined circumstances prior to diagnosis the delay 
was considered unacceptable (figure 3.4) (88).   
Summary statistics presented varied between studies, see Table 3.1. The 
median and range were often presented for TTD, patient-interval (PI) and 
the diagnostic-interval (DI) due to extreme outliers and positively skewed 
distributions. However, the inter-quartile ranges were rarely cited. 
Furthermore only 4 of 32 papers presented the mean, median, range and 
standard deviation in combination (89-92).  
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3.3 Results 
3.3.1 Time to diagnosis, patient interval and diagnostic interval 
Time between symptom recognition and definitive diagnosis were described 
as: TTD (78, 88, 93), delay to diagnosis (89, 94-96), pre-diagnostic interval 
(85, 97-99), lag-time (26, 27, 86, 90, 91, 100, 101) and duration of symptoms 
(84, 92, 102-105).  
“Patient-Interval” (PI) (19, 93) was used to describe the time between 
symptom onset and first clinical presentation.  Other terms used were: 
patient delay (78, 83, 90, 91, 95, 101, 102), symptom-interval and onset of 
symptoms to presentation (103).  
Diagnostic-Interval (DI) referred to the period from primary engagement with 
a healthcare professional to definitive diagnosis (also referred to as doctor, 
physician or healthcare delay) (78, 83, 90, 91, 95, 101, 102).  
Initial comparison of median PI, DI and TTD, taken from the 10 studies that 
included these summary statistics, would suggest that the median TTD is not 
accounted for by the cumulative value of the median PI and median DI, see 
Figure 3.1. Further inspection of the summary statistics reveals that this 
discrepancy is due to the variable skew in each of the distribution for TTD, PI 
and DI within a study. It is therefore inappropriate to draw conclusions 
relating to the contribution of PI or DI to TTD based on the descriptive data 
provided.  
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Figure 3.1 Comparison of the median time to diagnosis, median patient-
interval and median diagnostic interval by year of publication  
 
 
3.3.2 Time to diagnosis and disease related factors  
In Chapter 2 the challenges facing early diagnosis research in CYA‟s were 
explored and factors relating to the disease, the patient and the healthcare 
system explored. Specific factors influencing the TTD in CYA‟s identified in 
the reviewed literature will be divided into these three key areas and are 
explored in the next three sections, the final section 3.3.5 will include any 
identified associations between TTD and outcomes. Thus establishing the 
present knowledge base for early diagnosis research in CYA‟s  
Eleven studies included multiple diagnostic groups (26, 27, 86, 87, 90, 91, 
93, 95, 96, 101, 105), but most focused on individual groups including brain 
tumours (n=10) (84, 85, 88, 94, 97-99, 106-108), retinoblastoma (n=5) (89, 
92, 100, 109, 110), bone tumours or soft-tissue sarcoma‟s (n=4) (82, 83, 
102, 103), central nervous system germ-cell tumours (n=1) (104) and 
adenocarcinoma of the colon and rectum (n=1) (111).  
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Wide variation exists between diagnostic groups regarding the frequency of 
reported median values for TTD. Brain tumours had the most frequently 
reported median TTD (n=12) and hepatic tumours the least (n=1) (Figure 
3.2). A wide range of median values for TTD were reported within each 
diagnostic group (Figure 3.2). TTD varied by diagnostic group, e.g. there 
was no overlap between the reported median TTD for leukaemia and 
lymphoma, whilst the renal tumours appeared to have the shortest TTD. Ten 
papers reported the median values for the TTD, PI and DI (Table 3.1). 
Diagnosis of bone tumours (27, 87), brain tumours (86, 90, 105), germ cell 
tumours (93) and retinoblastoma (87, 93) were associated with longer TTD 
compared to leukaemia (26, 87, 105) and renal tumours (Figure 3.2) (86, 87, 
90, 93, 105). There were significant variations by sub-type, e.g. 
medulloblastoma had a significantly shorter TTD than other brain tumours 
(85, 106), Ewing‟s sarcoma a longer TTD than osteosarcoma (83) and non-
rhabdomyosarcoma soft-tissue sarcomas (NRSTS) a longer TTD compared 
to Ewing‟s-family Soft Tissue Sarcomas (82). 
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Figure 3.2 Graph of median values for time to diagnosis by diagnostic group 
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Tumour site was associated with variations in TTD, PI and DI in solid 
tumours. Soft tissue sarcomas (STS) in the bodies‟ extremities were 
associated with a prolonged TTD (82) as were peri-articular tumours in CYA 
patients (102), whereas axial bone sarcoma‟s were found to have a longer 
TTD compared to limb tumours (83). Tumours presenting with an abdominal 
mass or distension such as Wilms‟ tumours and neuroblastoma have been 
associated with a shorter TTD (93, 96). The location of a brain tumour was 
associated with a variable TTD with brain stem tumours exhibiting a longer 
TTD compared to all other locations (106) and supratentorial midline 
tumours having a longer TTD than supratentorial hemispheric and 
infratentorial tumours (85). 
A prolonged TTD was associated with a larger tumour volume at 
presentation in STS in CYA (82, 83). The size of the tumour at diagnosis is 
associated with a poor prognosis in STS and osteosarcoma. However in 
CYA with osteosarcoma a prolonged TTD has not been associated with 
increase tumour size at diagnosis at the present time. This fact may reflect 
predominant influence on TTD of tumour grade, hence higher grade tumours 
grow faster and have a worse outcome than slower growing lower grade 
tumours (63).  
The relationship between the stage of disease at presentation and TTD was 
variable in brain and retinoblastoma studies, with more advanced disease at 
presentation associated a longer TTD (89, 90, 92, 109). In other brain 
tumour studies more advanced stage and grade of tumour at presentation 
was associated with shorter TTD (84, 85, 107). As discussed in the tumour 
biology section, the grade of a brain tumour influences the outcome and 
aggressiveness of the treatment strategy, with higher grade tumours growing 
faster, therefore less time afforded for the body to adapt and presenting 
symptoms can be severe. Slow-growing lower grade tumours may progress 
at speeds that allow the body to compensate for changes to brain 
functioning and the symptoms and signs of resulting deficits more subtle. 
In terms of delay, brain tumours were the most extensively investigated 
group of tumours with presenting symptoms repeatedly highlighted as 
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factors influencing TTD (85, 88, 97, 99, 106, 107). Prolonged TTD was 
associated with psychological symptoms, motor dysfunction, ataxia, head tilt, 
cranial nerve palsies, reduced visual acuity and endocrine or growth 
abnormalities at presentation (88, 94, 97), however, these findings were not 
consistently shown (107). The systematic review of childhood CNS tumour 
presentations by Wilne et al 2007 identified 56 symptoms or signs at 
presentation in 4171 patients in 74 studies. The more common signs and 
symptoms, identified as the 28 signs and symptoms occurring in more at 5% 
of cases, were included in further analysis. It is therefore difficult to 
adequately investigate TTD with respect to the presentation of CNS tumours 
due to the highly variable patterns of symptoms and signs at presentation 
occurring in relatively small groups of patients. 
 
3.3.3 Time to diagnosis and patient related factors  
The majority of reviewed articles included childhood and teenage 
populations, 7 papers included cases 20 years or over (26, 27, 82, 83, 90, 
103, 111) Martin et al 2007 was the only study focusing solely on teenagers 
and young adults (15-29) (26). Authors often sub-divided the study 
population into age groups for comparison. However different age divisions 
were used with the studies and were dictated by the overall age-range, the 
peak incidence of a tumour or age thresholds for certain treatments.  
A longer TTD was significantly associated with older age at diagnosis in a 
number of studies that involved childhood and young adult bone tumours, 
leukaemia, lymphoma, brain tumours, retinoblastoma and soft-tissue 
sarcoma (27, 85, 90, 96). Nevertheless, no correlation between age and 
TTD was shown in some brain tumour studies and the study focusing solely 
on teenagers and young adults (91, 95, 107, 108). Most authors hypothesise 
that as children become young adults they are subject to reduced parental 
surveillance, have limited knowledge of their own physical health and face 
hurdles when accessing healthcare (26, 46). Childhood and young adult 
patients would appear to have a longer TTD than older adults for certain 
cancers such as bone tumours, possibly due to the rarity of such tumours in 
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this population and a resulting lack of awareness of the diagnosis amongst 
general healthcare professionals (112). 
 
3.3.4 Time to diagnosis and healthcare related factors 
The country of publication varied: Europe (n=15) (82, 83, 85, 86, 93, 94, 97, 
99-102, 107-110) with 6 from UK populations, 8 from North America (USA 
n=6, Canada n=2) (26, 27, 84, 87, 104-106, 111), 4 from Asia (China n=2, 
Japan n=1, Singapore n=1) (89, 96, 98, 103), 2 from Africa (South Africa and 
Nigeria) (91, 95), 2 from the Middle East (Israel) (88, 90) and 1 from South 
America (Brazil) (92). In order to consider TTD on a global scale the studies 
were divided according to their Organisation of Economic Co-operation and 
Development (OECD) status at the time of study. The median and mean 
TTD for studies that represented TTD across multiple ICCC tumour types 
are plotted in Figure 3.3. Haimi 2010 is included in the non-OECD group as 
Israel did not undergo accession to OECD until 2010 and the study was 
conducted from 1993 to 2001 (113).  
On inspection the median values do not appear to show a difference 
between the 2 groups however the mean TTD are both shorter in the OECD 
inclusion group compared to the non-OECD countries. In the study by 
James et al 2010 of Nigerian children with cancer, the author concluded that 
a longer TTD compared to the developed world was due to significantly 
longer DI due to patients seeking alternative health-care such as witch 
doctors and the church as well as financial constraints (91). Alternatively, 
Haimi et al 2010 in their study of the Israeli healthcare system suggested 
that a small group of paediatric specialist get involved early in the care of 
children admitted with “persistent and progressive symptoms” leading to 
earlier diagnosis (90). The differences in these two studies in non-OECD or 
developing countries suggests a predominant influence of the healthcare 
system over the economic status of the country. 
The first medical contact was found to influence TTD. For example, a person 
presenting to a non-paediatric specialist was found to have a longer TTD in 
Turkey (93) and Israel (88). In the UK a CYA patient presenting to a health 
visitor rather than a GP, or a GP rather than an A&E had a longer TTD (83, 
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98). A study of children and adolescents diagnosed with leukaemia or 
lymphoma in the Canadian healthcare system found that a longer PI was 
associated with a shorter time to treatment in a study of the time taken to 
receive treatment. The finding in this Canadian study by Dang-tan et al 2010 
suggest that a longer PI results in more advanced disease stage at 
presentation to a healthcare professional and therefore more striking 
symptoms and signs that expedited the diagnostic process through to 
treatment. This finding is of particular interest as this was a prospective 
cohort study including over 1200 patients in the Canadian healthcare 
system, which is often seen as being most akin to that of the UK (114).  
  
Figure 3.3 A comparison of the median and mean time to diagnosis by 
Organisation of Economic Co-operation and Development inclusion at 
the time of study 
 
 
Dividing the studies by OECD status is crude and does not account for 
variations in the health-care structures within countries. The UK is seen as 
having a “gate-keeper” style healthcare service with GP‟s acting as the 
primary point of contact and referral, where as in the US and many 
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European countries the patient can directly access a specialist. The rare 
nature of cancer in the young means most UK GP‟s are unlikely to encounter 
more than a single case of childhood or TYA cancer in 20 years experience 
(115). It is therefore unlikely that personal experience and reflection will 
improve the diagnosis of CYA cancers by GPs. The strategy of increasing 
the awareness and knowledge of GP‟s to the symptoms and signs of 
potential cancers within CYA may have an impact. Awareness campaigns in 
CYA cancers are already in place, as previously discussed the HeadSmart 
campaign sets out to raise awareness of the potential symptoms and signs 
of CNS tumours in patients and healthcare professional in order to improve 
on survival and neurocognitive outcomes for patients (12). The campaign 
has set a target to reduce the median TTD in the UK for brain tumours from 
13 weeks to 5 weeks. The initial results of the campaign have suggested a 
reduction in the TTD (described as symptom-interval by the authors) and DI 
after the launch of HeadSmart, though they concede more data are need to 
identify a sustained reduction (116).   
There are two sides to the story of presentation of CYA cancers to GPs, 
which are highlighted in three studies done in UK primary care services: The 
first is a study by Fern et al 2011 of Scottish GP practises that found around 
70% of registered 15-24 year-olds attended their GP in a year and only 4% 
of consultations could be classified as relating to potential “alert” symptoms 
for cancer (66). This study suggests a small proportion of GP consultations 
maybe amenable to targeted interventions within the TYA population. Two 
studies by Dommett et al 2012 used a population-based, nested case-
control method to investigate the features of childhood cancer (72) and 
teenager and young adult cancer (117) in primary care. These studies found 
a low positive predictive value of individual alert symptoms and consultations 
and suggested further studies of symptoms and consultation clustering to 
increase the positive predictive value. The three studies referenced the 
NICE guidelines for referral of suspected cancer in the identification of alert 
symptoms, the relevance of this document to this project will be discussed 
further within the methods section. 
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3.3.5 Time to diagnosis and outcome 
Three distinct patterns of survival emerged from the review:  
 An almost linear decrease in survival probability with increasing TTD. 
Observed in the Ewing‟s-family of Soft Tissue Sarcomas (82). 
 A non-linear relationship showing an initial fall in survival probability to 
a nadir at a relatively short TTD, followed by an increasing survival 
probability with increasing TTD.  Observed in children and young 
adults with brain (85) and non-rhabdomyosarcoma (82) tumours, a 
contrast to adult colorectal cancer populations (118). 
 No significant difference in survival with increasing TTD was observed 
in the bone sarcoma population (83). 
The relationship between TTD and outcome is also unclear. Differing 
patterns of survival with increasing TTD were reported across diagnostic 
groups, most notably in brain, bone and STS populations (82-84).  Peaks 
and troughs in survival outlined earlier may signify the presence of other 
factors that have a stronger influence on outcome, such as tumour biology or 
response to treatment (85). Analysis comparing TTD in the low-grade glioma 
population and the medulloblastoma population concluded that tumour 
biology is “dominant and overwhelms any opposing effect on survival of a 
delay in diagnosis” (85). 
Overall survival is not the only measure of outcome relevant to early 
diagnosis; other measures include recurrence, quality of life, treatment late-
effects and survivorship (10). In the UK five-year survival for retinoblastoma 
between 2001-2005 was nearly 100%, yet the median TTD for this group of 
patients was amongst the longest (3). Furthermore, studies consistently 
showed a significant association between increasing TTD and other poor 
outcome measures including advanced localised or metastatic disease and 
increased treatment burden (89, 92, 100, 109). Improving TTD would 
therefore aim to impact on survivorship by reducing the treatment burden 
from chemotherapy, improving visual outcomes and long-term quality of life. 
CYA CNS tumour outcomes such as neurocognitive status at diagnosis and 
subsequent to treatment could be improved by reducing TTD, in a similar 
fashion to the aforementioned retinoblastoma population. 
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3.4 Conclusion 
The overwhelming opinion amongst patients, clinicians and public health 
professionals is that improving TTD for childhood and young adult cancers 
will impact positively upon survival and survivorship. However the 
conclusions drawn from early diagnosis research in children and young 
adults to date are far from clear. This review highlights some limitations in 
this research area. It is clear that a theoretical framework is lacking from the 
vast majority of publications and subsequently the definitions used for key 
time-intervals and milestones are neither robust nor reproducible.  
The Aarhus statement discussed in section 2.1 provides clear guidance for 
the early diagnosis researcher and the “Model of pathways to treatment” 
Walter et al 2011 provides a clear theoretical framework. The framework 
presented in Figure 2.2 will underpin the development of the method within 
this research project. Further considerations regarding the application of the 
term “delay” and a simple set of milestones will be discussed further in 
sections 3.4.1. 
 
3.4.1 Qualifying the application of the term “delay” 
The term “delay” is used in the majority of articles, most frequently 
describing an unqualified period of time between symptom onset and 
definitive diagnosis (85, 87, 89, 90, 92, 95, 96, 100, 101, 110). When authors 
attempted to qualify the point from which a delay becomes unacceptable or 
excessive they often used an arbitrary time point defined by their 
observations (104) or the median delay value for the study population (96, 
103). Given the negative connotations of the term “delay” a set of defined 
criteria should be outlined at the start of the study to identify unacceptable 
circumstances during which a delay is experienced (78, 104). Shay et al 
2011 and the National Patient Safety Agency (2010) defined criteria for 
delay in a thematic review of delayed diagnosis of cancer (figure 3.4) (88, 
119). Such criteria should be accompanied by a clear model for time 
intervals to be studied and hierarchies for identification of major time points 
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(similar to the hierarchy of defining the date of diagnosis issued by the 
European Network of Cancer Registries) (24). 
  
Figure 3.4 Table of Criteria for defining delays in diagnosis of cancer in 
children and young people 
 
 
3.4.2 Milestones in early diagnosis research 
An outline of milestones to aid TTD research has been developed based on 
this review (figure 3.5). The terms PI, DI and TTD are purely descriptive and 
infer nothing about the significance or modifiability in duration of time lapse 
within each period. “Delay” describes a variable time within the PI, DI or TTD 
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that occurs if the outlined criteria for delay are met.  More extensive models 
of pathways to treatment and milestones in early diagnosis research are 
outlined by Weller et al 2012. These should be used as the theoretical 
models from which early diagnosis research can develop (19).  
 
Figure 3.5 Diagram of milestones in the time line to diagnosis of cancer with 
the presentation of delay intervals 
 
 
3.4.3 Limitations of the Literature review 
Potential language bias was caused through a lack of scope to access and 
translate foreign language papers. Search strategies did not identify papers 
that considered prognostic-factors or quantified TTD, PI or DI within the main 
text of the paper but not in the abstract. Publication bias has not been 
addressed within this study; however, we believe the effect of this is 
minimized due to the wide range of results obtained between and within 
diagnostic groups.  
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3.4.4 Summary points of Literature review 
Summary points for the limitations found from the literature review were: 
 Little consistency in the terminology of TTD and heterogeneity of 
research methods made comparisons between studies difficult. 
 Summary data reported was inconsistent and incomplete, leading to 
difficulty interpreting comparative data. This is important as the data 
are skewed and contain extreme outliers. 
 There was marked variability in reporting the association between 
TTD and outcome.  
These points mirror the conclusions from the Aarhus statement, which 
identifies the common limitations in early diagnosis research to date across 
the age spectrum (19). There are distinctions to be made in early diagnosis 
research between the adult cohort and CYA cohort and this review and the 
Background (Chapter 2) highlights these. Cancer in CYA consists of a rare 
and heterogeneous population of tumours with distinct and varied inter and 
intra-diagnosis patterns of biology and behaviour that vary across the age 
range. The challenges faced by patients and their carers in receiving the 
diagnosis of cancer are compounded by the rarity of the diagnosis, however 
the fact that cancer is still a major cause of mortality and morbidity in this 
population justifies the intensity with which we strive to improve cancer care 
in this population. There are gaps in our knowledge regarding early 
diagnosis research and in the UK as with many other countries the focus has 
fallen on the primary care setting. Secondary care is incorporated in some 
research, but the majority of guidance is aimed at the primary care clinician, 
as such this project provides a unique opportunity to explore the role of 
secondary care services in the diagnostic pathway for CYA cancer patients.    
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Chapter 4 Methods 
4.1 Overview 
This study seeks to tackle the aims set out in Chapter 1 through the 
investigation of the time taken to diagnose cancer within secondary care 
services in a population of children and young people in the geographical 
region of the Former Yorkshire Regional Health Authority (FYRHA). The 
distribution of TTD within this population will be analysed against population 
demographics and disease profiles to identify if sub-groups exist within the 
population who are at risk of a prolonged TTD. There are two aims of this 
study; firstly the development of recommendations for healthcare providers 
that will aim to improve TTD, and secondly to assess and advance the use 
of HES data linked to population based cancer registries in the field of CYA 
cancers. This is a descriptive study that will employ survival analysis along 
with clinical knowledge of paediatric oncology. 
The requirement for this study follows the evidence presented in chapters 1, 
2 and 3. In the first two chapters the high profile of early diagnosis in cancer 
care service planning and research in the UK and across the globe was 
identified. The assumptions around the impact of prolonged TTD are 
explored along with the challenges facing researchers in the field of early 
diagnosis and cancer in CYA. Chapter 3 discussed specific considerations 
from the reviewed literature on early diagnosis research in CYA cancers as 
well as identifying general recommendations for early diagnosis research. 
This chapter outlines the study design providing the justification for this 
approach, the data sources used, data sampling and analysis. Section 4.2 
will provide a description of the overall study design and section 4.3 
describes the ethical approval for this project. Following this 4.4 will identify 
and discuss the sources of data for the project; how they were developed, 
how the information for these sources was acquired and finally how this data 
was linked together to provide the dataset from which the study population 
was sampled. The sampling and identification of cases, hospital episodes 
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and cancer “alert” symptoms is discussed in section 4.8.4. Final sections 4.9 
and 4.10 will outline the statistical analysis, data presentation methods and 
survival analysis for the subsequent results and discussion sections.    
 
4.2 Study design 
This study sits within the broad field of epidemiology, defined as “The study 
of the distribution of health-related states or events in specified populations 
and the application of this study to control of health problems” (Eva 
Steliarova-Foucher).  This is an observational study design, as information is 
collected on factors associated with outcomes of interest within a population 
without any attempt to modify the exposure of the study population. This is 
also a health services research study involving retrospective analysis of a 
cohort identified using a population-based cancer register linked to hospital 
admissions data. The study cohort is used to assess the impact of an 
exposure (prolonged TTD of cancer) within a defined population (CYAs with 
cancer in Yorkshire) upon a certain outcome (survival). As a retrospective 
study the information will have already been recorded for the population, 
allowing the review of information over a long period of time. 
  
4.2.1 Limitations of study design 
There are a number of advantages and disadvantages to the design of this 
study. The observational nature means it is relatively cheap to conduct 
compared to other study designs such as Randomised Control Trials (RCT). 
However observational studies are not as robust as RCT in establishing 
causal links and adjusting for the effects of known and unknown confounding 
factors (120). The retrospective nature of the study allows access to 
information already collected and therefore the study needs only a short 
period of time for data collection compared to prospective studies that must 
collect information as they follow cases up. The fact that the information has 
already been collected is also a limitation as the study can only work from 
information recorded and is reliant on the completeness of data collected. If 
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data are missing or incomplete, this will impact on the validity and 
generalisability of the conclusions drawn.   
The population-based design of this study is in contrast to the institution-
based design that predominated in the CYA early diagnosis research studies 
identified in the systematic review section 3.3. Within the field of 
epidemiology based health services research a population-based study 
design is the gold standard, it allows the assessment of the impact of an 
exposure across a defined population and can be used to generate 
incidence rates, mortality rates and population-based survival rates. The use 
of this design will facilitate the development of recommendation more 
applicable to healthcare provision at local, national and international levels. 
The study is also at risk from the influence of bias at a number of points, 
which is defined as a systematic error that could result in the inaccurate 
conclusions of the true effect of an exposure on the outcome. Specific areas 
for bias within this study will be discussed later within this chapter. 
 
4.3 Ethical approval 
This project forms part of the ongoing research programme of the Yorkshire 
Specialist Registry for Cancer in Children and Young People (YSRCCYP). 
National Information and Governance Board approval for the YSRCCYP 
comes under the United Kingdom Association of Cancer Registries NIGB 
application number 0001, available at  
http://www.nigb.nhs.uk/s251/registerapp/register311012.xls 
The YSRCCYP protocol is currently in its 4th version protocol, where this 
project is outlined – Protocol Version 4 December 2011 REC: MREC/0/3/1. 
Hospital Episodes Statistics data linked to the YSRCCYP will be used to 
analyse the TTD of cancer for children and young people (0 to 24 years) 
within secondary care services in the FYRHA. Approval to work with HES 
data was provided by Data Access Advisory Group – DAAG reference: 
OC/HES/015, as part of the work approved within the YSRCCYP. 
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The sole purpose for accessing the medical records as part of this project is 
to validate what is recorded within the HES records. Information is required 
from a small sample of less than 50 cases and will include: 
 Corroboration of demographic details. 
 The list of inpatient events preceding transfer to the tertiary care 
centre. 
 Comparison of the diagnostic codes listed within the HES episodes 
with what is recorded within the medical records. 
 The project will only publish data which is non-patient identifiable in 
line with the requirements of the registry protocol. Data protection will 
be discussed in more depth in section 4.7. 
 
4.4 Data sources 
This project will utilise data extracted from 2 main sources: the Yorkshire 
Specialist Register of Cancer in Children and Young People (YSRCCYP) 
and HES data. Clinical notes will be used as a third source for validation of 
HES data. 
 
4.4.1 Yorkshire Specialist Register of Cancer in Children and 
Young People (YSRCCYP) 
The YSRCCYP is a population-based register of young people with cancer 
who are diagnosed within the Yorkshire & Humber Strategic Health Authority 
(SHA) aged under 30-year at the time of diagnosis. The register has 
collected data on children aged under 15 at diagnosis since 1974 and young 
adults aged 15-29 at diagnosis since 1990. The register covers a population 
of around 5 million, nearly 2 million of whom are aged under 30 years. The 
geographical area covered includes the Yorkshire and Humber SHA and 
recently has been extended to incorporate the local authority areas of 
Barnsley, Doncaster, Rotherham and Sheffield.  
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The register contains demographic, diagnostic and clinical data relating to 
treatment. The diagnostic data are classified according to the ICCC 
classification system. The date of diagnosis is taken from the medical 
records and is recorded as the date of histopathological confirmation of the 
cancer diagnosis.  
The use of the register to identify cases allows a population-based approach 
to this retrospective research. Each case is recorded within an Access 
database held on a secure server within the Centre of Epidemiology and 
Biostatistics, University of Leeds. Cases are ascertained using a number of 
different sources. The principal source for childhood cancer cases is the 
tertiary paediatric oncology centre based at the Leeds General Infirmary and 
there are also links to regional, extra-regional and national registries. 
Utilisation of multiple sources for case accrual allows the registry to present 
highly accurate data on all cancer cases diagnosed in the Yorkshire region.  
    
4.4.2 International Statistical Classification of Disease  
The International Statistical Classification of Disease (ICD) is a classification 
that has evolved over the last century to allow the counting of disease, 
symptoms, injuries, reasons for disease and health encounters as well as 
external causes of death (32). Developed by the WHO, this standard 
diagnostic tool is currently in its 10th edition (32). This system is designed to 
allow the classification of disease and health issues in many types of 
healthcare and health research as well as from vital health records such as 
death certificates. Globally it is used by a number of different organisations 
and disciplines such as: 
 Epidemiologists to monitor incidence and prevalence of disease and 
other health issues, it is also used to compile mortality and morbidity 
data. The ICD codes are often used within cancer registries to 
generate comparable and meaningful summaries of data contained 
within patient records. 
 Health management and policy makers to monitor quality, facilitate 
health economic analysis and inform provision of healthcare 
resources.  
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 Clinicians to monitor quality of care and perform healthcare research. 
ICD-10 groups information about diseases and their causes into 22 chapters  
that cover: 
 Communicable diseases (codes A00-B99). 
 General diseases that affect the whole body (codes C00-F99), this 
section contains a section of codes relevant to the classification of 
neoplasms (codes C00-D48).   
 Local diseases arranged by site (codes G00-N99). 
 Developmental disease (codes O00-Q99). 
 Injuries (codes S00-T98). 
 External causes (codes V01-Y98). 
 Symptoms, signs and abnormal clinical and laboratory findings, not 
elsewhere classified (codes R00-R99). 
Each ICD-10 code starts with a letter followed by two digits which are further 
divided in sub-categories indicated by a point and a third digit to create a 
four unit character (32).   
 
4.4.3 Hospital Episodes Statistics (HES) 
Hospital Episodes Statistics (HES) are a data warehouse for all inpatient 
admissions for NHS funded patients treated within English NHS Trusts 
(including the private sector) since 1989 (121). HES inpatient data provides 
information relevant to the patients diagnosis and treatment, demographics 
including ethnicity, administrative information such as waiting time and 
geographical information such as where a patient was treated (121). The 
process of generating HES data involves non-clinical staff collecting 
information recorded by medical staff in clinical notes. The data are collated 
centrally and quality assessed before being made available. A wide variety 
of organisations and individuals use this data including the government and 
the NHS, as well as researchers and institutions studying health economics, 
cancer intelligence and epidemiology. The outpatient data has been 
recorded in HES since 2003 and A&E attendances recorded since 2007. 
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For the purposes of this project, HES records for inpatient and outpatient 
admission have been linked to the diagnostic data in the YSRCCYP.  
The multilevel data structure of HES is complex; containing episodes which 
lie within spells which lie within continuous inpatient spells (CIPS) as 
represented in Figure 4.1. This project will mainly focus at the level of patient 
episodes, rather than spells or CIPS, although CIPS will be considered in the 
analysis of admission routes. The use of episodes allows the analysis of 
diagnostic information included in HES for inpatient events in secondary 
care and focuses on individual consultant led teams. The focus on CIPS for 
admission routes allows for the analysis of the initial point of contact for an 
inpatient event. 
Each Finished Consultant Episode contains a series of ICD-10 diagnostic 
codes which are used to describe the hospital event, and a sequence of up 
to 20 ICD-10 codes can be used to describe the episode. 
 
Figure 4.1 Outline of HES inpatient time intervals 
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4.4.4 Data coding 
In order to understand the process of coding of healthcare events I met with 
the lead coding trainer for Leeds Teaching Hospitals trust. This provided key 
information on how medical information is translated from the case notes to 
a sequence of diagnostic codes, the source from which HES episodes 
records are generated. Several key considerations are outlined for those 
working with HES data generated by medical coding:  
 Coding is only as good as the information recorded within the clinical 
notes. 
 There is no universal approach to coding within the NHS.  
 The process of coding inpatient events has come under increasing 
scrutiny and is now subject to increasingly strict regulations.  
 At the end of the month coders have 5 days to complete 95% of the 
coding and then a further month to complete the last 5%. 
 Coders utilise a number of sources for coding information such as the 
case notes and electronic resources (e.g. results server). 
 A symptom or sign is only recorded if it fails to relate to the diagnosis 
made during the episode. If a symptom appears and is found to relate 
to the diagnosis made at a later date within the episode this symptom 
is omitted from the list of diagnostic codes. 
 A governing body exists for clinical coders that can help with queries 
or difficult cases. 
 The quality of coding is scrutinised by a regular audit process. 
 If a diagnosis, symptom or procedure cannot be coded, relevant 
consultants are contacted to discuss the issue. 
 Back coding is not allowed, coders must only use information within 
case-notes, associated referral, discharge letters or other resource 
that relate to the episode being coded. 
o Therefore if a co-morbidity is not recorded it can‟t be back filled 
from a previous entry. 
 The clinical information within case notes can only be coded if an 
entry starts with the key words: 
o Diagnosis…. 
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o Treat as…. 
o Probably…. 
o Presumed….  
 Some coders will code the Δ symbol, recorded by some medical 
professionals to indicate a differential diagnosis, however this is not a 
universally accepted approach. 
 Coders cannot code if an entry in the medical notes starts with the 
key words: 
o Impression…. 
o Likely…. 
o Possible…. 
In 2002 the Department of Health consulted on its plans for NHS financial 
reforms and introduced the concept of Payment by Results (PbR) for the 
reimbursement of NHS hospitals in England for their activities (122). PbR 
works by assigning tariffs to patient treatments within a cluster of diagnosis 
and procedures which consume similar resources. This system was 
introduced in 2003-2004 and has been developed incrementally; in 2005-
2006 the system included the majority of trusts but only elective cases; 
2006-2007 saw the inclusion of non-elective, accident and emergency, 
outpatient and emergency admissions; 2008-2009 saw the final stage of 
financial implementation. The application of the financial currency that 
dictates the national tariffs was only applied to outpatient activity in 2009-
2010 (122). 
There are several key time points within the implementation of PbR that 
merit consideration within the methods of this study (122). The threshold 
year of 2006 saw a change in attitude within the NHS towards the accuracy 
of coding, which was driven by the desire to improve the recording of 
healthcare activity to facilitate more accurate reflection of utilisation of 
resources. This had the secondary effect of improving HES records for 
healthcare researchers and this transition will be explored as part of the 
validation process within this project. The later implementation of PbR to 
outpatient activity and the exclusion of diagnostic information from the 
mandatory requirements reduces the quality of information contained within 
outpatient HES records. The NCIN routes to diagnosis work did not consider 
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any of the diagnostic information in the process of sequencing secondary 
care events prior to diagnosis and therefore included outpatient HES data 
within the analysis (71).        
 
4.5 Data linkage 
The YSRCCYP cases were linked to the HES data using specified identifiers 
(NHS number, date of birth, sex, and postcode). The YSRCCYP therefore 
provided unique information on patient demographics and diagnosis, whilst 
the HES data provided unique information relevant to all inpatient hospital 
episodes and mutual data was included by the identifiers outlined (Figure 
4.2). Within the study population only three cases identified from the 
YSRCCYP did not link to a single HES record. 
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Figure 4.2 Linked cancer register and HES dataset structure . 
YCTR_ID Date of DiagnosisICCC ICCC GroupDate of Death SEX Postcode Date of Birth NHS Number Admission Methodspellstart spellend ICD-10 Code 1 ICD-10 Code 2 ICD-10 code 3 ICD-10 Code 4 ICD-10 Code 5
2006145 12/05/2006 61 6 . F LSX XXX 24/06/2003 4567000000 28 28/11/2004 29/11/2004 N180 Z911 N038 Z992 Z940
Patient A 2006145 12/05/2006 61 6 . F LSX XXX 24/06/2003 4567000000 21 01/02/2005 01/02/2005 T393 X600 F329 N180
2006145 12/05/2006 61 6 . F LSX XXX 24/06/2003 4567000000 11 02/05/2006 16/05/2006 R31X N288
2007245 29/12/2007 61 6 . M WFX XXX 11/04/2005 4890000000 82 11/04/2005 15/04/2005 P070 Z380 P590 P742 E872
2007245 29/12/2007 61 6 . M WFX XXX 11/04/2005 4890000000 21 18/01/2006 18/01/2006 K409 K429
Patient B 2007245 29/12/2007 61 6 . M WFX XXX 11/04/2005 4890000000 12 19/01/2006 21/01/2006 K409
2007245 29/12/2007 61 6 . M WFX XXX 11/04/2005 4890000000 21 29/10/2006 29/10/2006 B349 R062
2007245 29/12/2007 61 6 . M WFX XXX 11/04/2005 4890000000 21 30/12/2006 30/12/2006 B349
2007245 29/12/2007 61 6 . M WFX XXX 11/04/2005 4890000000 21 01/11/2007 02/11/2007 R31X R934
Patient C 2008556 12/02/2008 62 6 24/06/2010 M HGX XXX 05/10/1998 4230000000 21 02/02/2008 15/02/2008 R190
Variables Used for Linkage Variables Merged from National Information Centre HES data Variables Merged from YSRCCYP
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4.6 Data quality and bias 
Several areas of potential bias must be considered within the design of this 
study and the data sources used for the study. As previously stated the 
presence of bias within any research study is the presence of factors that 
influence the validity of the estimate of the true relationship between the 
study exposure and outcome measure (120). The main areas for 
consideration are in the ascertainment of cases for the study, the 
completeness of information within the retrospective records, classification of 
cases and assessment of TTD and the measurement of the outcome. 
 
4.6.1 Ascertainment bias 
The population based nature of this study ensures the study population 
includes all cases of cancer in CYA in the defined FYRHA and period of 
study, as long as they meet the inclusion criteria. As such the influence of 
selection bias upon the case profile of the population should not influence 
assessment of the exposure on the outcome. However, the fact that the 
cases are being sourced from a registry does raise the issues of 
completeness of the cohort, particularly raising the question; is the 
ascertainment of cases of cancer in CYA in Yorkshire complete within the 
Registry? This issue is discussed within the YSRCCYP protocol version 4, in 
which they identify a number of sources from which information is gathered 
and also sources used to cross-reference against those patients on the 
Registry, some are which listed below: 
 Leeds Teaching Hospitals Trust Paediatric Oncology Department is 
the tertiary centre for CYA cancer within the Yorkshire region and 
provides the key source of notification for cases. 
 The Northern and Yorkshire Cancer Registry and Information Service 
provides an annual list of CYA cancer patients within the region from 
which the YSRCCYP can cross-reference. 
 The National Registry of Childhood Tumours provides another source 
for cross-checking annually. 
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Ascertainment bias is therefore likely to be minimal and as such the use of 
the YSRCCYP for identification of cases for inclusion within the study is 
robust. There is also a risk of ascertainment bias through the linkage of the 
two data sets, however as discussed within section 4.5 the data linkage 
within this project was high.  
 
4.6.2 Information bias 
The retrospective nature of this study means the completeness of data 
recording must be considered and is a key issue for this project. As stated 
within the coding section the process of coding medical records and the 
generation of HES records has changed dramatically with the introduction of 
PbR in 2003-2004, the implementation of which occurred gradually over the 
intervening years (122). The variable approach to coding of medical records 
between hospital trusts was also touched upon in section 0. These two 
factors brings into question the accuracy of the information recorded with the 
HES records, especially during the earlier period of the study. In order to 
assess the completeness and accuracy of HES records, a small population 
of hospital notes was reviewed. The process of HES record validation is 
discussed in section 4.11.2. 
Unfortunately the use of case-notes review in retrospective studies also 
raises the question of missing information bias, especially an issue for 
studies of patient interval to healthcare engagement. The duration of 
symptoms as recorded within the medical notes is questionable and subject 
to recall bias and prone to incomplete recording. The alternative method of 
patient interview as outlined in the majority of CYA studies discussed in the 
systematic review (Chapter 3) is also prone to recall bias as the patient may 
have a skewed view of their disease given the outcome or their experiences 
during treatment. For these reasons this project will focus on the diagnostic 
interval; recorded as the duration of time in days between the presence of 
alert symptoms within a HES record and the date of definitive diagnosis.   
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4.6.3 Misclassification error 
The method of analysing HES records against national CYA cancer 
awareness resources for the identification of alert codes is prone to bias 
given the processes of interpretation involved. There is a risk of 
misclassifying hospital events as not containing an alert code, given the 
presence of an established diagnosis. The ICD-10 classification system is 
based on diagnosis codes and generalised symptoms, symptoms which will 
not be recorded by coders unless they cannot be explained by the given 
diagnosis within each episode. For example, „headache‟ will only appear in 
the HES record if no other explanation can be extracted from the hospital 
record, such as the diagnosis of „migraine‟.  
There is also a risk of over subscribing significance to the codes of an 
episode due the fact the diagnosis of cancer is made after the occurrence of 
the episodes being studied. Many of the symptoms present within the CYA 
awareness campaigns occur within a number of paediatric conditions, an 
issue highlighted by Dommett et al 2012 in relation to the low positive 
predictive value of NICE referral guidance (72).  
The issue of misclassification error is discussed within the NCIN routes to 
diagnosis work, where the authors concede they could not be sure the 
events occurring prior to diagnosis were related to the subsequent cancer 
diagnosis (71). Unlike this study, no attempts were made to relate the pre-
diagnosis events to the subsequent diagnosis based on the coded content of 
the HES episodes. Therefore the method applied to this study adds another 
valuable and unique level of complexity to the analysis of routes to 
diagnosis.   
 
4.7 Data security and confidentiality 
Working within the ethical approval for the YSRCCYP this project is 
presented in a manner such that no patient identifiable data (PID) or 
potentially PID are divulged. Extreme care and attention was taken to ensure 
confidentiality and data security. All work with PID was carried out in 
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accordance with the guidance set out for those working in the YSRCCYP 
outlined in the data security policy of the Centre for Epidemiology and 
Biostatistics (CEB), the department in which the YSRCCYP Register is held. 
The YSRCCYP outlines conditions for holding PID: 
 No information will be published in which an individuals can be 
identified. 
 No individuals whose information is present on the Registry will be 
approached directly. 
 Data will only be released in accordance with the data security policy.  
 
4.7.1 Working with Patient Identifiable Data (PID) 
This project has worked with patient level data that was identifiable on many 
levels, however this work took place within the remit of the policy of data 
security. Work at the PID level took place within the CEB, which has 
restricted user access and can only be processed on a secure server where 
the YSRCCYP Register resides.  
 
4.7.2 Presenting results that are non-Patient Identifiable 
The results for this study will be non-PID, however the division of data into 
PID and non-PID is not straightforward. There are clear pieces of information 
that can identify patients when results are presented at an individual case 
level. Clear definitions of what constitutes PID have been taken from the 
guidelines issued by the UK Association of Cancer Registries (UKACR) 
“Data will be regarded as identifiable if it includes any of the following data 
items: name, address, postcode, date of birth, date of death, NHS number, 
hospital number” (123).  
This is not the only constraint on presented data: there is still the potential 
for data to become identifiable despite the omission of the above identifiers. 
Patients can also be identified by non-classical indicators, such as a unique 
diagnosis (123). If a case falls within a defined geographical area or 
recognised population they may be identified by the amalgamation of 
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identifiers traditionally perceived as non-PID, such as age at diagnosis, route 
to diagnosis and diagnosis. The UKACR also provides guidance for 
potentially identifiable patient information: 
“As a general rule, the following categories of data should be 
regarded as potentially identifiable:  
Individual records even if they do not include variables, such 
as names, full postcodes, and dates of birth which would 
make them obviously identifiable;  
Tabular data, based on small geographic areas, with cell 
counts of fewer than five cases/events (or where counts of 
less than five can be inferred by simple arithmetic) – hereafter 
referred to as “sparse cells”  
Tabular data containing cells that have underlying population 
denominators of less than approximately 1,000.” (123) 
 
4.8 Population and sampling 
A clear set of inclusion and exclusion criteria outlined in this section was 
applied to the linked dataset in order to define the population for this study.  
 
4.8.1 Inclusion criteria 
The study population was identified through a set of inclusion criteria: 
1. Patients diagnosed with cancer up to their 25th birthday as recorded 
on the YSRCCYP. 
2. Cases diagnosed between 1st January 2004 and 31st December 
2009. 
3. Cases treated in the FYRHA as recorded on the YSRCCYP.  
The first criteria defines the study population as CYA, comprising a 
heterogeneous population of tumours as discussed in the background 
section (Chapter 2).  
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The second criteria defines a retrospective cohort of patients that covers a 
six-year time period, allowing for the analysis of variation in TTD across a 
changing healthcare system for a large geographical population. The second 
criteria also provided the follow-up time scale to allow 1 and 3 year survival 
analysis within the time frame of this research project. 
The third inclusion criteria was imposed due to changes in the YSRCCYP in 
recent times with the introduction of cases from South Yorkshire. This data 
was still being retrospectively collected at the time of analysis and therefore 
these cases have not been included within the study.     
 
4.8.2 Exclusion 
Within the YSRCCYP a patient can potentially have an unlimited number of 
cancer diagnoses, which are identified by a diagnosis number. Most patients 
have one diagnosis, however, multiple diagnoses can occur and signify; 
relapsed disease, secondary malignancy or occasionally duplication of 
cases due to the revision of a primary diagnosis. Within this study all 
diagnoses other than the primary diagnoses were excluded from further 
analysis. This was an important step as the analysis of TTD in relation to 
cases of relapsed or secondary malignancies is more relevant to tertiary 
care services, due to the fact that the case will have had or still have 
ongoing contact with the oncology department prior to relapse or secondary 
diagnosis. The HES data doesn‟t allow differentiation between episodes 
relating to the different diagnoses, especially as some cases may have a 
recorded second diagnosis while still receiving treatment for their primary 
cancer.  
 
4.8.3 Episodes (FCE) 
Episode (FCE) level data is the base unit of representation for inpatient 
hospital events within HES records, as outlined in Figure 4.1, enabling  the 
data to be investigated at a consultant event level. The analysis of inpatient 
events for the purposes of alert code identification was conducted at the 
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episode level due to the potential for multiple episodes with variable 
diagnostic sequencing.  
 
4.8.3.1 Pre-diagnosis episodes 
The linked HES inpatient data set contains the catalogue of inpatient events 
for the cases identified from the YSRCCYP. The pre-diagnosis episodes 
were separated from episodes subsequent to diagnosis for the process of 
data analysis. The date of diagnosis was taken from the date recorded within 
the YSRCCYP, and was defined as the date when the pathological 
specimen was taken. When a histopathological diagnosis was not made, the 
date of radiological confirmation was used as the date of diagnosis.  
Using code written in Stata, episodes with a date of admission that preceded 
the date of diagnosis or coincided with the date of diagnosis were identified. 
Any episode in which a date of admission was subsequent to the date of 
diagnosis were removed from further analysis.     
 
4.8.3.2 Cancer code containing episodes 
The date a pathological specimen is taken may be preceded by the date a 
diagnosis made via another means such as clinical suspicion or radiology. In 
cases where the medical records identify a clinical or radiological diagnosis 
prior to the pathological diagnosis, there is a potential for an ICD-10 code for 
malignancy (C-codes) within a pre-diagnosis episode. The pre-diagnosis 
episodes will therefore be analysed for the presence of pre-diagnosis C 
codes and these codes can then be cross-referenced with the ICCC 
classification. The extent to which discrepancies in date of clinical diagnosis 
and pathological diagnosis occur will be assessed.   
The NHS has also introduced guidance that outlines the duration of time 
deemed acceptable for referral, diagnosis and treatment of cases with 
cancer and suspected cancer. The guidance aims to promote timely care for 
cancer cases in order to improve outcomes. Cancer waiting times guidance 
applies to children and adults, and the main pathways are (124): 
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 Two-weeks from urgent GP referral for suspected cancer to first 
hospital assessment 
 31 days from decision to treat to first treatment  
 62 days from urgent GP referral for suspected cancer to first 
treatment, however this threshold is 31 days for suspected childhood 
cancer, testicular cancer and acute leukaemia. 
The 31 day period from urgent referral to treatment for suspected childhood 
cancer will be adapted for this study to a 31 day period from first alert code 
occurrence to date of diagnosis. A 31 day threshold will be used within the 
analysis of alert code events in order to differentiate between cases where 
the first alert code event occurs within an appropriate time prior to diagnosis 
and cases where potentially there is a more prolonged TTD in secondary 
care. 
 
4.8.4 Alert codes 
In order to facilitate earlier diagnoses, patients must be aware of the 
potential importance of their symptoms, and the healthcare professional at 
the point of initial contact must regard the symptoms as concerning. A 
number of government, private and third sector organisations have been 
working to develop awareness and early diagnosis campaigns. For the 
purposes of this project, major awareness and early diagnosis guidance will 
be used to define „alert‟ symptoms for an initial presentation of cancer in 
CYA patients. The identified „alert‟ symptoms will be cross-referenced 
against the ICD-10 diagnostic codes and those codes identified as 
potentially relating to an „alert‟ symptom will be highlighted and identified 
within HES episodes as they appear in the full data set.  
The „alert‟ symptoms were divided into one broad category relating to a 
general diagnosis of cancer, which do not vary across ICCC diagnostic 
groups. A second group of specific alert codes were defined within each 
ICCC group and these alert codes were group specific. The specific „alert‟ 
symptoms for each diagnostic group were taken from the sources outlined in 
the next section. The awareness literature was selected as it aims to 
increase patient awareness, facilitate early diagnosis in professionals and is 
- 71 - 
 
 
relevant to CYA cancers combined with the fact that they are easy to access 
online for patients and professionals. Any code directly relating to the 
treatment of a neoplasm was also included within the pre-diagnosis alert 
codes.    
 
4.8.4.1 Awareness campaigns 
4.8.4.1.1 National Institute for Clinical Excellence guidance 
The Department of Health first published guidance on referral to suspected 
cancer in 2000, this was revised in light of new evidence by NICE, in 2005 
the document “Referral guideline for suspected cancer” were published and 
is still in use to date (125). The guidelines are aimed at the primary 
healthcare provider and offer best practice advice for the referral of 
suspected cancer in adults and children. The document identifies the 
importance of good communication and patient choice in delivering patient 
centred care, while at the same time acknowledging the difficulties of making 
a diagnosis of cancer, a point which is stressed in the childhood cancer 
population. Three categories are defined for acceptable referral times, which 
are as follows (125): 
 Immediate – admission or referral within hours of suspecting the 
diagnosis. 
 Urgent – within the 2 week national target. 
 Non-urgent -  All other referrals. 
The bulk of the document relates to adult cancers categorised by primary 
site, however there is a chapter relevant to certain childhood cancers, this 
chapter categorises the tumour types in accordance with ICCC diagnostic 
groups. There is guidance of several of the major childhood cancers 
including: leukaemia, lymphoma, central nervous system tumours (children 
under two-years of age and children over two-years of age), neuroblastoma, 
Wilms‟ tumour, bone tumours, soft tissue sarcoma and retinoblastoma, see 
appendix 1 (125). The guidelines are not exhaustive, however they provide a 
clear baseline for what should be expected from the healthcare provider at 
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the point of contact, for this reason the guidelines are pertinent to secondary 
care providers.  
The terms „unexplained‟ and „persistent‟ appear repeatedly in relation to 
symptoms and signs and provide a challenge when cross-referencing signs 
and symptoms from the guidelines to HES diagnostic codes. The term 
„unexplained‟ refers to a symptoms and/or sign that is present but lacks a 
clear diagnosis after history, exam and investigations by the primary 
physician, the term „persistent‟ refers to a symptom and/or sign present 
beyond that expected of a self-limiting illness, an upper limit of 4-6 week is 
described (125). The method for identification of ICD-10 diagnostic codes 
relevant to „alert‟ symptoms is described later within the methods section.  
The NICE guidelines discussed provide a clear foundation from which to 
develop a portfolio of „alert‟ symptoms and signs, but they only cover certain 
types of childhood cancers. TYA cancers are not covered and the adult 
guidance is aimed at specific cancer sites in the majority of cancer, therefore 
alternative sources were sort to provide a wider scope including young adult 
specific cancers. 
4.8.4.1.2 Teenage Cancer Trust Awareness 
The Teenage Cancer Trust is a UK charity dedicated to improving the lives 
of TYA‟s between the ages 13 to 24 who are diagnosed with cancer (25). In 
April 2012 the charity launched an awareness week that aimed to „educate 
young people, parents, teachers and healthcare professionals about the 
signs and symptoms of cancer in young people‟ (17). The campaign 
provides information packs for teachers and awareness posters for young 
people covering several tumour types: leukaemia, lymphoma, bone tumours, 
brain tumours, testicular cancer, ovarian cancer and skin cancer (17). A 
patient story relevant to the presentation accompanied the guidance for each 
tumour type outlined above, highlighting the reality as well as the rarity of 
cancer within this population. 
4.8.4.1.3 HeadSmart 
The HeadSmart campaign was launched in 2011 aims to „enhance 
awareness of symptoms of brain tumours in children and young adults‟. This 
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is a partnership between the Royal College of Paediatric and Child Health, 
the Brain Tumour Charity, the Childrens Brain Tumour Research Centre and 
the Health Foundation Trust and the campaign is aimed at children, parents 
and healthcare professionals. The campaign introduction highlights the 
prolonged median TTD for brain tumours within the UK childhood population 
of 12 to 13 weeks as „unfavorable‟ compared this to 5 weeks in other 
countries (12). 
The guidance provided is relevant to the presenting symptoms of brain 
tumours in different age groups ranging from 0 to 18 years (12): 
 Preschool or under 5-years 
 Children or 5 to 11-years 
 Young people 12-18- years 
 Additional symptoms for all ages 
As well as information leaflets, posters and symptom cards there are 
educational modules on-line for healthcare professional to access.  
4.8.4.1.4 MacMillan Cancer 
The Macmillan Cancer support is a registered charity that provides practical, 
medical and financial support and strives for better cancer care (126). The 
charity has an annual awareness week that takes place at the end of 
January each year, in 2013 the Cancertalk week encouraged schools to talk 
and teach students about cancer. The charity also provides referenced 
information on signs and symptoms of cancer in children and adults. The 
information provided is often only very brief but is relevant to a wide variety 
of childhood specific diagnoses, including: acute lymphoblastic leukaemia, 
acute myeloid leukaemia, brain tumours, Ewing's sarcoma, germ cell 
tumours, Hodgkin lymphoma, liver tumours, neuroblastoma, non-Hodgkin 
lymphoma, osteosarcoma, rare tumours, retinoblastoma, 
rhabdomyosarcoma and Wilms‟ tumour (126). 
4.8.4.1.5 Bone Cancer Research Trust 
The Bone Cancer Research Trust (BCRT) is a charity dedicated to primary 
bone cancer within the UK and Ireland. The charity is committed to 
improving outcomes for patients with primary bone cancer through 
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awareness and information. The BCRT website contains awareness 
information for osteosarcoma and Ewing‟s sarcoma, which is aimed at 
patients, their families and friends and the general public (127).  
The methodology outlined below will aim to identify if the information 
provided in the identified awareness literature, above, can be converted into 
ICD-10 diagnoses and used to identify ICD-10 codes indicative of a potential 
cancer within pre-diagnosis HES inpatient episodes. The awareness 
resources used within this study span a range of publication dates, 2005 to 
present day, these fall both within and following the time period of this study 
(2004 to 2009). The resources are therefore used to retrospectively analyse 
the HES data for potential signs and symptoms of cancer preceding a 
diagnosis and this study is not aiming to critique these resources against 
contemporary healthcare events.     
 
4.8.4.2 Alert codes 
The „alert‟ symptoms identified from the awareness and early diagnosis 
sources outlined earlier within this chapter were collated into a single list of 
broad „alert‟ symptoms and signs and lists of ICCC diagnostic group specific 
„alerts‟ symptoms and signs.  
The main HES dataset was separated into twelve broad diagnostic groups 
according to the ICCC code taken from the YSRCCYP. The ICD-10 codes 
contained within each patient spells were extracted, collated and a list of 
bespoke codes for each of the diagnostic groups was generated. This was 
an important step due to the often unique and varied „alert‟ symptoms and 
signs identified within each specific diagnostic group, the ICD-10 codes were 
matched to the „alert‟ symptoms and signs on a group by group basis. The 
broad cancer „alert‟ symptoms and signs could be matched across the full 
dataset. All the extracted codes were labeled in-line with the following list of 
categories: 
A. ICD-10 code relevant to a specific „alert‟ symptom or sign of cancer in 
an ICCC diagnostic group.  
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B. ICD-10 code relevant to a broad „alert‟ symptom or sign of cancer in 
the CYA population.  
C. ICD-10 Cancer code.  
The categorised lists of ICD-10 codes were then independently reviewed by 
two reviewers; SK an expert in CYA haematology and SP an expert in CYA 
oncology, in order to validate the selection process. Any disputed codes 
were discussed and agreement on inclusion was achieved between 
reviewers. Once a complete list of broad and specific „alert‟ codes was 
identified the relevant codes were highlighted within the full HES data set 
using Stata. Episodes containing „alert‟ codes were identified and the 
potential relevance of the episode to the subsequent diagnosis of primary 
cancer could be assessed. 
4.8.4.2.1 Broad cancer diagnosis alert codes 
Once the ICD-10 codes were extracted from the pre-diagnosis episodes for 
the study cohort, a list of alert codes relating to the broad diagnosis of 
cancer was generated from the awareness campaigns outlined above. The 
list of broad alert symptoms is included within appendix 2 with the 
corresponding ICD-10 codes.  
4.8.4.2.2 Diagnostic group specific alert codes  
The specific alert ICD-10 codes identified within the pre-diagnosis episodes 
from the renal tumour population, ICCC group VI, are outlined below and 
provides an example for the method applied across all diagnostic groups, 
Figure 4.3.  
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Figure 4.3 Children and young adults Renal tumour early diagnosis sign and 
symptoms (white cells) with the matched ICD-10 codes and descriptions 
identified (grey cells) 
Early diagnosis & awareness resources HES inpatient data 
Symptoms Source Year ICD-10 code Description of code 
Painless mass Persistent or 
progressive distension 
NICE 2005 R222 Localized swelling, mass and lump, 
trunk 
Swelling in 
the abdomen 
Usually painless NICE 2005 R190 Intra-abdominal & pelvic swelling, 
mass & lump 
Haematuria   NICE 2005 R31X Unspecified haematuria 
Hypertension   Macmillan 2011 I10X Essential (primary) hypertension 
        I120 Hypertensive renal disease with 
renal failure 
fever   Macmillan 2011 R509 Fever, PUO 
Abdo pain   Macmillan 2011 M545 Low back pain 
        R103 Pain localized to other parts of 
lower abdomen 
        R104 Abdominal & pelvic pain - Other & 
UN 
wt loss   Macmillan 2011 R634 Abnormal weight loss 
Lack of 
appetite 
  Macmillan 2011     
Family 
History 
1 in 100 cases Macmillan 2011 Z805 Family history of malignant 
neoplasm of urinary tract 
 
A full list of specific alert codes is provided in appendix 3.  
4.8.4.3 Admission method 
The method of admission to a secondary care hospital is coded via the 
„admimeth‟ variable within the HES data. A two digit „admimeth‟ code is 
assigned to every inpatient HES episode (FCE), these fall into four broad 
categories:  
 Elective admissions include waiting list (11), booked (12), planned 
(13). 
 Emergency admissions  include A&E (21), GP (22), consultant clinic 
(24) and seven other codes.  
 Maternity admissions include ante-partum (31) and post-partum (32). 
 Other admissions include birth of a baby in this healthcare provider 
(82) or outside the healthcare provider (83.) 
4.9 Data analysis 
The linked data set was analysed using the statistical programme Stata 
(128). A copy of the Stata “do file” for each of the main commands relating to 
data analysis is included in appendix 4. 
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4.9.1 Summary statistics 
The descriptive analysis of the study population within section 5.2 of the 
results chapter include summary data on: the demographics of the 
population including age, sex and geography; the distribution of cancer 
diagnoses across the study population and period; and the patterns of 
inpatient events across the study population and study period.  
All data presented within this thesis or any publication relating to this thesis 
will be non-PID as discussed in section 4.7. Thus, all data are presented in a 
grouped format and contain a minimum of five cases.  
4.9.1.1 Analysis of episodes for alert code 
The time interval between the date of admission and the date of primary 
cancer diagnosis for each episode contained within the linked dataset was 
calculated using Stata.  
Each episode identified as containing an ICD-10 „alert‟ code was analysed 
and the TTD in days was generated as the number of days between episode 
start date and the date of definitive diagnosis. The frequency and distribution 
of alert code containing episodes was calculated. The population was 
therefore divided into those patients with alert code containing episodes and 
those with no alert code containing episodes. The cases with alert code 
events were further divided into those that appear to spend an appropriate 
time in secondary care and those that potentially have a more prolonged 
TTD, as defined by the 31 day threshold discussed in section 4.8.3.2. These 
sub-populations were then described in more detail and the variation in 
outcome between the populations analysed.  
The route of the presentation for each inpatient alert code event was taken 
as the initial admission route for the CIPS in which the alert code episode 
occurred. The admission route for the alert code containing episode was not 
used as multiple episodes can occur within CIPS and once a case has 
entered a CIPS, the admission codes for each included episodes will be 
transfer codes. The transfer codes give little information into how the case 
accessed the healthcare system. From these results, the route and duration 
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of the primary alert code containing episode was generated for the group of 
patients with alert codes episodes.   
 
4.9.2 Data cleaning 
The full dataset was cleaned using a bespoke set of Stata command codes 
designed to remove duplicated entries and identify missing or incorrectly 
coded dates within the HES date prior to analysis. Specific cleaning tasks 
focused on: 
 Duplicated episodes – Identified as episodes where the same 
admission date and discharge date contained the same ICD-10 codes  
 Missing admission dates – Identified as episodes with either no date 
recorded within the admission date variable or an inappropriate date 
such as before the patient‟s date of birth or the date 15th October 
1562, a date that incorrectly identifies a missing value in Stata.   
 Discharge dates – Some episodes did not have a discharge date due 
to the patient being transferred within the hospital. In this senario, 
dates were ordered for each patient and the discharge date for the 
sequence of events was used where the dates were missing.  
 Patients treated outside the FYRHA - The development of a visual 
representation of all episodes at a patient level was done to check for 
patients mistakenly recorded as receiving treatment within the 
FYRHA.  
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4.10 Survival analysis 
Survival estimates are often summarised as the proportion of a population 
alive at a specified period following diagnosis (120). The specified time 
periods vary depending on the focus of the research or the relative time-
scales afforded within the study period, in the majority of cases one, three or 
five-year survival rates are quoted. The longer measure of five-year survival 
is the most commonly quoted as it incorporates the effects of the disease, 
comorbidity, treatments and often overall patient management, therefore 
reflecting the long-term outcome or „cure‟.  
One-year survival has been used as a proxy for early/late diagnosis in adult 
cancers and as such is a proxy for stage at diagnosis (129). This has been 
widely adopted as an outcome measure in adult cancers, however the 
appropriateness of utilising short-term survival periods as proxy measures of 
early/late disease presentation in childhood and young adult cancers is 
highly debatable. As previously stated adult tumours are predominantly 
carcinomatous in origin, whilst most childhood tumours originate from 
embryonic tissue. The different origins result in different behaviour profiles 
and as such the rules and assumptions applied to adult populations are 
often not transposable to CYA cancers.  
Conducting survival analysis for a population requires careful consideration, 
for example not all participants will enter the study at the same time, 
participants may leave follow-up at variable time intervals and participants 
will die at variable time points. Survival analysis is widely used in medical 
research to study time lapse from a defined entry time point (e.g. diagnosis 
date) to an outcome or end-point. Survival times are referred to as censored 
if the lifespan of a case is not fully observed by the study end point; for 
example, if a participant lives beyond the end of the study, their observed 
lifespan ends at the study end point, but the true lifespan is unknown (130)..  
For the purpose of survival analysis within this project several assumptions 
are required: 
 All participants are subject to the same circumstances and the 
survival probability is the same if recruited early or late.  
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 The event has occurred at the recorded time point, in other words, all 
deaths within the population studied are accurately recorded with the 
YSRCCYP.  
Kaplan-Meier survival estimates (130), presented as a survival curve, is the 
most commonly used method to summarise time to event data within 
medical research. This is not a true curve but rather a step function where 
the steps represent the changes in survival probability over short time 
intervals within the study period. The probability of survival for each 
subsequent period is conditional on the probability of surviving all preceding 
time periods. The proportion of survivors therefore remains unchanged 
between events.   
The data requirements for a survival analysis within the population of 
patients within this study are: 
 Defined start date – date of definitive diagnosis of a primary cancer as 
recorded on the YSRCCYP. 
 Censoring date – the date at which the study period terminates. 
 The period of survival time to be studied – for this project this will be 
one and three-year survival. 
 Participants who have died during the study period. 
 Participants who have been lost to follow-up during the study period – 
due to the nature of registry data this is a very small proportion of 
cases estimated to be around 0.1% of cases. 
The survival analysis within this project was conducted using Stata statistical 
software (128). 1098 cases from the YSRCCYP were included if diagnosed 
with a primary tumour between the start of 2004 and the end of 2009. The 
censoring date for this analysis was the 31st of December 2012 allowing a 
full three year period to lapse from the most contemporary date of diagnosis 
for the cohort. The date of death was available for patients who died prior to 
31st December 2012, which was obtained from the YSRCCYP and an ONS 
flagging system.  Anyone without a date of death was assumed to be alive 
on the censoring date. One and three-year survival probabilities were 
estimated using Kaplan-Meier estimates for each diagnostic group, and 
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Kaplan-Meier curves were assessed for the following variables which were 
identified from the literature review: 
 Age at diagnosis 
 Sex 
 Route of engagement with secondary care relevant to subsequent 
cancer related event (defined by the admission method associated for 
the first alert code containing inpatient spell) 
 Time period of study: 2004-2006 vs. 2007-2009 
 Whether alert codes were present in the HES episodes prior to 
diagnosis (yes/no); did these alert codes occur within an appropriate 
time period preceding diagnosis (yes/no). 
Figure 4.4 Time to diagnosis and confounding variables for analysing  
survival in children and young adults with cancer 
 
Sex
Tumour 
DiagnosisAge
Survival
Time to 
Diagnosis
3
2
1
5
8
9
7
4
6
5. Age varies between the diagnostic groups 
6. Survival varies with age 
4. Age influences time to diagnosis 
9. Survival varies by tumour diagnosis 
7. Tumour diagnosis varies the 
age at presentation of a tumour 
1. Sex influences how people access healthcare
2. Sex influences the profile of tumours 
diagnosed – especially in TYA cancers
3. Sex influences survival as it is generally 
accepted girls do better than boys Year of 
Diagnosis11
10
8. Tumour diagnosis dictates presenting signs 
and symptoms potentially influencing TTD
10. Survival trends can vary over time
11. Time to diagnosis can change over time 
 
The independent effect of TTD upon survival will be estimated using Cox 
proportional hazards regression, whilst adjusting for confounding factors. 
Figure 4.4 shows the potential confounding factors for survival in CYA 
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cancers, as shown by previous literature (see Chapter 3). These variables 
are therefore incorporated within the survival analysis model. 
The Cox model makes no assumptions around the distributions of survival 
time, however it assumes the effects of different variables on survival are 
constant. Including age and year of diagnosis as continuous variables in the 
model will assume that these effects are linear in relation to survival. 
Therefore a likelihood ratio test will be used to determine if these 
assumptions are valid or not. If there is significant evidence against linearity 
then a categorical variable will be used instead.  
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4.11 Validation 
 
4.11.1 Introduction 
All clinical information analysed within this study was provided by HES data 
with the exception of the age, sex, date of diagnosis, the ICCC diagnosis, 
which were provided by the YSRCCYP. The clinical information within the 
HES data is collected by clinical coders from the medical records as 
discussed in section 0. Corroboration of the pre-diagnosis clinical 
information including the number of inpatient events, the clinical content of 
an event and the admission methods for an event was not possible for each 
case within the study cohort. Therefore a small sample of case-notes were 
reviewed across the range of diagnosis dates, diagnostic groups and ages 
contained within the study population.  
The aim of the validation process was to assess the correlation between the 
clinical notes and HES records in terms of frequency of events and important 
clinical information such as date of diagnosis. The validation process was 
not designed to validate the alert codes identified as part of this study or 
provide additional information on diagnostic or patient intervals. 
 
4.11.2 Methods 
A limited sample of 30 cases were identified from the 1098 cases within the 
study. Ideally given more time a larger more representative sample of 5-10% 
of the study cohort would have been reviewed in order to test for clear 
correlation between the case notes and HES data. The selection process 
was not random in order to generate a representative sample of case notes 
across the CYA cancer population studied between 2004 and 2009. A pro 
forma was developed that specified key comparator information collected 
from the clinical notes, including: 
 Date of Diagnosis 
 Diagnosis 
 Number of inpatient events 
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 Route of admission for referral for suspected cancer 
The YSRCCYP was used to identify patient demographics and these were 
used to identify the location of case notes using the Leeds General Infirmary 
PAS system. LTHT is the principle treatment centre for paediatric and TYA 
haemato-oncology in the FYRHA and has clinical notes for all patient treated 
at the centre, including copies of the primary case notes in most instances.  
The cases included leukaemia, lymphoma, CNS tumours, renal tumours, 
bone sarcomas, soft-tissue sarcoma, germ-cell tumours and carcinomas. 
The diagnosis dates reviewed included cases from each year between 2005-
2009, however no cases were reviewed from 2004. The ages of cases at 
diagnosis ranged from less than 6 months to 19 years of age. 
 
4.11.3 Findings 
The case notes for 15 of the 30 cases identified were located and reviewed, 
of the 15 not reviewed 8 had been transferred to a digital storage system 
and 7 were either in other case note libraries or untraceable within the time 
limits of the study. The 15 case notes reviewed were located either within 
the paediatric oncology departments dedicated case note filing areas or in 
one of the Leeds General Infirmary filing areas. In 11 out of the 15 sets of 
case notes reviewed there was a clear correlation between the number of 
HES events and the inpatient events identified within the notes. In all the 
cases in which there was discord between the case note events and HES 
events: more HES events were recorded than were identified within the case 
notes. Upon review of the HES events it would appear this is due to short 
attendances either for minor procedures or to an assessment unit. The 
clinical notes for such events may not migrate to the full clinical notes, 
alternativley the clinical coders have the superior skill and experience to 
identify such events within the notes. There is also a potential for incomplete 
information of pre-diagnosis events within the oncology case notes. Most 
contained information pertaining to the clinical events leading up to the 
referral but not necessarily prior to this. One case had a clear difference in 
the number of HES events and the events in the clinical notes which was 
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due to a chronic illness and the full history of inpatient involvement was not 
maintained within the oncology notes.  
The date of diagnosis, recorded as the date a specimen was taken that 
confirmed the diagnosis of cancer, was correctly recorded in all but two of 
the 15 cases. In one case there appeared to be a discrepancy of one day, 
while in the other case this was unclear as the medical records did not 
appear to be complete and I was unable to establish whether a biopsy had 
been taken prior to surgery.   
 
4.11.4 Conclusions 
The process of reviewing case notes was not straightforward and there were 
a number of issues that came to light including availability and completeness 
of the case notes and clinical information recorded within. From the limited 
review conducted it is difficult to draw clear conclusions on the correlation 
between the information in the case notes and HES data. Within the cases 
reviewed there appears to be a correlation between HES events and case 
note events and in some cases HES data appeared to record more events 
than the case notes, which is most likely due to the multiple sources of 
medical information that make up the case notes and not all sources 
merging successfully. There was a high correlation between the date of 
diagnosis recorded within the YSRCCYP and the specimen dates within the 
case notes. In order for clear conclusions to be drawn from the validation 
process a larger sample size of 5 to 10% of cases from the study population 
would be required, which was not possible within the time constraints of this 
study.   
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Chapter 5 Results 
5.1 Introduction 
The cohort of 1098 patients was identified from the Yorkshire Specialist 
Registry for Cancer in Children and Young People and these cases were 
linked to Hospital episodes statistics with a high degree of linkage (99.7%). 
Only 3 patients did not link and were not included within the study 
population. At this point it is important that the levels of data representation 
within this chapter are clearly defined. There are three main levels at which 
the data can be presented, outlined below: 
1. Case-level – Data presented at the case level will reflect results at an 
individual cancer patient level. The descriptive statistics for cases are 
outlined in section 5.2 and the YSRCCYP is the main data source for 
these results.  
2. Inpatient event level – As identified in Figure 4.1 the HES data can be 
divided into a number of different units depending on the healthcare 
structure being analysed. The dataset was analysed at the episode 
level data for the purposes of alert code identification given that each 
episode is summarised by a unique set of diagnosis codes. It 
therefore follows that each of the 1098 cases can have multiple 
episodes; the quantity and nature of which will be described within 
section 5.3. The dataset was analysed at a CIPS level for the purpose 
of admission route identification, a CIPS can be made up of multiple 
episodes and once the initial episode in a CIPS has passed, each 
subsequent episode will be punctuated by a transfer admission code. 
Therefore the admission code for the first episode within an alert code 
containing CIPS will be used to identify the admission method for that 
inpatient event.  
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3. Code-level – Each hospital episode contains a series of ICD-10 
diagnostic codes which are used to describe the hospital event, and a 
sequence of up to 20 ICD-10 codes can be used to describe the 
episode. The individual codes have been analysed in conjunction with 
national CYA cancer awareness resources in section 5.4. The aim of 
this analysis was to identify either diagnoses or symptoms suggestive 
of cancer within hospital episodes occurring prior to the date of 
definitive diagnosis. 
Combined analysis of codes, episodes and cases within this CYA cancer 
cohort will aim to identify those cases where there may have been hospital 
involvement suggestive of cancer prior to the date of definitive diagnosis. 
The time taken to receive a diagnosis for such highlighted cases will be 
described in section 5.5 and the effect on survival of a prolonged TTD within 
hospital care will be analysed in section 5.7. Finally the key findings are 
summarised in section 5.8. 
 
5.2 Descriptive statistics 
5.2.1 Demographic profile 
Dividing the cohort into the 12 broad ICCC diagnostic groups leukaemia is 
the most common diagnosis constituting around a quarter of the study 
population followed by lymphoma (17.9%), CNS tumours (16.6%) and Germ-
cell tumours (13.7%). The least common diagnosis being Other cancers 
(ICCC group XII), have been omitted from Table 5.1 due to the low level of 
cases, hepatic tumours and retinoblastoma were also very rare. The 
patterns of tumour incidence are generally in keeping with published data for 
the CYA population (24, 32).  
Table 5.1 summarises the number of cases and the incidence rates per 
million population within the study cohort. Included is the breakdown of 
cases by sex, five-year age ranges and broad ICCC diagnostic groups with 
the overall case number, percentage of the cohort and incidence rate per 
million. Overall 1098 cases of CYA cancer were included within the study 
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population there is a higher proportion of males than females (1.35:1). The 
crude incidence rates of cancer were highest at the extremes of age in this 
cohort: 206 per million in the very young (0 to 4-years inclusive) and 169 per 
million 20 to 24-year olds, lowest crude incidence rates seen in the 5 to 9 
year olds 102 per million. These crude incidence rates by sex and age are in 
keeping with those presented for children and young people in the current 
literature (3, 28, 36). 
 
Table 5.1 Case distribution by frequency, percentage cohort and crude 
incidence per million of the general population by sex, five-year 
bands and diagnostic group 
 
 
The number of cancer cases diagnosed each year fluctuated across the 
period of study, the peak being in 2005 when 125 cases were diagnosed 
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and a trough in 2008 when 88 cases of CYA cancer where diagnosed. A 
clear pattern across the study population could not be established, though 
the relatively narrow timescale restricts any firm conclusions to be made 
relating to the temporal changes in incidence. Figure 5.1 presents the year 
on year percentage changes in the number of cases diagnosed by each 
ICCC grouping using 2004 as a baseline. Whilst the absolute figures are not 
important it is worth noting the general uniform rates of cases diagnosed for 
each ICCC group across the study period, with the exception of the group 
IV/neuroblastoma population. The apparent sharp rise in the number of 
cases of neuroblastoma diagnosed from 2005 onwards is an outlier within 
the data and likely reflects how small variations within a small population of 
cases can result in high percentage changes, no specific interpretation of 
this pattern is apparent. The data in Figure 5.1 was presented due to the low 
number of cases in a number of subgroups when separating the study 
population by year of diagnosis and diagnostic group, thus avoiding 
potentially patient identifiable data being presented. 
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Figure 5.1 Trends in incidence by diagnosis 2004-2009  
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Figure 5.2 Cancer in 0 to 24 year-olds in Former Yorkshire Regional Health Authority by five year age bands (%) 
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Figure 5.2 presents the breakdown of cases by diagnostic group within the 
five-year age bands across the study population, this graph elaborates the 
variation in case profile across age in the study cohort. In the younger 
population 0 to 4-years at diagnosis there is a clear predominance of 
leukaemia which contributes over a third of cancer diagnoses with other 
solid tumours such as CNS tumours, neuroblastoma, retinoblastoma, renal 
tumours and soft-tissue sarcoma also featuring. The predominance of 
leukaemia continues in the 5 to 9-years group, where there appears to be a 
higher proportion of CNS tumours and lymphoma with a reduction in some of 
the aforementioned paediatric solid tumours. The proportion of CNS tumours 
subsequently reduces with increasing age similar to leukaemia, however 
both these diagnoses are still major contributors to the cancer burden across 
all age ranges within the study population. The percentage of lymphoma 
diagnoses markedly increases within the 10 to 14 year age group and this 
increase is sustained in the older age-ranges. There is a steady increase in 
the contribution of germ-cell tumours and carcinoma within the 15 to 24 year 
population. Figure 5.2 highlights the challenge of analysing the CYA 
population and how clearly the profiles of cancer diagnosis and 
subsequently the biology and behaviour of tumours changes with age.    
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5.3 Hospital events 
5.3.1 Inpatient events 
The 1098 cases that met the inclusion criteria for this study were linked to 
nearly 30,000 inpatient HES episodes. These case were further restricted to 
only those episodes for which the episode start date preceded or coincide 
with the date of definitive diagnosis of a primary cancer, hereafter such 
episodes will be referred to as “pre-diagnosis episodes” (n=3,558). From the 
1098 eligible cases, these included 47 cases which were identified as having 
no pre-diagnosis inpatient episodes. The median age at diagnosis for these 
47 cases was 22 years, whilst a diagnosis of either a germ-cell tumour or 
carcinoma, more commonly seen in TYAs, was present in 23 cases. These 
cases were incorporated within the overall descriptive analysis and survival 
analysis but were excluded from episode and code level analysis.  
The cases with no pre-diagnosis inpatient involvement included: 16 germ-
cell tumours, 8 lymphomas, 7 carcinomas, 6 leukaemias and 5 or fewer 
cases with soft-tissue sarcoma, bone sarcoma and CNS tumours. No cases 
were represented in the neuroblastoma, retinoblastoma, renal and other 
tumour groups. The age of these 47 patients ranged from 2.6 to 24.9 years 
and the median age at diagnosis was 21.5 years with a mean of 12.7 years. 
This suggests a skewed distribution towards an older age at diagnosis for 
these cases.     
 
5.3.1.1 Pre-diagnosis events 
Figure 5.3 presents the frequency of pre-diagnosis inpatient episodes by the 
year according to the episodes starting date. The highest frequency of 
episodes occur during the years corresponding to the inclusion criteria for 
date of definitive diagnosis; 2004 to 2009 inclusive. No episodes were 
included beyond the end of 2009 as they will all occur after the date of 
diagnosis of the final case. The steady increase in episodes toward 2004 
most likely reflects the year on year addition of cases as more children are 
born. It is worth noting the 13 year time span of pre-diagnosis inpatient 
events highlighted within the HES episodes for this study cohort. 
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Figure 5.3 Frequency of pre-diagnosis inpatient episodes by year (taken from the episode start date) 
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Figure 5.4: Year of pre-diagnosis inpatient episode occurrence (taken from episode start date) by year of definitive diagnosis 
of cancer  
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Figure 5.4 presents the stacked percentages for the year a pre-diagnosis 
episode occurred separated into the year of definitive cancer diagnosis. This 
highlights that the majority of pre-diagnosis inpatient episodes occurred in 
the same year as the case was diagnosed. 
The frequency of episodes only portrays parts of the picture and as stated in 
the introduction a single case can have multiple pre-diagnosis episodes. 
From the 1098 cases identified 47 were found to have no inpatient episodes 
in the linked HES dataset, out of the remaining 1051 cases with pre-
diagnosis inpatient involvement the maximum number of episodes per 
patient was found to be 62. Figure 5.5 is a box (median and inter-quartile 
ranges Q1-Q3) and whisker (Q3+1.5*(Q3-Q1) and Q1-1.5*(Q3-Q1) plot of total 
inpatient episodes per case by sex for each of the five year age-groups, the 
data are summarised in such a manner due to the highly skewed distribution 
of the pre-diagnosis inpatient episodes per case. There were statistically 
significant differences in the median number of pre-diagnosis inpatient 
episodes between the five age-range groups based on the Kruskall-Wallis 
test (p=0.001): a median of three episodes per case in children under 10 
years old at diagnosis compared to a median of two pre-diagnosis episodes 
per case in the older cases (10-14, 15-19, 20-24). The median number of 
pre-diagnosis episodes is the same between the sexes for each age group 
with the exception of 20 to 24 years olds for whom females have a higher 
median of three episodes compared to two for males. Females in the 20 to 
24 year age group also have a markedly wider inter-quartile range (0 to 12 
pre-diagnosis episodes) compared to all other age and sex categories. 
The findings of variation in the number of pre-diagnosis episodes by age-
bands could reflect the interaction between age and the underlying 
diagnosis, Figure 5.6 indicates variations in the median number of pre-
diagnosis episodes per case by sex for each ICCC diagnostic group. The 
largest median number of pre-diagnosis episodes per case occurs in 
paediatric solid tumours such as neuroblastoma, hepatic tumours and renal 
tumours. The lowest median pre-diagnosis episodes per case are seen in 
tumours which predominate in the young adult populations such as 
carcinoma, germ-cell tumours, bone sarcoma and lymphoma. The reduced 
secondary care involvement in the aforementioned tumour groups may 
- 97 - 
 
 
reflect different patterns of healthcare engagement within TYAs. Another 
potential explanation for the differences in pre-diagnosis inpatient episodes 
by age-range and diagnosis is incomplete recording of pre-diagnosis 
inpatient events within increasing age. The earliest year of inpatient 
involvement was 1996, see Figure 5.3, suggesting there is incomplete data 
availability due to the poor quality of information available prior to this date. 
This variability in inpatient episodes with time is likely to reflect the evolution 
and implementation of HES and coding within healthcare structures. There is 
a roughly similar distribution presented between the sexes for each 
diagnostic group with the exceptions of neuroblastoma and soft-tissue 
sarcoma where there are wider inter-quartile ranges in the males compared 
to females, whilst the reverse is seen in the germ-cell tumour population.  
The admission route, coded in HES by the „admimeth‟ variable, may give an 
indication of the extent of missing data as age increases, particularly 
focusing on admissions assigned to birth and maternity involvement. The 
number of episodes by admission method is summarised in the Figure 5.7. 
Admission method codes relating to maternity services admissions 
(admimeth 31,32) and admission for birth (admimeth 82,83) are presented in 
Figure 5.7 as “Maternity” (admimeth 31, 32) and “Other” (admimeth 82,83). 
When considering these two admission methods for pre-diagnosis episodes 
between the age-ranges there are clear opposing patterns seen with 
maternity codes peaking in the older age group 20-24 and other codes in the 
0-4 age, see table 5.2. The predominance of codes relating to a case being 
born and classified as “other” in the 0 to 4 years age range is the most likely 
explanation for the statistically significant difference in the distributions of 
total pre-diagnosis inpatient episodes by age range. This finding reflects the 
incomplete availability of data relating to birth for the older cases within the 
study cohort.  
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Table 5.2 Admission method by age at definitive diagnosis in five-year 
age bands, all pre-diagnosis episode level data  
5-year age bands
0 to 4 5 to 9 10 to 14 15 to 19 20 to 24
Emergency A&E 212 121 114 181 215
Emergency GP 149 73 65 63 91
Emergency Outpatient 19 9 18 26 31
Emergency Transfer 124 36 53 40 36
Elective 243 98 216 302 316
Transfer 134 71 48 36 26
Maternity ≤5 0 0 19 103
Other 250 53 ≤5 0 0
Not Known ≤5 0 ≤5 0 0
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Figure 5.5 Box and whisker plot of number of pre-diagnosis episodes per case of children and young adults cancer by 5 year 
age bands  
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Figure 5.6 Box and Whisker plot of number of pre-diagnosis episodes per case of children and young adults cancer by sex 
and diagnostic group 
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Figure 5.7 Frequency of pre-diagnosis inpatient events by admission method 
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5.3.2 Outpatient events 
Outpatient HES episodes were linked to the YSRCCYP data, and are 
contained in a separate dataset to the inpatient data.  
5.3.2.1 Pre-diagnosis events 
The appointment date variable was used in a similar fashion to the episode 
start date and pre-diagnosis episodes were separated if the appointment 
date preceded or coincided with the date of definitive cancer diagnosis. 
There were 4,353 pre-diagnosis outpatient episodes identified within the 
HES data for the study population. Only 790 cases had pre-diagnosis 
outpatient HES events from the 1098 cases in the study cohort. The 
attendance code variable was used to highlight appointments that were 
attended, the exclusion of non-attended appointments reduced the overall 
number of pre-diagnosis outpatient appointments to 3,648. Figure 5.8 
presents the number of pre-diagnosis outpatient appointments attended by 
ICCC diagnostic group. There is a predominance of the first three tumour 
groups as with the inpatient data, however there are fewer appointments 
seen in the paediatric solid tumour population compared to the germ-cell and 
carcinoma groups, which is in contrast to the inpatient data.  
The priority of the requested outpatient appointment may help identify those 
appointments for cases where a cancer is suspected. The two week referral 
pathway for suspected cancer applies in the CYA population as with adults, 
however within this study population only 10 pre-diagnosis outpatient 
appointment were coded as two week cancer referrals. This identifies either 
an extremely poor uptake of the pathway by referring doctors in CYAs 
suspected of cancer or a deficiency in coding of this pathway. 
In reviewing the diagnostic coding data within the outpatient events it is clear 
that there is no effort made by the coder to reflect the clinical events of the 
appointment as all codes are either R69X6 or R69X8 both falling into the 
category of “unknown or unspecified causes of morbidity”. The analysis of 
outpatient data for the presence of pre-diagnosis alert codes events was 
therefore not possible within this study. 
- 103 - 
 
 
Figure 5.8 Frequency of pre-diagnosis out-patient appointments and number of cases with pre-diagnosis out-patient 
appointments by diagnostic group (excluding group XII)  
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5.4 Diagnosis and symptom codes suggestive of cancer 
This section will provide results of the analysis of ICD-10 codes contained 
within the pre-diagnosis inpatient episodes. This analysis will focus on ICD-
10 codes identified as potentially relating to the subsequent diagnosis of 
cancer, as referenced against national CYA cancer awareness campaigns 
identified in section 4.8.4. The linked outpatient dataset will not feature within 
this section due to the lack of adequate presentation of ICD-10 codes within 
this data as discussed in section 4.8.3. The data within this section will be 
presented at a code level, codes per episodes or codes per case level. The 
section will comprise four main sub-sections: the first section will briefly look 
at ICD-10 cancer codes occurring prior to the definitive cancer diagnosis as 
recorded by the YSRCCYP, the second section is describes the identified 
pre-diagnosis codes relating to a broad diagnosis of cancer and as such will 
be referred to as “broad diagnosis alert codes”, the third section related to 
those codes relevant to each specific ICCC diagnostic group and as such 
will be referred to as “diagnosis specific alert codes”. Finally, the fourth 
section will bring together the broad diagnosis alert codes and the diagnosis 
specific alert codes to discuss the TTD for CYA cancer within the study 
population. 
At the outset of this stage of analysis it is important to refer back to the 
background section. The ICD-10 classification system provides the codes for 
the HES episodes and up to 20 ICD-10 codes can be as used to provide a 
clinical description of an inpatient episode. The ICD-10 coding system is 
predominant based around diagnosis codes however there are symptom 
codes within the R section of the system. As discussed in section 4.8.4.2 the 
symptom codes are only present within episodes where a symptom or sign 
appears that cannot be directly attributed to the underlying diagnosis for that 
episode. For example, if a case has a headache recorded within an episode 
but the episode related to a lower respiratory tract infection the headache 
will be recorded by the coder.  
Table 5.3 summarises the number of ICD-10 codes, the pre-diagnosis 
inpatient episodes and the number of cases by the ICCC diagnostic group. 
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Table 5.3 Summary table of frequency of pre-diagnosis ICD-10 codes, 
inpatient episodes and cases by diagnostic groups  
 
 
5.4.1 ICD-10 codes relevant to a diagnosis of cancer 
The difference in the date of diagnosis and a C-code date is given in section 
4.8.3.2.  A high proportion (29%) of the total number of episodes contained a 
C code: 1,018 C-code containing episodes from the 3,558 pre-diagnosis 
episodes. Figure 5.9 presents stacked percentages of episodes by C code 
status for each diagnostic group excluding group 12. Leukaemia, 
retinoblastoma, bone tumours and carcinoma all have C codes present in 
greater than 30% of the pre-diagnosis episodes. 95% of the C code 
containing episodes occur within the month preceding diagnosis though 
there are cases which have C code containing episodes as long as 2 years 
prior to the date of definitive cancer diagnosis. The lymphoma, CNS 
tumours, retinoblastoma and germ-cell cases all contain C codes at a 
duration of more than a month preceding the date of definitive cancer 
diagnosis.       
Diagnostic group Number of Codes Number of Episode Number of Cases
Leukaemia 1808 736 262
Lymphoma 1419 707 196
CNS tumours 1296 686 182
Neuroblastoma 458 201 41
Retinoblastoma 85 63 19
Renal Tumours 490 196 38
Hepatic Tumours 291 96 15
Bone Tumours 230 139 62
Soft-Tissue Sarcoma 429 228 67
Germ-Cell Tumours 629 347 150
Carcinoma 405 200 63
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Figure 5.9 The cancer codes (ICD-10 C codes) status (present or not) of pre-diagnosis inpatient episodes for children and 
young adult cancers in FYRHA by diagnostic group (stacked percentages of total pre-diagnosis episodes per 
diagnostic group) 
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5.4.2 Diagnostic and symptom codes suggestive of a general 
cancer diagnosis 
The NICE 2005 referral guidance and the TCT awareness campaign provide 
the majority of awareness resource relevant to a broad diagnosis of cancer, 
see appendix 2. 64 broad cancer alert codes were identified by cross 
referencing the awareness resource against the 1402 unique ICD-10 codes 
extracted from the pre-diagnosis episodes for the study population of 1051 
cases with pre-diagnosis inpatient episodes. Of the 64 identified codes over 
half occurred in more than five cases within the population (n=34). Figure 
5.10 summarises those broad cancer alert codes which occur in five or more 
cases within the study population. The ICD-10 symptom codes or “R” codes 
provided 24 of the 34 codes presented in Figure 5.10.  There are four ICD-
10 codes presented in Figure 5.10 that related directly to the investigation or 
treatment of cancer or a personal or family history of cancer. These codes 
were included within the analysis to provide quality markers for the HES 
data, identifying pre-diagnosis episodes where cancer was suspected or 
treatment for cancer was already underway. Such codes were included to 
identify cases where the diagnosis of cancer was known well before the 
definitive diagnosis was made, however the occurrence of such codes 
appear to coincide closely with the date of definitive diagnosis.   
The three most common ICD-10 codes contained within the codes relevant 
to a broad cancer diagnosis are related to “Constipation”, “Abdominal & 
pelvic pain” and “Headache. It is also apparent that the number of cases with 
alert codes is similar to the number of episodes with alert codes as one can 
see by the close correlation of the two bars in general in Figure 5.10. This 
reflects the fact that each broad alert code only occurs once within the pre-
diagnosis codes for each cases. 
Figure 5.10 presents the longest, the shortest and the median duration of 
time from the point of initial occurrence of a broad alert code to the date of 
definitive diagnosis, this is presented as case level data. For a number of 
broad cancer alert codes there are outlier cases for whom that code is 
present long before date of definitive diagnosis, however in the majority of 
cases when a broad alert codes occurs it is within close proximity to the date 
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of definitive diagnosis, as reflected by the proximity of the median TTD to the 
date of diagnosis. Codes that appear to have a median TTD well before the 
date of definitive diagnosis include; “Heamoptysis”, “Abnormalities of 
breathing”, “ Pain localised to other parts of the lower abdomen” and 
“Abdominal and pelvis pain”. 
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 Figure 5.10 Frequency of pre-diagnosis broad cancer diagnosis alert code containing episodes by episodes and case 
presented along-side the longest, median and shortest duration of time between the first occurrence of such episodes 
at case level  
 
0 20 40 60 80 100
Frequency
Family history of malignant neoplasm of other organs
Chemotherapy session for neoplasm
Observation for suspected malignant neoplasm
Other antineoplastic drugs
Abnormality of diagnostic imaging - Intracranial SOL
Abnormal weight loss
Feeding difficulties and mismanagement
Enlarged lymph nodes - Generalised
Localized enlarged lymph nodes
Malaise and fatigue
Headache
Fever, PUO
Unspecified haematuria
Spontaneous ecchymoses
Localized swelling, mass and lump, unspecified
Localized swelling, mass and lump, trunk
Localized swelling, mass and lump, neck
Localized swelling, mass and lump, head
Intra-abdominal & pelvic swelling, mass & lump
Nausea and vomiting
Abdominal & pelvic pain - Other & UN
Pain localized to other parts of lower abdomen
Chest pain, unspecified
Other chest pain
Abnormalities of breathing
Dyspnoea
Cough
Haemoptysis
Epistaxis
Pain of limb
Low back pain
Pain in joint
Haemorrhage of anus and rectum
Constipation
Compression of vein
Cases with Alert code
Episodes with Alert code
0-1-2-3-4-5-6-7-8-9-10-11-12
Time to diagnosis from first alert code
occurrence at a case level - Years
Shortest TTD Median TTD
Longest TTD
Longest TTD 
(Days)
Median TTD 
(Days)
Shortest TTD 
(Days)
-3 -1 -1
-3052 -2 0
-2653 -5 0
-3301 -16 -1
-3103 -7 -1
-542 -7 -1
-405 -1 -1
-1405 -277 -7
-1779 -18 -2
-40 -3 0
-1371 -633 -1
-2541 -17 0
-2250 -14 -1
-2064 -739 -3
-4187 -119 0
-3745 -15 0
-92 -7 0
-1150 -4 0
-171 -10 0
-63 -6 -1
-2434 -8 -1
-1634 -2 0
-126 -6 -1
-2841 -3 0
-3039 -9 0
-1494 -7 -1
-1620 -6 0
-1082 -6 0
-1615 -63 -2
-1590 -7 -2
-3102 -9 0
-259 -1 0
-63 -4 0
-253 -1 0
-3 -1 0
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5.4.3 Diagnostic and symptom codes suggestive of a specific 
cancer diagnosis 
When analysing the 1402 unique ICD-10 codes for their potential relevance 
to a specific cancer diagnoses, the data had to be segregated by ICCC 
diagnosis, resulting in the generation of twelve separate datasets. This was 
necessary due to the constraints of Stata12 programming. From the twelve 
diagnostic groups 216 unique ICD-10 codes were identified across the study 
cohort, Table 5.4 presents the number of alert codes identified for each 
ICCC diagnostic group, group XII is not presented as there was no available 
awareness literature and less than five cases overall. The diagnosis specific 
alert codes occurring in five or more cases are presented in Table 5.4.  
 
Table 5.4 The number of diagnosis specific alert codes in all cases and 
the number of diagnosis specific alert codes occurring in five or 
more cases by diagnostic groups 
 
 
Diagnosis specific alert codes for the 262 cases within the leukaemia 
population are presented in Figure 5.11, these codes predominantly relate to 
either pain or some degree of haematological deficiency. Eight of the twelve 
ICCC-3 group
Unique Diagnosis Specific
Alert Codes
Codes occurring 5 or more 
cases
Leukaemia 28 12
Lymphoma 49 11
CNS tumours 58 8
Neuroblastoma 17 1
Retinoblastoma 4 0
Renal Tumours 11 3
Hepatic Tumours 4 0
Bone Tumours 19 1
Soft-Tissue Sarcoma 15 2
Germ-Cell Tumours 25 4
Carcinoma 6 0
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codes presented in Figure 5.11 occur in close proximity to the date of 
definitive diagnosis, of the remaining four only “Down‟s syndrome” appears 
to have a prolonged median time between first occurrence and diagnosis. 
The presence of Down‟s syndrome within the specific alert codes for 
leukaemia is based around the NICE referral guidance that advises a doctor 
should have increased awareness of this cancer type in children with Down‟s 
syndrome (125). This code applies to the diagnosis of Down‟s syndrome 
which is made early in a child‟s life, it therefore appears during all the 
inpatient events and will be coded in HES episodes from the point a 
diagnosis is made. Where present, this alert codes will result in an apparent 
long TTD for a case.  
“Agranulocytosis” is by far the commonest diagnosis specific alert code 
within the leukaemia population and is applied to a finding of a severe 
deficiency of white blood cells called granulocytes. Within the ICD-10 system 
this code most commonly relates to the deficiency of a specific granulocyte 
called the neutrophil, severe deficiency of which can result in life threatening 
immune-suppression. Agranulocytosis can occur in certain autoimmune 
conditions common or viral and bacterial infections or as a side-effect of 
drug therapy, however it can also occur due to bone marrow infiltration often 
seen at diagnosis in the leukaemia‟s and as a result of bone marrow 
suppression secondary to the effects of chemotherapy (131). This code 
occurs in 99 cases prior to the date of diagnosis, the median duration 
between the first occurrence of this code and the definitive diagnosis is just 
one day. The first occurrence within this population is over two years prior to 
diagnosis in a case where there is an underlying diagnosis of aplastic 
anaemia a condition which can predispose to the development of leukaemia.    
Within the lymphoma cases (n=196) a total of 49 diagnosis specific alert 
codes were identified, see Figure 5.12. Eleven of the forty-nine codes 
occurred in five or more cases of which 10 were R codes relating to 
symptoms and signs not elsewhere classified, the other code being 
“agranulocytosis” a code discussed in the previous section on the leukaemia 
cases. The commonest pre-diagnosis specific alert codes in the lymphoma 
population was “enlarged lymph nodes-generalised” followed by “abdominal 
pain”, “agranulocytosis” and “localised swelling, mass and lump, neck”.  
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“Fever, PUO” and “abdominal & pelvic pain” were the only two codes for 
which the median duration from first occurrence to date of definitive 
diagnosis was greater than 14 days. The longest duration of time between 
first occurrence to definitive diagnosis for these two codes was greater than 
six-months prior to diagnosis, as was case for “enlarged lymph nodes-
generalised” and “abnormal diagnostic imaging of the lung”. This all adds to 
the picture of common lymphoma specific alert codes occurring in close 
proximity to the date of definitive diagnosis. Though the predominance of R 
codes highlights the presence of unexplained symptoms or signs within the 
inpatient episodes for these case preceding diagnosis. 
The CNS tumour population had the most diagnosis specific alert codes; 58 
codes. This was possibly due to increased pre-diagnosis signs and 
symptoms suggestive of cancer within this population or alternatively the 
extent of the awareness literature in this tumour type relevant to CYA‟s, see 
Figure 5.13. Indeed the HeadSmart campaign provides CNS tumour specific 
awareness advice for 0 to 18 year olds. Within the CNS specific alert codes 
codes a number relate to the diagnosis of epilepsy, headache, cranial nerve 
palsies, hydrocephalus as well as a number of R codes. There are also 
codes relevant to the underlying diagnosis of Tuberous Sclerosis and 
Neurofibromatosis. From the 58 diagnosis specific alert codes identified only 
eight appear in five or more cases. However, when grouping codes of a 
similar nature; codes relevant to epilepsy appeared in 29 cases, specific 
diagnoses of “headache or migraine” appeared in five cases, “focal 
neurological signs” were present in 24 case and symptoms or signs not 
elsewhere classified were present in 101 cases. The “epilepsy” and 
“convulsion” codes have a high ratio of episodes to cases, indicated by the 
height of the episodes bar comparative to the cases bar in Figure 5.13, 
suggesting these codes appear multiple times for each case prior to the date 
of definitive diagnosis. For “epilepsy” this finding is understandable as it is a 
known diagnosis, however “convulsion” is an R code which suggests its 
occurrence within an episode is unexplained. Couple this with the finding 
that the median duration between first occurrence of a “convulsion” codes 
and definitive diagnosis is more than one year identifies this code as a 
potentially concerning alert code within the CNS population. The codes 
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relevant to a diagnosis of epilepsy also appear to have a prolonged duration 
of time between first occurrence and definitive diagnosis, however the 
median duration for the other commonly occurring codes appears to be 
short. 
From the 115 cases of solid tumours that predominate in childhood; 
neuroblastoma, retinoblastoma, renal tumours and hepatic tumours, only 35 
disease specific alert codes were identified. Only four codes were contained 
within five or more cases, with no codes present from the retinoblastoma or 
hepatic tumour groups, see Figure 5.14. The 41 neuroblastoma cases only 
yielded a total of 17 diagnosis specific alert codes and from these only “intra-
abdominal & pelvic swelling, mass & lump” was a common code in five or 
more cases. This code only occurred in close proximity to the date of 
definitive diagnosis. The renal tumour group comprised 38 cases and 
yielded 10 diagnosis specific alert codes with three occurring in five or more 
cases. “Intra-abdominal & pelvic swelling, mass & lump” was the most 
frequent diagnosis specific alert code featuring in 15 cases preceding 
diagnosis and at a frequency of once per case. All the commonly occurring 
renal tumour specific alert codes occurred in close proximity to the date of 
diagnosis. 
The Bone Cancer Research Trust provides a specific awareness resource 
for bone tumours in CYA‟s and in combination with the NICE 2005 referral 
guidance identified nineteen diagnosis specific alert codes in the 62 bone 
tumours cases. Codes relating to pain were present prior to diagnosis in 
eight cases, six cases had codes referencing a bony injury, four codes in 
four cases related to the mechanism of injury such as a fall and four codes 
present in five cases related to abnormalities of musculoskeletal imaging. 
Only “Pain in joint” appeared in five or more cases with a median duration 
from first occurrence to definitive diagnosis of 11 days, however the longest 
duration between the first occurrence of this code and definitive diagnosis 
being 1.6 years, however there was no further inpatient involvement for this 
particular case until the time immediately preceding diagnosis. This case 
highlights the fact that this study only provides a part of the healthcare 
pathway to diagnosis due to the focus on secondary care. 
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Soft-tissue sarcoma awareness resources were limited to the NICE 2005 
guidance, which identified fifteen diagnosis specific alert codes present in 
the pre-diagnosis episodes of the 67 included cases. In a similar manner to 
the bone sarcoma population only one code appeared in five or more cases 
and was the “Intra-abdominal & pelvic swelling, mass & lump” code seen in 
several other tumour groups. Due to the varied primary presenting site of 
STS in CYA‟s there was a wide range of anatomical sites included within the 
diagnosis specific alert codes included were codes relevant to pathology in 
the ear, nose and throat, cranial nerves, genitourinary system and 
musculoskeletal system. 
Germ-cell tumours are the fourth most common diagnostic group 
contributing 150 cases to this study. This is a diagnosis that can affect any 
age, although the peak incidence is in the infant and then teenagers and 
young adults. Germ-cell tumours can present at a variety of sites around the 
body though they predominantly appear in the sex organs, along the midline 
of the body and in the central nervous system. The awareness information 
for germ-cell tumours was taken from NICE 2005 referral guidance, the TCT 
awareness campaign, Macmillan website and also incorporated awareness 
resources relating to CNS tumours. These resources identified 25 diagnosis 
specific alert codes within the codes extracted from the pre-diagnosis 
episodes: 19 cases contained codes relating to the central nervous system, 
23 cases contained codes relating to the abdomen and 24 cases contained 
codes specifically relevant to either the male or female genitourinary 
systems. Only four codes were present in five or more cases, the most 
common being “other specified disorders of male genital organs” present in 
14 cases, “other and unspecified ovarian cysts”, “abdominal & pelvic pain” 
and “intra-abdominal & pelvic swelling, mass & lump” each occurred in five 
cases, see Figure 5.14. The duration of time between first occurrence and 
diagnosis was prolonged for “abdominal & pelvic pain” with a median 
duration of more than four years preceding diagnosis. The longest duration 
between first occurrence of a code and diagnosis being over 10 years seen 
in “other specified disorders of the male genital organs”, however the median 
duration in cases containing this code was one day. 
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There was very limited awareness literature available for the carcinoma 
group, which is the predominant cancer in adults. The awareness literature 
for the adult cancers however is based on the primary site of a cancer and 
was not always relevant to this study population, as such the awareness 
resources used in the analysis were limited to the diagnosis of thyroid 
carcinoma. Only six diagnosis specific alert codes were identified using the 
applied methods and none of these occurred in five or more of the 63 
carcinoma cases included within the study cohort.                       
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Figure 5.11 Frequency of pre-diagnosis leukaemia specific alert code containing episodes occurring in five or more cases by 
episodes frequency and number of cases presented along-side the longest, median and shortest duration of time 
between the first occurrence of such episodes at case level  
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Frequency
Malaise and fatigue
Spontaneous ecchymoses
Hepatosplenomegaly
Splenomegaly
Down's syndrome
Pain of limb
Low back pain
Pain in joint
Agranulocytosis
Thrombocytopenia
Anaemia
Aplastic anaemia
Cases with Alert code
Episodes with Alert code
0-1-2-3-4-5-6-7-8
Time to diagnosis from first alert code
occurrence at a case level - Years
Shortest TTD Median TTD
Longest TTD
Longest TTD 
(Days)
Median TTD 
(Days)
Shortest TTD 
(Days
-841 -2 0
-29 -1 0
-6 -1 0
-841 -1 0
-24 -2 -1
-3103 -6 -1
-55 -13 -1
-2425 -630 0
-6 -2 0
-3 -2 -1
-7 -2 0
-13 -2 -1
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Figure 5.12 Frequency of pre-diagnosis lymphoma specific alert code containing episodes occurring in five or more cases 
by episodes frequency and number of cases presented along-side the longest, median and shortest duration of time 
between the first occurrence of such episodes at case level  
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Abnormal diagnostic imaging of lung
Abnormal weight loss
Enlarged lymph nodes - Generalised
Fever, PUO
Localized swelling, mass and lump, trunk
Localized swelling, mass and lump, neck
Ascites
Abdominal & pelvic pain
Chest pain, unspecified
Dyspnoea
Agranulocytosis
Cases with Alert code
Episodes with Alert code
0-1-2-3-4-5-6-7-8
Time to diagnosis from first alert code
occurrence at a case level - Years
Shortest TTD Median TTD
Longest TTD
Longest TTD 
(Days)
Median TTD 
(Days)
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(Days)
-171 -1 0
-40 -3 -1
-63 -8 -1
-2467 -179 -1
-14 -3 -1
-171 -10 0
-58 -8 -2
-2262 -963 -1
-1082 -8 0
-14 -6 -2
-431 -8 -2
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Figure 5.13 Frequency of pre-diagnosis Central Nervous System tumour specific alert code containing episodes occurring in 
five or more cases by episodes frequency and number of cases presented along-side the longest, median and shortest 
duration of time between the first occurrence of such episodes at case level  
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Convulsion
Headache
Dizziness and giddiness
Nausea and vomiting
Hydrocephalus in neoplastic disease 
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Epilepsy
Generalized idiopathic epilepsy & epileptic syndromes
Cases with Alert code
Episodes with Alert code
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Time to diagnosis from first alert code
occurrence at a case level - Years
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(Days)
Median TTD 
(Days)
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(Days)
-1548 -177 -4
-3039 -439 -1
-32 -3 -1
-12 -3 -1
-703 -9 0
-2342 -18 -2
-3039 -11 0
-3215 -348 0
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Figure 5.14 Frequency of pre-diagnosis specific alert code containing episodes occurring in five or more cases by episodes 
frequency and number of cases all other diagnostic groups presented along-side the longest, median and shortest 
duration of time between the first occurrence of such episodes at case level 
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Germ-cell
STS
Bone
Renal
Neuroblastoma
Intra-abdominal & pelvic swelling, mass & lump
Abdominal & pelvic pain - Other & UN
Other and unspecified ovarian cysts
Other specified disorders of male genital organs
Intra-abdominal & pelvic swelling, mass & lump
Pain in joint
Unspecified haematuria
Intra-abdominal & pelvic swelling, mass & lump
Essential (primary) hypertension
Intra-abdominal & pelvic swelling, mass & lump
Cases with Alert code
Episodes with Alert code
0-1-2-3-4-5-6-7-8-9-10-11
Time to diagnosis from first alert code
occurrence at a case level - Years
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-45 -8 0
-12 -6 -4
-92 -8 -2
-126 -6 -1
-612 -12 -9
-56 -6 -1
-3900 -1 0
-20 -1 0
-2128 -1629 -4
-37 -24 -1
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5.5 Time to diagnosis and codes suggestive of cancer 
This section will bring together the three levels of analysis discussed in the 
results so far, to analyse TTD for those CYA cancer cases with alert code 
containing episodes preceding the date of definitive cancer diagnosis as 
recorded in the YSRCCYP. The section will also describe the broad cancer 
diagnosis alert code containing episodes and the diagnosis specific alert 
code containing episodes and refer to the combined as alert code episodes. 
It was not possible to preserve in a single combined data all the diagnosis 
specific alert code variables generated in the diagnosis specific datasets 
analysed in section 5.4. Therefore the episodes containing the diagnosis 
specific alert codes were tagged within each of the diagnosis specific 
datasets and this variable was added to the full cohort dataset, thus limiting 
the analysis to specific alert codes across the full cohort.   
Figure 5.15 presents the episodes by alert code status for the 11 main ICCC 
diagnostic groups. This graph reflects the findings of the group specific 
analysis in section 5.4 and the fact that in all groups there was a 
predominance of non-alert code containing episodes. 
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Figure 5.15 Frequency of pre-diagnosis alert codes episodes and non-alert codes episodes by diagnostic group 
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Figure 5.16 outlines the distribution of cases with alert codes and the 
proximity of alert code episodes to the date of definitive diagnosis within 
these cases. While 641 cases contain an alert code within an episode 
preceding the date of a definitive diagnosis of cancer, only 204 cases had 
alert codes more than a month prior to diagnosis and of these, in 70 cases 
the alert codes episodes only occurred at greater than 6 month preceding 
diagnosis.  
Figure 5.16 Flowchart of case breakdown through the pre-diagnosis, 
and alert code analysis  
 
 
Figure 5.17 presents the time from the first alert code episode to the date of 
definitive diagnosis as a percentage of all cases by one-year interval 
preceding the date of definitive diagnosis. This graph identifies 41% of the 
study population as not having a pre-diagnosis alert code episode and over 
50% of the study population with the first alert code episode confined to the 
year preceding diagnosis. Figure 5.16 identified 641 cases with pre-
diagnosis alert codes. 63% of these cases have alert code episodes 
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confined to the month preceding diagnosis, thereafter 15.7% of alert code 
containing episodes occur in the remaining 11 months of the year and 21.3% 
of alert code episodes occur at more than one year prior to diagnosis, see 
Figure 5.18. 
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Figure 5.17 Time from the first alert code episode to the date of definitive diagnosis as a percentage of all cases by one-year 
interval preceding the date of definitive diagnosis 
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Figure 5.18 Time from the first alert code episode to the date of definitive diagnosis as a percentage of all alert code cases 
by month intervals in the year preceding the date of definitive diagnosis 
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There are three distinct population sub-groups identified from this 
preliminary analysis: 
1. Cases with no alert code involvement preceding the date of definitive 
cancer diagnosis (N=457), comprising those cases either with no 
inpatient involvement (n=47) or those cases with no alert code 
containing episodes (n=410) preceding the date of a definitive 
diagnosis of cancer. 
2. Cases with alert code containing episodes only within the month 
before diagnosis (N=437). 
3. Cases with alert code containing episodes more than a month prior to 
diagnosis (N=204).  
The three populations outlined above were defined within the TTD 
categorical variable within the dataset. For the rest of the results and 
discussion Group 1 is referred to as the “no alert code” group, group 2 as 
the “alert codes immediately prior to diagnosis” group and group 3 as 
the “potentially prolonged time to diagnosis” group. The distinction 
between groups 2 and 3 is important. Cases in group 2, identified as having 
alert codes only within the month preceding diagnosis, fall within the adapted 
standard guidance for referral and diagnosis of cancer in use at the time of 
study. Group 3 cases, for whom alert codes appear prior to the month 
preceding diagnosis, are highlighted as the cases with a potentially more 
prolonged TTD in secondary care. Analysis of the cases within group 3 may 
identify characteristic features in disease type, age, sex or admission routes 
for those cases at risk of a more prolonged TTD in secondary care. 
Furthermore, survival differences between the three groups and within the 
three groups may identify cases for whom a prolonged TTD in secondary 
care could have an impact on survival outcome. 
There was evidence of significant differences in the TTD status between the 
age groups and diagnostic groups, using the chi-squared test both tests had 
a p-value=0.000. However there was no difference in TTD status by sex, p-
value=0.488, TTD is therefore summarised by age groups and diagnosis but 
not sex.  
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Figure 5.19 summarises TTD by age group, with the absolute numbers of 
cases within each group are presented at the top of each of the percentage 
stacks. All three TTD groups are presented within each age group, though 
there is variation in the proportion of cases within each TTD group between 
each age group. The 15-19 and 20-24 age groups appear to have the 
highest percentage of cases without alert code episode prior to diagnosis, 
around 45% and 60% respectively. The proportion of cases with alert codes 
present during the month preceding diagnosis reduces as age increases 
across the five age groups, nearly 60% in 0-4 year olds compared to 20% in 
20-24 year olds. The older age groups 10-14, 15-19 and 20-24 have a 
higher proportions of cases with more prolonged TTD, over 20% of 
population, compared to the 0-4 and 5-9 age groups. 
Figure 5.20 summarises the TTD variable by diagnostic group, excluding 
retinoblastoma, hepatic tumours and other tumours due to few cases within 
each population. The three alert code categories are represented within 
each of the common diagnostic groups, however there are variations in the 
number of cases between the diagnostic groups. More the 60% of cases 
with bone sarcoma, germ-cell tumour and carcinoma groups had no alert 
codes preceding the date of diagnosis. Over 60% of cases with renal 
tumours and leukaemia have alert codes within the month preceding 
diagnosis. CNS tumours, neuroblastoma and carcinoma have the highest 
percentage of cases within the potentially prolonged TTD group with more 
than 25% of cases within this TTD group.  
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Figure 5.19 Time to diagnosis groups by five year age groups 
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Figure 5.20 Time to diagnosis groups by diagnostic groups (retinoblastoma, hepatic tumours and other tumours excluded) 
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5.6 Routes to Diagnosis 
Table 5.2 summarises the admission codes for each pre-diagnosis inpatient 
episode identified within the linked dataset. Pre-diagnosis inpatient events 
that contain cancer alert codes have been identified through the study of  
episode level HES, however consecutive episodes can contribute to a 
continuous inpatient event, known as CIPS, see Figure 4.1. The initial 
admission code in a sequence of episodes that make up a CIPS will record 
the point of entry into secondary care, subsequently each episode within that 
CIPS are punctuated by a transfer admission code. Therefore, as discussed 
in the Methods section 4.9, when considering the point of entry for a pre-
diagnosis secondary care inpatient event the initial admission code for a 
CIPS is extremely useful at demonstrating the route to diagnosis.  
There are a number of admission codes that make up the admimeth variable 
in HES data, which can be divided into nine groups as identified in table 5.2. 
These nine groups can be further combined into two main categories; 
„emergency‟ and „non-emergency‟ routes to admission. Figure 5.21 
summarises the initial admission route for CIPS as a percentage stack for 
the three TTD categories identified in the previous section. It is clear that the 
emergency admission route predominates in alert code containing inpatient 
events. There is no appreciable difference in emergency verses non-
emergency admission route for cases with alert code immediately preceding 
diagnosis and those cases with potentially a more prolonged TTD.      
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Figure 5.21 The first admission route, emergency versus non-
emergency, by the time to diagnosis groups  
 
Routes to diagnosis for CYA cancers previously studied within the NCIN 
routes to diagnosis work, separated the 0 to 24 year age group into 
childhood cancers defined as 0 to 14 years and teenage and young adult 
cancers defined as 15 to 24 years. Figure 5.22 compares the percentage of 
emergency and non-emergency admissions for cancer cases in the NCIN 
study with results from this study. Within the NCIN results there are clear 
differences by age group: the childhood cancer cases had a higher 
percentage of emergency admissions (54%) compared to TYA cancer cases 
(24%). The reverse of this was found for the first admission route for all 
cases regardless of alert code status (n=1051) within this study: 32% of  
admissions were emergencies compared to 49% for TYA cancers. For the 
cases with alert codes (n=641) emergency admission routes were the 
predominant route into inpatient secondary care for both children and TYAs , 
with around two-thirds of cases with alert codes being admitted to inpatient 
through this route. 
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Figure 5.22 Emergency versus non-emergency admission routes for 
the alert code cases within the Yorkshire study population 
compared to the NCIN routes to diagnosis study (71) 
 
In Figure 5.22 the results for 0 to 24 year olds in the NCIN routes to 
diagnosis study were taken from all newly diagnosed malignant cancers, 
excluding non-melanoma malignant skin cancer, diagnosed between 2006-
2008 resident in England. The method for defining the route to diagnosis did 
not take into account clinical information contained within the HES data, 
however it did sequence the inpatient and outpatient events preceding the 
diagnosis of cancer. Therefore the study period, population sampled and 
method of analysis applied within this study differs from the NCIN routes to 
diagnosis work, as such any comparison of results in the two studies must 
be interpreted with this in mind.    
There were four types of emergency admission routes: emergency A&E, 
emergency GP, emergency outpatients (OP) and emergency other. The 
pattern of emergency admission routes for the two groups with alert codes 
were similar between the age groups (Figure 5.23). Emergency A&E was the 
predominant emergency route for admission to inpatient care for cases with 
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alert codes, and was the most common route for cases with potentially 
prolonged TTD in both age groups. Emergency GP made up a larger 
proportion for the 15 to 24 year olds with alert codes immediately prior to 
diagnosis compared to the 0 to 14 year olds. Emergency outpatient 
admissions appeared to be less prominent in the 0 to 14 year olds compared 
to 15-24 year olds.  
Variations in emergency admission routes for each diagnostic group were 
explored but are not presented due to the small numbers. The data are 
therefore difficult to interpret at a regional level and may require a national 
cohort.    
 
Figure 5.23 The specific emergency admission routes for alert code 
cases 
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5.7 Survival 
The results within this section are presented either as univariable Kaplan-
Meier survival curves or multivariable Cox proportional hazards regression 
estimates. One-year survival is presented as a proxy for late or early 
diagnosis and three-year survival is presented as a measure of long-term 
survival.  
 
5.7.1 Overall survival 
Figure 5.24 presents the overall survival for this study population.  
There were 204 deaths overall from the 1098 cases studied, representing 
18.6% of the study population. The survival at one-year following diagnosis 
was 91.5% compared to 83.6% at three-years.  
 
5.7.2 Survival by sex 
Figure 5.25 presents the Kaplan-Meier survival patterns by sex. The figures 
for one-year survival were very similar for males (91.2%) and females 
(91.0%) as were the three-year survival figures (males 83.2%, females 
84.1%). 
 
5.7.3 Survival by year of diagnosis 
 
Figure 5.26 presents the survival by year of definitive diagnosis grouped 
according to the period of diagnosis. The survival percentages at both one 
and three years for cases diagnosed between 2007 to 2009 (92.6%, 85.1%) 
was higher than that for cases diagnosed between 2004 to 2006 (90.6%, 
82.3%). However the difference in survival for the two groups was not 
statistically significant (p=0.151). 
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5.7.4 Survival by age 
Figure 5.27 presents the survival curve by five-year age groups. 
There was variation across the five age groups with one year survival of 
89.2% in cases diagnosed at 0 to 4 years compared to 93.7% for cases 
aged 10 to 14 years. Three-year survival was highest in the 10 to 14 year 
olds (87.3%) followed by the 0 to 4 year olds (84.9%) and lowest in 15 to 19 
year olds (80.4%). The differences however are not statistically significant 
using univariable Cox analysis. Figure 5.28 presents the survival curves for 
0-14 year olds and 15-24 year olds. This shows a more favourable survival 
immediately following diagnosis for TYA cases compared to childhood 
cases. The survival trends then converge at one year and by three years 
TYA survival percentages are poorer than childhood cases.     
 
5.7.5 Survival by diagnosis 
Figure 5.29 presents the survival curves by the ICCC diagnostic group, with 
the exception of retinoblastoma and other tumours, both excluded due to the 
small number of cases. Figure 5.30 presents the one and three-year survival 
percentage with confidence intervals for the 10 ICCC groups included within 
the survival curves.  
From the 10 ICCC groups presented in Figure 5.29, six have a one-year 
survival above 90%; lymphoma highest at 95.9%, renal tumours 94.7%, 
germ-cell 93.3%, leukaemia 92.8%, carcinoma 92.1% and neuroblastoma 
90.2%. The lowest one-year survival is seen for hepatic tumours 73.3%, 
followed by soft-tissue sarcoma 86.6%, CNS tumours 86.8% and bone 
tumours 88.7%. The number of deaths in some of the ICCC groups are very 
few, reducing the reliability of the results and is reflected in the wide 
confidence intervals particularly within the hepatic tumour population.  
Three-years the survival differences between the 10 groups were more 
marked. Survival for lymphoma (91.3%), renal tumours (92.1%) and germ-
cell tumours (90%) remained at 90% or above. Three-year survival for 
leukaemia and carcinoma fell to 85.1% and 82.5% respectively. whilst 
neuroblastoma displayed the largest difference between one and three years 
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dropping nearly 20% to 70.7% at three years. CNS tumour survival at three-
years only fell 7% to 79.1%, whilst in contrast bone tumours and soft-tissue 
sarcoma survival fell markedly to 71% and 70.2% respectively. Hepatic 
tumours had the worst three-year survival falling to 60%.   
There was no statistically significant difference in survival between 
diagnostic group based on the univariable Cox regression analysis.
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Figure 5.24 Survival all cases 
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Figure 5.25 Survival by sex 
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Figure 5.26 Survival by year of definitive diagnosis 
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Figure 5.27 Survival by five year age groups  
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Figure 5.28 Survival by age groups 0-14 and 15 to 24  
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Figure 5.29 Survival by International Classification of Childhood Cancer diagnostic group (groups V & XII are not presented) 
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Figure 5.30 Percentage of cases surviving to one and three years by diagnostic group  
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5.7.5.1 Unadjusted survival by alert code status preceding a diagnosis 
of cancer in children and young adults 
Figure 5.31 presents the survival curves to three years by alert code status. 
The proportion of cases surviving at both one and three-years was highest 
for those cases without alert code episodes preceding the date of diagnosis, 
being 94% and 87% respectively. The cases with alert codes immediately 
prior to diagnosis had a lower proportion of cases surviving at one-year 
compared to cases with a potentially prolonged TTD (89% vs 91%), however 
at three years the proportional survival for these two group was similar at 
81%.  
The hazard ratio of cases with alert codes immediately prior to diagnosis 
was 1.41, indicating a 41% increased risk of death in this group and the p-
value of 0.029 indicates this was a statistically significant effect. The hazard 
ratio for the group of cases with a potentially prolonged TTD also showed an 
increased risk of death compared to those cases without alert codes. 
However, this effect was not statistically significant.  
There was no statistically significant difference in survival for each of the 
TTD groups by gender, using the log-rank test. Comparing TTD by age 
group, showed a significant difference in survival function for those cases 
with potentially prolonged TTD (0-14 HR 0.98, 15-24 HR 2.48) (Figure 5.32). 
TYA cases had a poorer survival estimates compared to the childhood cases 
with potentially prolonged TTD; one-year survival 89% for TYA‟s and 94% 
for childhood cases, three-year survival 75% for TYA‟s and 87% for 
childhood cases.  
Comparison of the survival functions for the diagnostic groups by each TTD 
group did not yield robust results due to the low number of cases. Figure 
5.33 presents the percentage of cases alive or dead within the TTD groups 
for each diagnostic group. The low number of cases within the multiple 
groups reduces the reliability of the analysis of survival function and 
consequently the results are not included.      
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Figure 5.31 Survival by alert code status 
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Figure 5.32 Survival for cases with potentially more prolonged time to diagnosis by age groups at diagnosis  
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Figure 5.33 Survival (%) at three years from diagnosis for the time to diagnosis status by the diagnostic group 
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5.7.5.2 Multivariable analysis of survival by alert code status preceding 
a diagnosis of cancer in children and young adults 
Univariable analysis of TTD does not take into account how other important 
factors such as age, sex or diagnosis influence survival. This section will 
develop a multivariable Cox proportional hazard model to analysis survival 
by alert code status. The initial model will include alert code status and 
additionally adjust for the following confounding factors (as determined in 
Figure 4.4):  
 Age at diagnosis – 0 to 14 versus 15 to 24; evidence against linearity 
(Likelihood ratio test p=0.0194) 
 Sex  
 Diagnosis  
 Year of diagnosis – continuous; no evidence against linearity 
(likelihood ratio test p=0.7447)  
Results of model 1 as described above are presented in table 5.5. 
Subsequently, interactions between TTD and age at diagnosis were tested 
to assess whether any effect on survival from TTD differed by age at 
diagnosis, the hazard ratios are summarised in model 2 (table 5.6). An 
interaction between TTD and sex was not included as preliminary analysis 
showed no difference in the TTD by sex (see 5.7.5.1). 
Table 5.5 Model 1: Cox regression model for survival in CYA cancer 
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Model 1 shows a significant increased risk of death of 67% for cases with 
alert codes less than one month prior to diagnosis compared to those 
without alert codes. Although the model shows an increased risk of death for 
cases with more prolonged alert code involvement, this result is not 
statistically significant within model 1 when adjusting for age at diagnosis, 
sex, diagnosis and year of diagnosis.   
Table 5.6 Model 2: Cox regression model for survival in CYA cancer  
 
 
The interaction term in model 2 shows that the effect of TTD on survival 
differs between age groups. In model 2 there is a 71% increased risk of 
death in the 0 to 14 year age group, compared to those cases without alert 
codes which was statistically significant (p=0.030); the finding for cases with 
alert codes more than a month prior to diagnosis compared to those without 
alert codes was not statistically significant. These findings are consistent 
with results from model 1 which looked at all age groups combined. For 15 
to 24 year olds, model 2 shows a statistically significant difference in survival 
for TYAs with alert codes within the month preceding diagnosis, similarly to 
0-14 year olds, however, the effect is much larger (HR=2.41) in this age 
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group.  Furthermore, for 15 to 24 year olds there is also an increased risk of 
death (HR=2.48) for those with alert codes occurring more than a month 
preceding diagnosis.  
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5.8 Summary Points 
 The incidence of cancer in 0 to 14 year olds within the study 
population is in keeping with nationally accepted figures. However, 
comparisons with national incidence rates in the 15 to 24 year-olds 
are more difficult due to marked geographical variations across the 
UK and inconsistent age definitions within previous studies. 
 The profile of cancer cases across this population of children and 
young adults varied with age and is in keeping with nationally 
accepted figures. 
 The majority of CYAs with cancer have some secondary care 
inpatient involvement prior to their date of definitive diagnosis. Only 
4% of the study population did not have any pre-diagnosis inpatient 
involvement, of those case with pre-diagnosis inpatient involvement 
39% had inpatient involvement confined to the month preceding 
diagnosis. 
 Early cancer diagnosis awareness resource can be used to identify 
alert codes within HES inpatient data, however this approach was not 
applicable to outpatient HES data due to a lack of clinical information 
coded within the outpatient HES data . 
 The analysis of outpatient data is limited by the quality of the coding 
within episodes, however from the study population very few cancers 
were referred to tertiary oncology services through the two-week 
cancer referral route. 
 The date of definitive diagnosis of cancer is often preceded by the 
presence of an episode containing an ICD-10 cancer code with more 
than 95% of such episodes occurring within a month of definitive 
diagnosis. 
 From the 216 diagnosis specific alert codes identified from the pre-
diagnosis inpatient events only 41 codes occurred in five or more 
cases within each ICCC diagnostic group.  
 The majority of diagnosis specific alert codes occurred within the 
month immediately prior to diagnosis, however there were frequently 
outlying cases with codes at many years preceding diagnosis. 
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 Emergency admission were the predominant routes into secondary 
care for cases with alert code events preceding diagnosis. 
 In two-thirds of the cases with pre-diagnosis alert codes the episodes 
occur only within the month preceding diagnosis.  
 A TTD of more than one month in secondary inpatient care is not 
significantly associated with a poor survival for cancer in children. 
 A TTD of more than one month in secondary inpatient care was 
significantly associated with a poor survival for cancer in TYAs 
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Chapter 6 Discussion & Conclusions 
6.1 Introduction 
This study has primarily examined the period of time preceding a diagnosis 
of cancer for a cohort of children and young adults in Yorkshire, focusing on 
their hospital involvement prior to diagnosis. This is the first study to focus 
on secondary care services in this population and through the use of linked 
health data aimed to identify potential early warning signs for CYA cancer 
and investigate the association between time spent in secondary care pre-
diagnosis and survival up to three years after diagnosis. The study also 
aimed to examine the application of HES data in the investigation of TTD 
within secondary care for CYA cancer. To date in the UK, the CYA cancer 
awareness literature has been focused on patients and primary care 
services. There is often an assumption that secondary care services have a 
minimal influence on the TTD for cancer (12, 25, 125).  
This chapter will cover the following areas: firstly, an evaluation of the results 
presented in Chapter 5, providing a discussion of how the study population 
relates to the overall UK population, pre-diagnosis secondary care 
involvement, pre-diagnosis CYA cancer early warning signs and symptoms, 
TTD and its association with survival as well as a discussion of the 
application of HES data within CYA early diagnosis research. Secondly, 
reflecting on the strengths and limitations of this study, along with the future 
application of current CYA cancer awareness literature in secondary care 
services. The third sub-section sets out considered recommendations for 
improving TTD within secondary care services for CYA cancers informed by 
the results of the analysis and literature review. This third section will also 
include health service research recommendations to aid researchers utilising 
linked data sets in future studies. The chapter will end with a conclusive 
summary of the thesis and outline of suggested future CYA early diagnosis 
work.   
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6.2 Evaluation of study findings 
6.2.1 Key findings 
This study identified increasing inpatient involvement towards the date of 
diagnosis for CYA cancer cases, primarily occurring within the month 
preceding diagnosis. Increasing healthcare involvement for CYA cancer 
cases toward the date of diagnosis has been highlighted in the primary care 
setting in a large population-based Danish study (132). This pattern of 
healthcare engagement was further emphasised by the CYA cases identified 
as having cancer alert codes within inpatient events preceding diagnosis 
within this Yorkshire cohort.  
Less than 20% of cases (n=204) within this study were identified as 
potentially having cancer signs and symptoms further than a month from 
diagnosis. The period of time between first inpatient alert code event and 
diagnosis in these cases therefore potentially exceeded UK guidance for 
referral, diagnosis and treatment of suspected cancer (124), thus 
highlighting a group for whom early diagnosis interventions within secondary 
care could improve TTD. Further analysis of the study population identified 
differences in the TTD status of cases by age group and diagnosis, though 
no differences between gender.  
For the cases identified as having alert code inpatient events prior to 
diagnosis, there were more cases entering hospital via an emergency route 
compared to any other referral method for cases diagnosed aged 0-14 and 
15-24 years. This finding is similar to that shown within the NCIN routes to 
diagnosis work for 0-14 year olds. However the NCIN study showed fewer 
emergency routes into hospital for the older TYA cases (ages 15-24 years) 
in contrast to the observations within this study.  
Within the overall study population of CYAs there was no clear association 
between a prolonged time spent in secondary care and a worse outcome. 
Sub-group analysis by age and TTD revealed a poorer outcome for cases 
aged 15 to 24 years with a more prolonged TTD compared to their 
counterparts with no alert codes and all 0 to 14 year-olds. There was a 
significantly poorer survival outcome in cases with alert codes events within 
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a month of diagnosis, potentially identifying cases presenting with clearly 
identifiable cancer signs and symptoms and therefore more advanced 
disease. Unfortunately there was a lack of reliable staging data within the 
health services data used within this study and the association between 
TTD, stage and outcome could not be explored within this work.   
A novel approach was the analysis of linked electronic health data; cross-
referencing of early awareness literature with diagnostic information 
contained within HES inpatient data to identify cancer alert codes preceding 
diagnosis. However, the sensitivity of referencing symptom and sign based 
awareness literature with the diagnosis based ICD-10 coding system applied 
within HES inpatient data is not clear and further work must be done to 
refine the method. One potential approach would be to focus on the 
occurrence of unexplained signs and symptoms, known as R codes, within 
HES episodes. The R codes made up a large proportion of the identified 
alert codes within this study. The method was not applicable to HES 
outpatient data due to the lack of diagnostic information recorded within 
these data. There was a paucity of awareness literature available for the 
common TYA cancers such as germ-cell tumours and carcinomas as well as 
the rarer childhood cancers such as hepatic tumours.  
The study assessed the reliability and accuracy of HES data through the 
analysis of a sample of case records. There was high level consistency 
between HES data and case records in the recording of pre-diagnosis 
inpatient episodes, the diagnosis and the date of diagnosis. However limited 
availability of case records resulted in only half the case notes for the 
sample population actually being reviewed. The sample was chosen to 
reflect a wide range of the case population, however the case notes review 
was limited to a principal treatment centre. Therefore future work should 
involve wider case record review, including secondary care centres other 
than the principal treatment centre.    
The aims and objectives set out in section 1.2 were met and TTD was 
described according to three distinct groups within the study population: 
cases with no signs suggestive of cancer preceding diagnosis, those with 
signs and symptoms suggestive of cancer within the month preceding 
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diagnosis who therefore fall with accepted guidance; and cases with signs 
and symptoms of cancer outside the accepted referral and diagnosis 
guidance. This population-based regional CYA cancer cohort study 
demonstrated variations in TTD by age and diagnosis and identified 
differences in survival by TTD most notably by age.   
 
6.2.2 Cancer in children and young adults in Yorkshire 
The study cohort was identified from cases within the population-based 
Yorkshire specialist registry of cancer in children and young people 
(YSRCCYP) including only cases recorded as living within the FYRHA. The 
register receives notifications from a variety of source including national and 
other regional registries as well as specialist NHS services (e.g. 
neuropathology) resulting in virtually complete case ascertainment. We can 
therefore be confident of the representative nature of the study cohort in 
relation to the general population of CYA cancer cases in Yorkshire, 
certainly in comparison to the predominantly institution based studies 
identified within the systematic review in Chapter 3. 
The overall incidence of childhood cancer (ages 0-14) in this study 
population was 139 per million per year; the variation in incidence rates by 
age, sex and diagnosis are summarised in Table 5.1. The incidence rates for 
cancer in 0-14 year-olds is in keeping with previously published regional and 
national rates. The incidence rates in this study are similar to those 
published for childhood cancer within Yorkshire between 1990-2001 (115). 
The crude incidence of childhood cancer (excluding non-malignant skin 
cancers) in England between 2008 and 2010 was reported as 137 cases per 
million per year (3).The established distribution of childhood cancer by 
diagnostic group within this study matches that seen in the wider childhood 
cancer literature (3, 67). To some extent this study population is 
representative of the national childhood cancer population and the 
conclusions drawn here are potentially directly applicable to the wider 
childhood cancer population. 
The crude incidence rate for 15 to 24 year olds within this study population 
was 159 cases per million population. Unlike the childhood cancer 
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population, the incidence rate of cancer in 15 to 24 years in the literature is 
harder to define, due to variations in the age boundaries used to define the 
TYA population. CRUK reports a crude incidence rate of 267 cases per 
million for all cancers in 15-24 year olds in England between 2008-2010 (3). 
There is considerable discrepancy which in part can be explained by 
regional variations in cancer incidence within England. In 2007 Alston et al 
published an overview of regional variations in incidence of cancer in TYAs, 
showing the lowest incidence rates in the north of England and rates 
increasing towards the south of the country (28). Alston et al published 
incidence rates for Yorkshire and Humber of 185 cases per million between 
1979 and 2000, however the age boundaries ranged from 13 to 24 years 
(28). The variations in incidence for TYAs described may reflect different 
boundaries set for inclusion within a population such as the diagnoses, the 
age limits or the geographical region covered or different tumour 
classification systems used between studies, which are eluded to in Figure 
5.1. Direct comparisons of incidence rates between this study population 
and national incidence rates for TYAs are therefore difficult, raising 
uncertainty around how representative this study population is of the TYA 
cancer population across England.  
 
6.2.3 Pre-diagnosis secondary care involvement 
This study provides a unique focus on secondary care services via the 
linkage of HES data sets for inpatient and outpatient events to the 
YSRCCYP.  
  
6.2.3.1 Inpatient 
Only 47 cases from the group of 1098 eligible study individuals were found 
to have no inpatient episodes prior to the date of definitive diagnosis. This 
finding could be either due to failure in linkage of events or alternative routes 
to diagnosis excluding inpatient activity. These cases arose throughout the 
study period and were distributed across the region according to residential 
postcode. This population may highlight cases in which the route of 
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diagnosis is atypical and require more in depth investigation that is beyond 
the scope of the information provided by the linked dataset. Such information 
may be contained within the case notes or maybe gleaned from patient 
interviews.  
In the remaining 1051 cases with pre-diagnosis inpatient involvement, the 
number of pre-diagnosis inpatient episodes varied by age and diagnosis 
(Figure 5.5 and Figure 5.6). Age at diagnosis influenced the approach to 
healthcare with younger children reliant on their parents and older TYAs 
practising more independent healthcare engagement. This may be reflected 
in the reduced number of median inpatient episodes for the older age ranges 
(15 to 19 and 20 to 24) compared to 0 to 14 years. Nonetheless, this finding 
raises important questions of completeness of information within the HES 
records, which will be discussed further in section 6.3.       
Within the study cohort, 48% of pre-diagnosis inpatient events occurred 
within the month preceding diagnosis involving 91% of the study population. 
The number of cases and episodes increased dramatically immediately prior 
to the date of diagnosis. This finding draws parallels with the pattern of 
engagement prior to diagnosis seen in primary care studies of childhood 
cancer (132). The findings of this study and those of primary care when 
taken together suggest increasing contact with the healthcare system 
leading up to the point of diagnosis. 
The results show a higher proportion of admissions were categorised as 
emergency routes (38%) compared to elective routes (33%) within the pre-
diagnosis episodes. Higher levels of emergency admissions are also 
observed by the routes to diagnosis work done in both primary and 
secondary care services in cancer patients across all ages in the UK 
healthcare service (16, 71). A comparison between the figures in the NCIN 
routes to diagnosis cohort and this study population for emergency and non-
emergency admissions for 0 to 24 year olds with cancer is summarised in 
Figure 5.22. However this study did not include any control group data to act 
as a comparison and this limits the conclusions which can be drawn. Further 
analysis of the admission route will be included later in this section within the 
discussion of alert codes episodes. 
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6.2.3.2 Outpatient 
As stated within the Results Chapter 5 the quality of the diagnostic coding in 
the outpatient data was very poor and limits the application of the data within 
this study. The inadequate presentation of diagnosis coding in relation to 
each outpatient appointment during the period of this study most likely 
reflects the fact that diagnostic coding is not a mandatory field in outpatient 
HES data (122).  
72% of the study population had pre-diagnosis outpatient appointments and 
30 cases from the 47 without pre-diagnosis inpatient episodes had pre-
diagnosis outpatient appointments. The frequency of pre-diagnosis 
outpatient appointments displays a similar distribution by diagnostic group as 
seen in the pre-diagnosis inpatient episodes. Only 84% of outpatient 
appointments were recorded as having been attended, thus the overall study 
population who attended pre-diagnosis outpatient appointments was 62%. 
The median duration between an attended outpatient appointment and the 
date of diagnosis was 254 days which is a longer duration than the 41 days 
seen in the inpatient episodes. Lower case involvement in outpatient care 
pre-diagnosis and increased median TTD in outpatient care comparative to 
inpatient care highlights the latter as the most frequently accessed form of 
healthcare within hospital services preceding the diagnosis of CYA cancers.   
Outpatient HES records the priority variable, which indicates the urgency 
required for consultant input in the outpatient setting. Within the attended 
appointments 20% were classed as urgent and only 12 pre-diagnosis 
outpatient appointments were given two-week wait priority; a referral route 
used commonly in adult care to fast-track suspected cancer cases through 
out-patient services. Limited use of this cancer referral pathway in children 
has been identified in the NCIN routes to diagnosis work and a study by 
Mant et al 2012 who found only 35 two-week urgent referrals were made in a 
three and a half year period from a study of referral patterns in a district 
general hospital with a shared care interest (69, 71). Only one out of 48 
cases diagnosed with cancer over the period of the study were referred by 
the two week wait route (69). The extremely low representation of the two 
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week referral pathway within this study population suggests there may be 
incomplete or incorrect coding of this referral type. However the findings 
from the wider literature suggest either a lack of awareness in the application 
of the two week referral pathway in childhood cancer or that this pathway 
has limited application to the age group. The latter is the most likely 
explanation as most parents of a child with suspected cancer would be 
unlikely to wait for a two week appointment. 
 
6.2.4 Pre-diagnosis cancer signs and symptoms 
The vast majority of widely accessible awareness literature relevant to CYA 
cancers is aimed at the patient or the primary care professional, it is 
therefore applied within this study to set a standard for CYA cancers 
awareness for secondary care professionals. There are a number of 
resources that cover various tumour types such as the NICE suspected 
cancer referral guidance, TCT awareness 2012 and MacMillan cancer signs 
and symptoms (12, 17, 125, 126). Certain campaigns focus on specific 
cancers such as the HeadSmart campaign (CNS tumours) and literature 
published by the Bone Cancer Research Trust (bone tumours) (12). There is 
a bias towards the promotion of early diagnosis of CNS tumours in children 
and teenagers, which has a dedicated awareness literature and the common 
tumour type in resources that cover multiple tumour types (17, 125). There is 
a paucity of CYA specific guidance for certain tumours, most notably 
carcinoma and germ-cell tumours. There is however widely published site 
specific guidance aimed at older adults with carcinomas and the CNS 
tumour literature is relevant to intra-cranial germ-cell tumours. 
From the 235 disease specific codes identified only 42 appeared in five or 
more cases and no disease specific alert codes occurred in five or more 
cases in hepatic tumour or carcinoma cases within the study population, 
reflecting the rare nature of hepatic tumours and the sparseness of 
awareness literature for carcinoma in CYA‟s. The most common disease 
specific alert codes appeared in CNS tumours with 58 codes identified, 
however only eight codes appeared in five or more cases, potentially 
reflecting the wealth of awareness literature available or the heterogeneity of 
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the clinical manifestations. “Intra-abdominal & pelvic swelling, mass & lump” 
is a common alert code that appeared in the disease specific codes for four 
diagnostic groups suggesting common clinical manifestations for certain 
CYA solid tumours. Many of the disease specific alert codes could be 
grouped into common themes such as epilepsy, focal neurological signs, 
headache and migraine and general signs and symptoms in CNS tumour 
cases. A summary of the disease specific codes is presented in table 5.4 
and extensive lists of broad cancer codes and disease specific codes for the 
ICCC diagnostic groups is included in appendix 3. 
There was also considerable overlap between the broad cancer alert codes 
highlighted in the full study cohort and the disease specific alert codes 
highlighted in the individual diagnosis cohorts see Figure 5.10 to Figure 
5.15. This overlap is reflected within the code level analysis. However it 
doesn‟t translate in the cases level analysis as alert codes were analysed 
simply for their presence within an episodes, whether they were broad or 
specific.  
The awareness literature relates to signs and symptoms suggestive of a 
diagnosis of cancer, however the ICD-10 classification system used to 
assign codes to the clinical findings in an inpatient event is a diagnosis 
based system. The R code section of ICD-10 is relevant to “Symptoms, 
signs and abnormal clinical and laboratory findings, not elsewhere 
classified”. This section of ICD-10 codes contributed 102 out of the 235 
disease specific codes and 29 of the 64 broad cancer diagnosis codes. 
When reviewing these codes in more depth it is clear they predominantly 
occur within close proximity to the date of diagnosis. It is worth highlighting 
that the coders only include R codes if a sign, symptom or finding cannot be 
explained by the other diagnosis codes applied to the events within an 
episodes. Therefore if an R code appears in a HES episode it relates to a 
significant unexplained clinical finding that is not related to the overriding 
diagnosis for that episode. Thus the R codes are of particular interest for the 
analysis of misinterpreted or missed signs and symptoms suggestive of 
cancer preceding the eventual diagnosis. Specific analysis of this population 
of codes was not feasible within this study but could form part of future work.  
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The development of symptom libraries for CYA cancers is challenging and 
the heterogeneous patterns of clinical manifestation in this differing 
population of tumours hinders the development of clear red flag identifiers. 
Wilne et al 2007 published a systematic review and meta-analysis of the 
features of childhood CNS tumours presentation, identifying 56 signs and 
symptoms present at the time of diagnosis, taken from 74 papers (80). They 
highlighted the varied pattern of presenting features of CNS tumours by age, 
primary site and presences of raised intra-cranial pressure. No universal 
features were highlighted, although more common items such as headache, 
nausea and vomiting, motor and sensory deficits and signs of raised 
intracranial pressure were highlighted (80). Wilne et al (2007) concluded that 
it is important to pay close attention to children with multiple symptoms and 
signs at presentation and this systematic review contributed significantly to 
the development of the HeadSmart campaign (12, 80). The development of 
guidance relevant to clustering of signs and symptoms may improve the 
specificity of guidance aiming to identify CYA cancers, although the 
clustering of clinical features may result in failure to identify cases with rare 
presentation or those with isolated signs and symptoms.       
The study method highlighted a number of alert codes occurring many years 
prior to the eventual cancer diagnosis (figures 5.10-5.14). A clear method for 
differentiating symptoms and signs of CYA cancer from those relating to 
more common illnesses within the pre-diagnosis episodes has still to be 
identified, given the low positive predictive value of „red-flag‟ symptoms in 
CYA cancer (72, 117). The noise created by symptoms and signs related to 
other illnesses and not the eventual cancer diagnosis within pre-diagnosis 
episodes impedes the identification of clear time-lines to diagnosis within the 
HES data for this CYA population.    
   
6.2.5 Time to diagnosis in secondary care 
In the majority of cases the first pre-diagnosis alert code containing episode 
occurred within the year preceding diagnosis (Figure 5.17) and of the cases 
for whom the first alert code occurred within the year preceding diagnosis, 
just under 70% appeared within a month of definitive diagnosis (Figure 
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5.18). This finding suggests that the identifiable clinical manifestation of CYA 
cancer within secondary care services are predominantly seen in the time 
period immediately prior to diagnosis, indicating that for the majority of CYA 
cancers secondary care services have a minimal role to play prior to 
diagnosis. A high proportion of cases had their first alert code episodes and 
the first cancer code episodes within the month preceding the date of 
diagnosis. This suggests many of the identified cases may have a clinical 
suspicion of cancer in the month prior to the date a tumour specimen is 
taken that confirms the diagnosis of cancer, which is then recorded as the 
date of diagnosis.   
The duration of time between the start of an alert code episode and the date 
of definitive diagnosis was calculated and the population divided into three 
cohorts as defined in section 5.5 and illustrated in Figure 5.19. Inpatient 
events with an alert code present preceding the date of definitive diagnosis  
were identified in 58% of the study population; in only a third of these cases 
was the duration between first alert code appearance and the date of 
definitive diagnosis longer than a month. As discussed previously there is a 
31 day period accepted within NHS cancer referral pathways for the urgent 
referral and starting of treatment in childhood cancer. This pathway model 
has been adapted and applied within this study. Therefore the cases with 
first alert code confined to the month prior to diagnosis would fall within this 
present standard.  
The profile of pre-diagnosis inpatient involvement varied by diagnostic group 
(Figure 5.17). It is generally accepted that the presentation of leukaemia 
whilst often vague has a short presentation pathway and exponential course  
which results in widespread disease at presentation, as discussed in 
Chapter 2. This is potentially reflected in the finding that nearly two-thirds of 
alert codes for leukaemia cases were identified within the month preceding 
diagnosis. A little over 10% of leukaemia cases had a duration of time 
between first alert code appearance and diagnosis of more than a month, a 
group likely to consist of a number of cases with a predisposing illness 
identified as carrying an increased risk of leukaemia, such as Down‟s 
syndrome (Figure 5.11). Alert codes relating to a predisposing illness can 
therefore be present from the point of initial diagnosis, which in the case of 
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Down‟s syndrome could be at birth resulting in what appears to be a 
prolonged TTD.  
The highest levels of prolonged secondary care alert code involvement were 
seen in CNS tumours, neuroblastoma and hepatic tumours. The hepatic 
tumour group comprised only 15 cases, 7 of whom had pre-diagnosis alert 
codes thus limiting the ability to draw firm conclusions concerning the 
significance of the aforementioned pattern of pre-diagnosis involvement. 
There were 41 neuroblastoma cases in the study population of whom 32 had 
pre-diagnosis alert codes and none of these related to an underlying 
diagnosis that predisposed to the development of neuroblastoma within the 
awareness literature. A prolonged TTD in secondary care was suggested in 
a third of these cases with associated pre-diagnosis alert codes, suggesting 
that neuroblastoma may be amenable to an early diagnosis intervention in 
secondary care services. Neuroblastoma cases were also shown to have the 
highest median number of pre-diagnosis inpatient events along with other 
predominantly paediatric solid tumours such as hepatic and renal tumours.  
There is a considerable amount of awareness literature published for the 
CNS tumour population compared to most other CYA cancers. The high 
mortality and morbidity associated with the diagnosis of a CNS tumour 
means a high potential to improve outcomes by minimising TTD. Within this 
study a number of alert codes appeared well before the date of diagnosis 
with the most common codes relating to epilepsy and convulsions. Almost 
30% of the 182 CNS cases within the study population appeared to have a 
prolonged time between first alert code and definitive diagnosis. CNS 
tumours therefore present a clear opportunity for targeting early diagnosis 
interventions. The HeadSmart campaign had not been published until after 
the most recent diagnosis included within the study population, therefore the 
TTD for CNS cases in more contemporaneous cases may have 
subsequently improved.        
The lowest frequency of alert codes was seen in the carcinoma, germ-cell 
tumour, bone tumour and retinoblastoma populations. The retinoblastoma 
group consisted of very few cases with limited alert codes and as for hepatic 
tumours, the discussion of this group is limited. There was a paucity of early 
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diagnosis awareness literature identified that was relevant to germ-cell 
tumours and carcinoma in CYAs and this is likely to explain the low levels of 
alert codes in these tumour groups. In contrast, a dedicated resource was 
identified for bone tumours. The pattern of alert code involvement seen 
within the bone tumour group may reflect a paucity of secondary care 
involvement associated with this disease preceding diagnosis, only 26 out of 
62 cases had alert code involvement preceding the date of diagnosis; 
indeed, out of the 19 alert codes identified only one occurred in five or more 
cases: “pain in joint”. The fact that there is a lot of early diagnosis 
information for bone tumours but a paucity of pre-diagnosis alert code 
identified within this study would suggest that prolonged secondary care 
involvement preceding the diagnosis is not an issue for bone tumours. Early 
diagnosis interventions should instead focus on pre-hospital services and 
patients in this specific tumour group.  
Admission methods for cases with alert codes were presented at the 
continuous inpatient spells (CIPS) level (Figure 4.1). The findings of this 
study suggest that CYA cancer cases with signs and symptoms of cancer 
preceding their date of diagnosis present to secondary care via emergency 
routes. This is in agreement with published results of other NHS routes to 
cancer diagnosis work (16, 71). There is a higher proportion of admissions 
through the emergency GP route in those cases where involvement occurs 
within the month prior to diagnosis only compared to cases with more 
prolonged TTD. A higher proportion of emergency A&E admissions was 
seen in cases with more prolonged TTD. The high proportion of emergency 
routes for admission associated with alert code status indicates a high 
degree of urgency relating to these inpatient events, which may reflect 
admissions associated with a concerning clinical picture.  
 
6.2.6 Survival for children and young adults with cancer in 
Yorkshire 
The overall survival probability for this study population at one-year was 
91.5% (95% CI 89.7-93.0%) compared to 83.6% (95% CI 81.3-85.7%) three 
years after diagnosis. One-year survival has been promoted within the DoH 
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as a marker for late/early diagnosis and reflects the mortality related to the 
severity of disease at presentation and immediate disease and treatment 
related complications (11). Three-year survival is used in this study as a 
longer-term measure of outcome, rather than the usual five-year follow-up 
period, due to censoring of individuals diagnosed within the study period 
(2004-2009). The 8% difference between one-year and three-year survival 
suggests a significant impact of treatment and patient management on the 
outcome for CYA cancer within the FYRHA. Stiller et al 2007 reported one-
year and three-year survival estimates for childhood cancer in Britain 
between 1991-2000 of 88% and 78%, compared to 91% and 85% for 0 to 14 
year olds within this study population (133). The more favourable survival 
seen at both one and three-years survival and the narrower gap between 
one and three-year survival within this study population compared to Stiller 
et al 2007 perhaps suggests improvements in earlier diagnosis and 
treatment effects between 1991 to 2000 and 2004 to 2009 (133). It must be 
noted that Stiller et al 2007 is based on a national population and 
additionally that there have been improvements in the case ascertainment 
and diagnostic sensitivity of cancer registration between the two study 
periods (133). There appears to be a slightly more favourable outcome at 
one-year for 15 to 24 year olds with 92% alive at one-year post diagnosis, 
with three-year survival falling to 82%. This 10% fall in survival may reflect 
the reduced involvement of 15 to 24 year olds within trials as these cases 
may fall between childhood and adult services (134). 
No difference in survival was observed by sex at one or three years within 
the study population. However within the wider literature, females are more 
likely to survive than males, emphasised by the prolonged treatment course 
for males with ALL (135). Nonetheless sex was retained in the multivariable 
survival model as it potentially impacts on the route to diagnosis especially in 
the older cases; girls are more likely to have contact with their GP for routine 
care and contraception (66, 134). 
The results of the EUROCARE-4 study indicated that overall teenagers and 
young adults with cancer had better five-year survival outcomes compared 
to children with cancer (5). However the survival for certain cancers, such as 
ALL, bone tumours and soft-tissue sarcomas is worse in TYAs compared to 
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children (4, 5). The 15 to 24 year olds within this study population had 
slightly better one-year survival rates compared to their younger 
counterparts, however further analysis is required as the difference was not 
statistically significant. 
Survival across the diagnostic groups varied widely, results for 
retinoblastoma (V) and other tumours (XII) were not considered due to the 
very low numbers of cases involved. Lymphoma and germ-cell tumours 
showed at least a 50% reduced risk of death compared to the leukaemia 
when correcting for age and sex, which was statistically significant (p<0.05). 
Several tumour groups showed an increased risk of death including CNS 
tumours (70%), osteosarcoma and soft-tissue sarcoma (120%). 
neuroblastoma (150%) and hepatic tumours (240%); all achieved statistical 
significance (p<0.05) when correcting for age at diagnosis and sex (Table 
5.5). The variable pattern of survival by diagnosis seen in this study reflects 
the generally accepted patterns within the wider literature, however due the 
limited number of cases further subgroup analysis within this study 
population was not conducted. The significant differences in the risk of death 
by diagnostic group identified within this study population supports the 
inclusion of diagnostic group within the multivariable Cox proportional 
hazards model used to analyse the association between survival and TTD. 
 
6.2.7 Time to diagnosis and survival outcomes 
The second aim of this study is to assess how variations in TTD within 
secondary care affect outcomes for CYA patients. Three groups of patients 
were highlighted within the previous Results Chapter:  
 Cases with no alert code involvement preceding the date of definitive 
cancer diagnosis (N=457), which is made up of those cases with no 
inpatient involvement (n=47) and those cases with no alert code 
episodes (n=410) preceding the date of a definitive diagnosis of 
cancer. 
 Cases with alert code episodes only within the month before 
diagnosis (N=437). 
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 Cases with alert code episodes more than a month prior to diagnosis 
(N=204).  
Cases with alert codes present immediately prior to diagnosis (group 2) were 
67% significantly more likely to die compared to all other cases across the 
study population, see table 5.5. This increased risk remained after correcting 
for age at diagnosis, sex, diagnostic group and year of diagnosis. A 30% 
increased risk of death was seen in cases 0 to 24 years with potentially more 
prolonged TTD (group 3). These findings indicate an increased risk of death 
for the cases where the clinical manifestation of their cancer are identified 
within secondary care preceding the definitive diagnosis. The cases with 
alert codes confined to the month preceding diagnosis have the worst 
outcome, potentially identifying those cases where there is an acute 
presentation or clinically apparent severe manifestation of disease. The 
limited inpatient involvement of cases with poorer outcomes raises the 
question of whether these are higher-grade fast growing tumours or is 
generally evidence of late presentation with advanced stage disease due to 
prolonged time spent within the PI or other healthcare settings. Dang-Tan et 
al 2009 provided a potential answer to the above question, they described a 
low risk of prolonged healthcare service delay associated with a prolonged 
patient delay in a population of in Canadian children and adolescence with 
leukaemia and lymphoma (114).    
Interaction tests identified a significantly worse outcome in the older age 
group for cases with potentially more prolonged TTD (group 3) compared to 
children within this group and all other TTD groups by age. The increased 
risk of death in TYAs with a prolonged TTD, identified within this study, was 
also a finding within a number of early diagnosis studies within the 
systematic review (Chapter 3). Despite the limited awareness literature for 
the common TYA cancers identified within this study, those TYA cases 
identified with potentially more prolonged TTD had a poor outcome, 
indicating improving TTD in secondary care for TYA could influence 
outcome.             
Gender did not appear to have any influence on survival within the three 
TTD groups. Once the population of cases were divided by the diagnostic 
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groups the number of deaths within each subgroup was very small (Figure 
5.33). This therefore limited the assessment of how variations in the TTD 
affected survival for each diagnostic group.       
The group with potentially more prolonged TTD were likely to include a 
higher proportion of cases for whom an underlying disease was identified 
within the awareness literature, such as Down‟s syndrome, tuberous 
sclerosis or neurofibromatosis. The alert codes identified within this group 
may also be relevant to clinical manifestations of more indolent or lower-
grade tumours. The specificity of the alert codes may decrease as time 
intervals between alert code occurrence and definitive diagnosis increases, 
with alert codes relating to other and unrelated illness due to the often vague 
and varied signs and symptoms seen in CYA cancers. This point will be 
discussed further within the limitation section.  
The high proportion of emergency admission routes in cases with alert 
codes preceding definitive diagnosis provides a valuable insight into 
healthcare engagement for CYAs presenting to secondary care. CRUK in 
2013 described one in four new cancer cases presenting via Accident and 
Emergency as unacceptable and associated this fact with thousands of 
preventable deaths, a statement relating to all cancers across all ages (136). 
The high proportion of emergency routes to diagnosis in CYAs, especially 
A&E, identified within this study and the NCIN routes to diagnosis work 
pertain to different patterns of healthcare engagement within CYAs compare 
to older adults. This highlights the value of emergency care for the diagnosis 
of CYA cancer and the need to work with rather than to avoid the emergency 
healthcare structures. 
There are other potential confounding factors which could have been 
included within the survival model, such as the initial secondary care centre 
accessed by the patient. The key findings outlined in this section and 
limitations discussed within the next section will be considered together and 
recommendations for early diagnosis in CYA cancer within secondary care 
developed in section 6.4, along with potential future work. 
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6.3 Strengths and Limitations 
6.3.1 Strengths 
This study introduces a novel population-based approach to analysis of 
objective health services data. The registry data used within this study has 
high case ascertainment and there was a high level of data linkage between 
the YSRCCYP and HES data sets.   
There were clear definitions within the study design for the time-intervals 
within the TTD informed by a systematic review of early diagnosis literature 
(Chapter 3), based upon an established theoretical framework for early 
diagnosis research. 
The study method introduces a reproducible coding scheme of relevant alert 
codes for CYA cancer applicable to both secondary and primary care. The 
scheme was developed from established and widely available early 
diagnosis resources for CYA cancers. The alert codes were scrutinised by 
experienced clinicians in the field of paediatric oncology and paediatric 
haemato-oncology prior to the inclusion within the analysis.     
 
6.3.2 Limitations 
In order for clear and appropriate conclusions to be drawn from this study 
the limitations of the study methods must be considered. This section will 
discuss the limitations of the data sources and applied methods, including 
the referencing of the early diagnosis alert codes and the intrinsic limitations 
of research within the CYA cancer population. It is important to consider the 
feasibility of achieving the aims and objectives of the study within the limits 
of the data and methods applied.    
The date of definitive diagnosis is the first and perhaps most fundamental 
point of consideration within the limitations of this study. This date was 
extracted from the YSRCCYP and is defined as the date when a specimen 
was taken that confirmed the diagnosis of cancer. This date provided the 
censoring point for the duration of time spent within inpatient care prior to 
diagnosis within this study. The process of making a diagnosis of cancer 
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begins before the date of pathological confirmation and from the tertiary care 
perspective begins with a clinical diagnosis based on the initial history and 
examination. It is possible to crudely identify the date of clinical diagnosis 
within the HES records as the date of first cancer code occurrence reflected 
by the presence of an ICD-10 C code within an episode. In section 5.4.1 the 
frequency of C code containing episodes preceding the date of definitive 
diagnosis is discussed, identifying over 1000 such episodes within the 
dataset. However, these C code episodes are mostly confined to the month 
preceding the date of definitive diagnosis. Only 4% of C code episodes 
preceding the definitive diagnosis occur more than a month prior to the date 
of definitive diagnosis. Given this, correcting the date of diagnosis for the 
date of the first C code episode may not have a huge impact on the duration 
to diagnosis. However, correcting for first C code episode could significantly 
impact on the number of cases with alert codes preceding the date of 
definitive diagnosis since poorer survival rates were observed in cases with 
alert codes immediately prior to the diagnosis for the overall study cohort. 
This population may consist of cases of CYA cancers with clinically apparent 
cancer diagnoses presenting acutely to secondary care with highly 
suspicious and obvious signs and symptoms potentially associated with 
more advanced or aggressive disease.         
A number of limitations were identified within the HES records used to 
analyse the inpatient and outpatient events preceding a diagnosis of cancer 
within this study. The pre-diagnosis inpatient involvement for the older cases 
was incomplete, a finding identified by the fact that the date of the first HES 
inpatient episode occurred in 1996. This means a maximum inpatient history 
of 8 years for cases diagnosed in 2004. This could impact on the number of 
episodes per case in the older cases and the TTD for those cases with an 
underlying condition that predisposes to the eventual diagnosis of cancer.  
The information contained within a HES episode will be heavily influenced by 
the coders reviewing the medical notes. The methods of coding have 
become more standardised due to the influence of payment by results, 
however the implementation of PbR occurred during the course of the time 
period for this study, the impact of this is most likely to be seen after 2006 
(122). Time spent within the coding department in Leeds Teaching Hospitals 
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Trust demonstrated the extent of the highly standardised approach and 
consistent audit of coding in current practise. However concerns remain 
about the quality and reliability of coding with regard to historical practises 
and inter-hospital variations. 
This study aimed to highlight misinterpreted or overlooked signs and 
symptoms of cancer within CYA‟s and is reliant on completeness of records 
relating to such clinical events. The CYA cancer awareness literature used 
within this study highlights symptoms and signs indicative of cancer. Yet the 
ICD-10 classification system used to code the clinical features within an 
inpatient episode are based on morbid entities which are mostly defined as 
diagnoses. ICD-10 does contain the R section describing unexplained 
symptoms and signs, which provided over 100 of the 235 alert codes 
identified (32). The discordance in focus between the referenced resources 
and the ICD-10 classification system applied to code the HES data does 
raise concerns regarding the appropriate utilisation of HES records for this 
study and the completeness of information presented. The validation of HES 
records with the information within the medical records is therefore an 
important process within this study. Incomplete presentation of the medical 
manifestations of cancer within the HES records will result in 
underrepresentation of early diagnosis signs in the identified cases with alert 
codes and underestimation of the number of cases with pre-diagnosis 
inpatient events suggestive of cancer.  
As previously stated the majority of the early diagnosis literature used within 
this study is aimed at patients and primary care professionals. The primary 
care professional is most often identified as making the predominant 
contribution to the doctor interval preceding a cancer diagnosis. The 
awareness literature used therefore acts as a base-line for secondary care 
doctors and as such could result in potential under-estimation of alert signs 
and symptoms identifiable within secondary care episodes. CYA cancer 
diagnosis guidance focused on secondary care professionals is not available 
at present and it is beyond the scope of this study to create this. 
The methods applied within this study rely on the completeness and 
accuracy of recorded data within the HES records for the identification of 
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pre-diagnosis alert codes. As previously discussed, the omission of key 
clinical information relevant to a diagnosis of cancer due to the fact it is 
ascribed an alternative misdiagnosis or missing because of failure to 
recognise it as significant would result in omission from analysis for the alert 
codes. Such information may be recorded in the clinical notes and the 
process of clinical coding may have inadvertently filtered this out. 
Alternatively, the medical professional may omit information from the 
medical records due to it being incongruous with an initial misdiagnosis, thus 
leading to over-estimation of cases without alert codes preceding diagnosis.   
As identified in the systematic review (Chapter 3), the relationship between 
TTD, stage and survival is the missing piece of the early diagnosis jigsaw. 
One of the main aims of this study was to investigate the association 
between TTD, stage and outcome for CYA cancers. There was a lack of 
available data on stage or grade limiting the ability to tackle this question in 
its entirety, and limited data on treatment meant this could not be used as a 
proxy for stage. At the time of this study the only means of achieving clear 
staging data was to conduct a complete case note review, again reliant on 
availability of complete records documenting staging. Alternatively one could 
conduct a prospective study on a new cohort with clearly define staging 
criteria from the outset. There are plans to improve the recording of stage in 
cancer registries across the UK and the Cancer Outcomes Service 
Database has made this a requirement for cancer registries. The challenge 
for specialist CYA cancers registries is maintaining a high level of data 
accuracy given the varied and ever evolving nature of cancer staging in CYA 
cancer. There must also be consideration of cancer grade alongside stage, 
the grade provides an indication of the aggressiveness of a tumour and 
reflects the speed of growth and tumour development. In the CNS tumour 
literature there is an established link between shorter times to diagnosis in 
higher grade tumours (84). It may be more practical in future to think of the 
TTD relative to the tumour grade when considering the impact of prolonged 
TTD in CYA tumours.     
The method also failed to identify clustering of signs and symptoms within 
episodes and across episodes and time. Disease specific alert codes were 
identified using Stata12 commands for each of the diagnostic groups 
- 174 - 
 
 
separately. Due to overlap in the alert codes between diagnostic groups, the 
Stata12 programming could not be easily written across for the entire 
population at once, which therefore didn‟t allow me to identify clusters of 
codes in the entire dataset. This is a code writing limitation and not an 
intrinsic limitation of the data used. Therefore with more time and advanced 
programme writing capabilities could overcome this issue.  
The rare nature of CYA cancers and the diverse patterns of presentation 
result in a low predictive value of alert symptoms for cancer within this 
population and marks a key obstacle to the development of „red-flag‟ 
symptoms and signs. This issue was clearly highlighted by Dommett et al 
(2012) in a large case-control study of alert symptoms in primary care for 
CYA cancers, identifying that …“of 10000 children with a recorded alert 
symptom, approximately 6 would be diagnosed with cancer within 3 months” 
(72). Within the setting of primary care there have been a number of recent 
publications which draw clear and important conclusions from CYA early 
diagnosis research through the use of case-control study methods (72, 132). 
The lack of control group data within this study limits the conclusions that 
can be drawn regarding the occurrence of alert codes, the admission routes 
and the frequency of inpatient involvement preceding the date of diagnosis.  
CYA cancers are a heterogeneous group of tumours with a diverse tumour 
biology and are rare. This study has struggled to conduct multi-level 
subgroup analysis due to the sample size and this was especially noted 
when assessing how variations in TTD affect survival for each diagnostic 
groups. A larger sample size may have allowed a more sophisticated 
modelling approach, such as the use of multi-level methods allowing us to 
account for the natural nesting of patients within diagnostic groups. 
Only a limited number of variables were used in the survival analysis models 
within this project, the variables used were well recorded and had all been 
implicated as influential to survival in CYA cancer. Future work could 
incorporate variables such as treatment, stage, geographical location, GP, 
deprivation, ethnicity, willingness to seek medical help (compliance).   
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6.4 Recommendations and future work 
6.4.1 Health care recommendation 
Hospital care plays an important role in routes to diagnosis for CYAs with 
cancer, often as the final step in the diagnostic pathway. This is reflected 
within this study as 96% of cases had pre-diagnostic inpatient involvement 
and more than a third of cases had inpatient involvement isolated to within a 
month preceding diagnosis. This study also identified evidence that 
secondary care is not just the final step for healthcare involvement leading to 
a diagnosis of CYA cancer. Just under 20% of CYA cancers in a large 
regional population based registry had identifiable signs and symptoms 
suggestive of cancer at more than a month preceding diagnosis within 
hospital care and their survival varied by age.  
No difference in survival was seen for children (0-14) with signs and 
symptoms suggestive of cancer more than a month preceding diagnosis 
compared to children without identifiable signs and symptoms suggestive of 
cancer. The survival was significantly worse for those children with 
symptoms and signs isolated within the month prior to diagnosis, suggesting 
interventions aimed at improving the TTD for childhood cancers in 
secondary care services would not impact on survival. This supports the 
hypothesis that interventions should be aimed at the pre-hospital admission 
and patient level in childhood cancer.  
TYA‟s (15-24) with potentially more prolonged TTD within secondary care 
had a worse survival compared to their counterparts without alert codes and 
also childhood cases with potentially more prolonged TTD. This study 
identified a lack of TYA specific awareness literature especially in relation to 
germ-cell tumours and carcinomas, there is however a large library of 
literature available for adult cancers by site that could be adapted for use in 
these more common TYA cancers. Adaptation and not application of adult 
literature is important as TYA carcinoma‟s can often behave differently to 
adult cancers and TYA‟s themselves will respond differently to awareness 
interventions.  
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In section 5.4.2 and 5.4.3 alert codes occurring in five or more cases pre-
diagnosis were relatively infrequent, especially the disease specific alert 
codes. It is also clear that in the majority of cases these codes occurred for 
the first time in close proximity to the date of diagnosis, although there were 
commonly extreme outliers in duration. The frequency of primary care 
attendances for CYA with cancer increases towards diagnosis, a pattern 
reflected within secondary care services in this study (132). It is therefore 
important to consider the clustering of alert codes within a certain time span 
for a case during the pre-diagnosis time period. In many accident and 
emergency departments in the UK there is a system of recording the number 
of previous attendances for a patient. This system could be adopted in the 
acute paediatric assessment room setting and possibly coupled with a 
means of producing previous attendance sheets. Highlighting previous or 
multiple attendances with related or concerning features potentially 
identifying cases for whom an undiagnosed or miss-diagnosed process may 
be ongoing. The emphasis should be on establishing the time line for each 
CYA seen in secondary care and the promotion of systems that record 
attendances will help in this effort. As electronic records continue to develop, 
we may also be able to develop linked attendance records across healthcare 
systems.  
Identification of an abdominal mass was a common first alert code within a 
number of tumour types as well as within the broad cancer alert codes. The 
duration to diagnosis from the first occurrence of this sign was often short. 
There is a suggestion in the literature that the UK has a worse outcome for 
tumours that present in childhood with an abdominal mass such as 
neuroblastoma and Wilms‟ tumours (47). In the case of the former, the 
abdominal mass may be an incidental finding; in the case of the latter, the 
TTD within the literature was consistently amongst the shortest duration. 
Both points reflect the fact that abdominal tumours can have an insidious 
onset and the disease may be extensive by the time it is eventually detected. 
It is therefore important that at the point of contact, a reviewing doctor has 
the experience and clinical skills to examine a child in a comprehensive 
manner. The abdominal examination must be a mandatory part of the 
assessment in every child seen in secondary care services. Education and 
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development of the clinical skills for medical professionals working with 
children could form part of a healthcare intervention to improve TTD for this 
specific tumour presentation.    
This study has utilised a number of CYA cancer awareness resources to 
highlight alert codes, the majority of which focused on the symptoms and 
signs that could indicate a potential cancer diagnosis. The HeadSmart 
campaign also provides the professional working with children with advice 
regarding the investigation of a child or teenager with a suspected CNS 
tumour (12). The campaign advocates the use of an MRI scan in any child 
suspected of having a brain tumour and only CT with contrast if MRI is not 
available. This advice is readily available online to professionals and there is 
an education module that accompanies the awareness campaign. This study 
has highlighted a number of alert codes, especially relating to convulsions 
and epilepsy, within the CNS tumour population which are present long 
before the date of definitive diagnosis. There is a suggestion from this study 
that cases with CNS tumours may have more prolonged secondary care 
involvement (Figure 5.13) especially for epilepsy and convulsions related 
admissions. The advice given within the HeadSmart campaign provides the 
secondary care services with a challenge as the provision of resources for 
MRI scans for all suspected CNS tumours would require major financial 
investment given the extremely low positive predictive value of headache 
and neurological signs published by Dommett et al 2012 (72). Improved 
access and resource for appropriate and indicated imaging techniques such 
as MRI for the investigation of suspected CNS tumours maybe key to 
improving the TTD in certain CYA cancer. However, this needs to be 
implemented in conjunction with improved access to healthcare services for 
CYAs and improved history and examination skills for point of contact junior 
staff engaging with CYA. 
Outpatient data was of limited use to this project due to the lack of diagnostic 
codes applied to each appointment, although it was clear that the two-week 
referral pathway for cancer is poorly recorded. It has been suggested that 
there is poor uptake of this referral pathway for suspected CYA cancers, 
although there have been limited studies of the use of this referral pathway 
in CYAs (69). This finding may reflect the inappropriate nature of this 
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pathway in CYA suspected of cancer, for whom even a two week wait is 
deemed unacceptable to parents and referring professionals. There is scope 
for reassessment of this pathway in CYA cancers as well as any resource 
attached, followed by development of more specific and targeted referral 
structures for CYAs suspected of cancer. This may take the form of 
development of communication structures across the region, for example 
improving links between specialists and primary and secondary care 
professionals who have contact with CYAs. 
 
6.4.2 Health services research recommendations & future work 
The systematic review section (Chapter 3) identified several requirements 
for robust and reproducible early diagnosis research in all age groups, 
including a theoretical framework from the outset, clear definitions for the 
time intervals and hierarchical approach to defining the time points for the 
study.  
This study has focused on TTD for CYA cancer in secondary care. 
Nonetheless, this is merely part of the complex picture of pre-diagnosis 
healthcare involvement for these young people. A key finding from this study 
was the association between prolonged secondary care involvement 
suggestive of cancer and worse survival rates in the 15 to 24 year olds. 
Unfortunately, due to the limited sample size a clear assessment of how 
variations in TTD affected survival within TYA specific diagnostic groups. 
The findings of this study support the need for future work in TYA cancers to 
identify how variation in TTD affect outcome for specific diagnoses, 
identifying at risk diagnostic groups and facilitating TYA specific early 
diagnosis strategies. A potential approach for future studies could involve 
inter-regional analysis of pathways to diagnosis for cancer; potentially 
identify variations in approach to TYA care and highlighting areas of best 
practise. 
Inpatient involvement only tells part of the story of secondary care and the 
outpatient and emergency contact also needs to be considered. 
Unfortunately the quality of outpatient HES as a resource for this type of 
health services research is poor as the diagnostic coding is currently 
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inadequate. The quality of outpatient HES data is unlikely to improve given 
that diagnostic coding is not a mandatory field, unlike inpatient HES. A 
combined data set of inpatient HES, outpatient HES and A&E HES would 
facilitate an enhanced view point of secondary care, however the lack of 
diagnostic information in outpatient HES data restricts its use to the 
sequencing of events, illustrated by the NCIN routes to diagnosis work (71). 
In order to provide a more complete picture of pre-diagnosis involvement 
secondary care data could be linked to primary care data. However, at 
present the national primary care data resource of Clinical Practise 
Research Datalink only covers a limited proportion of the UK population. 
Linkage to electronic health records for primary care such as SystmOne may 
provide a mechanism to include primary care data in the future, however the 
coverage and feasibility of exploiting such resources across a regional or 
national study would need investigating.      
This study aimed to assess how reliable and accurate HES data are in the 
analysis of TTD and survival. Unfortunately, this study was unable to provide 
an insight into the association between TTD and stage within secondary 
care services for CYA cancers. Due to the lack of staging data within the 
routine health datasets utilised this aim was not achieved. Findings from the 
systematic review show that the TTD is influenced by the biology of a 
tumour. It is therefore recommended that the grade and stage of the tumour 
be recorded for future TTD studies and the TTD be considered relative to the 
tumour biology. In high-grade fast growing tumours there is a more pressing 
need to achieve a prompt diagnosis and the key features that identify these 
aggressive tumours should be investigated and promoted within CYA early 
diagnosis interventions.  
At present early diagnosis research often defines the time of symptom 
recognition as the point of initiation (Figure 2.1), however there is a period of 
pre-symptomatic disease development that precedes this. The Background 
section (Chapter 2) discussed some limited knowledge of how the rate of 
tumour progression affects the TTD and this was further explored as part of 
the systematic review (Chapter 3). Investigation of markers for tumour 
proliferation such a Ki-67 and mitotic index may help inform this gap in 
knowledge regarding variations in tumour development and could form part 
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of a combined study of tumour biology and TTD. Markers for tumour 
proliferation could be incorporated into theoretical models of tumour 
development, helping to identify the point of initiation for a tumour, thus 
giving a definitive TTD. 
Survival is not the only outcome measure for CYA cancers. In fact, as 
survival increases the emphasis shifts more to the reduction of morbidity, for 
example in the UKALL 2011 trial currently underway in the UK (137). The 
challenge for the CYA early diagnosis researcher investigating morbidity as 
an outcome is the heterogeneity of endpoints being measured due to 
variation in disease biology and treatment modalities across CYA cancers, 
further compounded by the rarity of the disease. The association between 
TTD long-term outcome measures such as survival or morbidities may be 
difficult to clearly define due to the influence of confounding factors such as 
treatment. The stage at diagnosis could be the end-point for future TTD 
studies in CYA cancers, allowing investigation of more contemporaneous 
data for patients recently diagnosed who are more likely to have clear 
staging recorded.      
Beyond an internal assessment within diagnostic groups of the cohort, the 
study lacked a comparator group for CYA secondary care involvement in the 
general population. This would have improved the strength of conclusions, 
for example adoption of a case-control design, similar to other CYA early 
diagnosis research done in the primary care setting (72, 132). Challenges of 
this approach would include defining clear endpoints for analysis for those 
case not diagnosed with cancer.  
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6.5 Conclusions 
This is the first study to focus on the TTD for CYA cancers in secondary care 
services within the UK, using linked datasets to identify clinical manifestation 
of CYA cancers preceding the definitive diagnosis and investigate 
associations with survival. The use of the YSRCCYP allowed a population 
based approach for the study, resulting in a high level of case 
ascertainment. This study has a number of limitations that must be 
considered when drawing conclusions, relating mainly to the methods 
applied and the resources used. In particular, the limitations of analysis of 
clinical information contained within health data that has been collected and 
coded by non-standardised methods for a purposes other than health 
services research must be considered.    
This study shows increasing numbers of CYA cancer cases with inpatient 
involvement towards the date of definitive diagnosis. Maximal inpatient 
involvement occurred in the month immediately preceding diagnosis for both 
general inpatient episodes and alert codes containing inpatient episodes. 
This pattern of increased healthcare engagement prior to diagnosis is has 
also been identified in primary care studies of CYA cancers (72, 132).  
In this large regional population of CYA cancer cases a number of clinical 
features suggestive of the subsequent diagnosis of cancer have been 
identified from the codes assigned within individual HES inpatient episodes.  
When cases have clinical features suggesting a cancer diagnosis prior to the 
date of diagnosis they are most commonly admitted to inpatient services 
through emergency routes. A&E and GP emergency routes predominate, 
with the emergency GP route utilised mostly in admissions proximal to the 
date of definitive diagnosis. The utilisation of emergency pathways for CYA 
with cancer has been highlighted in previous primary care and secondary 
care routes to diagnosis work. The utilisation of emergency routes coupled 
with the lack of utilisation of the two-week cancer referral pathway shown in 
the outpatient data within this study highlights the potential need to reassess 
cancer referral structures in CYAs.  
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Cases with alert symptoms and signs isolated to the month preceding 
definitive diagnosis have a significant worse outcome compared to cases 
without alert codes. This suggest that these cases have marked and easily 
identifiable signs of disease and signs potentially indicating rapidly 
progressive disease or a prolonged period of development prior to engaging 
with inpatient care, which may reflect a prolonged primary care interval or  
patient interval. A significant or detrimental effect of a prolonged TTD in 
secondary for CYA cancers was identified within the 15-24 year olds within 
this study, but not the 0-14 year olds. This suggests secondary care specific 
early diagnosis interventions in the older population may be helpful and 
improve survival. 
This study suggests that secondary care services in Yorkshire appear to be 
organised effectively to deal timely diagnosis of cancer in CYAs. However, 
further investigation of TTD for CYA cancer across all healthcare services is 
required and the inclusion of staging data is imperative. The TTD relative to 
the tumour biology is a key component in future studies in order to facilitate 
clear conclusions with regard to the effect of TTD on outcome.  
 
 
  
- 183 - 
 
 
Reference List 
 
1. Cancer Research UK. CancerStats Incidence UK 2009. 2012. 
2. Birch JM, Pang D, Alston RD, Rowan S, Geraci M, Moran A, et al. 
Survival from cancer in teenagers and young adults in England, 1979-2003. 
Br J Cancer. 2008;99(5):830-5. 
3. Cancer Research UK. CancerStats - Childhood Cancer - Great Britain 
& UK. 2010. 
4. Eden T, Barr R, Bleyer A, Whiteson M, editors. Cancer and the 
Adolescent. Second ed: Blackwell Publishing & BMJ Books; 2005. 
5. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, 
Kaatsch P, et al. Survival of European children and young adults with cancer 
diagnosed 1995-2002. Eur J Pediatr. 2009;45(6):992-1005. 
6. Department of Health. Cancer Reform Strategy. 2007. 
7. Geraci M, Birch JM, Alston RD, Moran A, Eden TOB. Cancer mortality 
in 13 to 29-year-olds in England and Wales, 1981-2005. Br J Cancer. 
2007;97(11):1588-94. 
8. National Cancer Survivorship Initiative (NCSI). Children and young 
people living with and beyond cancer. Designing and implementing 
pathways to benefit patient aftercare: Continuing to build the evidence. 2011. 
9. Department of Health. The NHS Cancer Plan: A plan for investment, 
A plan for reform. 2000. 
10. National Institute for Health and Clinical Excellence (NICE). Guidance 
on Cancer Services: Improving Outcomes in Children and Young People 
with Cancer, The Manual. 2005. 
11. Department of Health. Improving Outcomes: A Strategy for Cancer, 
First Annual Report. 2011. 
12. RCPCH, SDBTT, CBTRC, The University of Nottingham and The 
Health Foundation. HeadSmart. 2011 [updated Date accessed: 28th June 
2012]; Available from: http://www.headsmart.org.uk/. 
13. Gill PJ, Goldacre MJ, Mant D, Heneghan C, Thomson A, Seagroatt V, 
et al. Increase in emergency admissions to hospital for children aged under 
15 in England, 1999–2010: national database analysis. Archives of Disease 
in Childhood. 2013. 
- 184 - 
 
 
14. Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom 
S, et al. Routes to diagnosis for cancer - determining the patient journey 
using multiple routine data sets. Br J Cancer. 2012;107(8):1220-6. 
15. Purkayastha D, O‟ Hara, C., Moran, T. Routes to diagnosis: 
investigating the different pathways for cancer referrals in England for 
Teenagers and Young Adults. In: National Cancer Intelligence Network, 
editor.: NHS North West Cancer Intelligence Service; 2013. 
16. Royal College of General Practitioners, National Health Service 
National Cancer Action Team, National Cancer Intelligence Network. 
National Audit of Cancer Diagnosis in Primary Care. In: Heath Do, editor. 
2011. 
17. Teenage Cancer Trust. Teenage Cancer Awareness Week. 2012; 
Available from: 
http://www.teenagecancertrust.org/workspace/documents/TeenageCancerTr
ustAwarenessWeek_Pack.pdf. 
18. Olesen F, Hansen RP, Vedsted P. Delay in diagnosis: the experience 
in Denmark. Br J Cancer. 2009;101 Suppl 2:S5-8. 
19. Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, et al. 
The Aarhus statement: improving design and reporting of studies on early 
cancer diagnosis. Br J Cancer. 2012;106(7):1262-7. 
20. Walter F, Webster A, Scott S, Emery J. The Andersen Model of Total 
Patient Delay: a systematic review of its application in cancer diagnosis. 
Journal of Health Services & Research Policy. 2012;17(2):110-8. 
21. Safer MA, Tharps QJ, Jackson TC, Leventhal H. Determinants of 
three stages of delay in seeking care at a medical clinic. Medical Care. 
1979;17(1):11-29. 
22. Andersen BL, Cacioppo JT. Delay in seeking a cancer diagnosis: 
delay stages and psychophysiological comparison processes. British Journal 
of Social Psychology. 1995;34(Pt 1):33-52. 
23. Hargrave D. Pontine glioma. To biopsy or not to biopsy: that is the 
question. British Journal of Neurosurgery. 2008;22(5):624. 
24. European Network of Cancer Registries. Recommendations for 
coding Incidence Date. 
- 185 - 
 
 
25. Teenage Cancer Trust. Teenage Cancer Trust - What we do/about 
us. 2013; Available from: http://www.teenagecancertrust.org/who-we-
are/about-us/. 
26. Martin S, Ulrich C, Munsell M, Taylor S, Lange G, Bleyer A. Delays in 
cancer diagnosis in underinsured young adults and older adolescents. 
Oncologist. 2007;12(7):816-42. 
27. Pollock BH, Krischer JP, Vietti TJ. Interval between symptom onset 
and diagnosis of pediatric solid tumors. J Pediatr. 1991;119(5):725-32. 
28. Alston RD, Rowan S, Eden TOB, Moran A, Birch JM. Cancer 
incidence patterns by region and socioeconomic deprivation in teenagers 
and young adults in England. Br J Cancer. 2007;96(11):1760-6. 
29. Birch JM, Pang D, Alston RD, Rowan S, Geraci M, Moran A, et al. 
Survival from cancer in teenagers and young adults in England, 1979-2003. 
Br J Cancer. 2008;99(5):830-5. 
30. Croucher C, Whelan JS, Moller H, Davies EA. Trends in the incidence 
and survival of cancer in teenagers and young adults: regional analysis for 
South East England 1960-2002. Clinical Oncology (Royal College of 
Radiologists). 2009;21(5):417-24. 
31. Tobias J, Hochhauser D, Souhami R. Cancer and its management. 
6th edition ed: Blackwell publishing; 2009. 
32. World Health Organisation. ICD-10, International Statistical 
Classification of Diseases and Related Health Problems. 2010. 
33. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International 
Classification of Childhood Cancer, third edition. Cancer. 2005;103(7):1457-
67. 
34. Birch JM, Alston RD, Kelsey AM, Quinn MJ, Babb P, McNally RJQ. 
Classification and incidence of cancers in adolescents and young adults in 
England 1979-1997. Br J Cancer. 2002;87(11):1267-74. 
35. Kaatsch P, Steliarova-Foucher E, Crocetti E, Magnani C, Spix C, 
Zambon P. Time trends of cancer incidence in European children (1978-
1997): report from the Automated Childhood Cancer Information System 
project. European Journal of Cancer. 2006;42(13):1961-71. 
36. Alston RD, Geraci M, Eden TOB, Moran A, Rowan S, Birch JM. 
Changes in cancer incidence in teenagers and young adults (ages 13 to 24 
years) in England 1979-2003. Cancer. 2008;113(10):2807-15. 
- 186 - 
 
 
37. Stiller C. Epidemiology of cancer in adolescents: Medical and 
Pediatric Oncology. 39 (3) (pp 149-155), 2002. Date of Publication: 2002.; 
2002. 
38. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours 
in European children and adolescents, 1978-1997. Report from the 
Automated Childhood Cancer Information System project. European Journal 
of Cancer. 2006;42(13):2124-35. 
39. Peris-Bonet R, Martínez-García C, Lacour B, Petrovich S, Giner-
Ripoll B, Navajas A, et al. Childhood central nervous system tumours – 
incidence and survival in Europe (1978–1997): Report from Automated 
Childhood Cancer Information System project. European Journal of Cancer. 
2006;42(13):2064-80. 
40. Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. 
Neuroblastoma incidence and survival in European children (1978–1997): 
Report from the Automated Childhood Cancer Information System project. 
European Journal of Cancer. 2006;42(13):2081-91. 
41. Pastore G, Znaor A, Spreafico F, Graf N, Pritchard-Jones K, 
Steliarova-Foucher E. Malignant renal tumours incidence and survival in 
European children (1978–1997): Report from the Automated Childhood 
Cancer Information System project. European Journal of Cancer. 
2006;42(13):2103-14. 
42. Arora RS, Alston RD, Eden TOB, Moran A, Geraci M, O'Hara C, et al. 
Cancer at ages 15-29 years: the contrasting incidence in India and England. 
Pediatric Blood & Cancer. 2012;58(1):55-60. 
43. Lewis I, Lenehan C. Report of the Children and Young People's 
Health Outcomes Forum. 2012. 
44. DEPARTMENT OF HEALTH. The Children and Young People‟s 
Health Outcomes Forum In: Health Do, editor. 2011. 
45. Estlin EG, R. Wynn, R., editor. Pediatric hematology and oncology : 
scientific principles and clinical practice: Oxford : Wiley-Blackwell, ; 2010. 
46. Bleyer A, Whiteson, M., Eden, T., Barr, R., editor. Cancer and the 
Adolescent. 2nd ed: Malden, Mass. : Blackwell, 2005; 2005. 
47. Powell JE, Esteve J, Mann JR, Parker L, Frappaz D, Michaelis J, et 
al. Neuroblastoma in Europe: differences in the pattern of disease in the UK. 
SENSE. Study group for the Evaluation of Neuroblastoma Screening in 
Europe. Lancet. 1998;352(9129):682-7. 
- 187 - 
 
 
48. Hachitanda Y, Ishimoto K, Hata J, Shimada H. One hundred 
neuroblastomas detected through a mass screening system in Japan. 
Cancer. 1994;74(12):3223-6. 
49. Ishimoto K, Kiyokawa N, Fujita H, Yabuta K, Ohya T, Miyano T, et al. 
Problems of mass screening for neuroblastoma: analysis of false-negative 
cases. Journal of Pediatric Surgery. 1990;25(4):398-401. 
50. Kerbl R, Urban CE, Ambros IM, Dornbusch HJ, Schwinger W, 
Lackner H, et al. Neuroblastoma mass screening in late infancy: insights into 
the biology of neuroblastic tumors. J Clin Oncol. 2003;21(22):4228-34. 
51. Schilling FH, Berthold F, Erttmann R, Michaelis J, Spix C, Sander J, 
et al. Population-based and controlled study to evaluate neuroblastoma 
screening at one year of age in Germany: interim results. Medical & 
Pediatric Oncology. 2000;35(6):701-4. 
52. Woods WG, Gao R-N, Shuster JJ, Robison LL, Bernstein M, 
Weitzman S, et al. Screening of infants and mortality due to neuroblastoma. 
New England Journal of Medicine. 2002;346(14):1041-6. 
53. Pastore G, Peris-Bonet R, Carli M, Martínez-García C, de Toledo JS, 
Steliarova-Foucher E. Childhood soft tissue sarcomas incidence and survival 
in European children (1978–1997): Report from the Automated Childhood 
Cancer Information System project. European Journal of Cancer. 
2006;42(13):2136-49. 
54. Bretherick KL, Bu R, Gascoyne RD, Connors JM, Spinelli JJ, Brooks-
Wilson AR. Elevated circulating t(14;18) translocation levels prior to 
diagnosis of follicular lymphoma. Blood. 2010;116(26):6146-7. 
55. Ferry JA. Burkitt's lymphoma: clinicopathologic features and 
differential diagnosis. Oncologist. 2006;11(4):375-83. 
56. Morley-Jacob C, Gallop-Evans E. An update on lymphoma in children 
and young adults: Paediatrics and Child Health. 22 (3) (pp 92-97), 2012. 
Date of Publication: March 2012.; 2012. 
57. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet 
A, et al. The 2007 WHO classification of tumours of the central nervous 
system. Acta Neuropathologica. 2007;114(2):97-109. 
58. Arora RS, Alston RD, Eden TOB, Estlin EJ, Moran A, Birch JM. Age-
incidence patterns of primary CNS tumors in children, adolescents, and 
adults in England. Neuro-oncol. 2009;11(4):403-13. 
- 188 - 
 
 
59. McKinney PA. Central nervous system tumours in children: 
epidemiology and risk factors. Bioelectromagnetics. 2005;Suppl 7:S60-8. 
60. Packer RJ, Vezina G. Pediatric glial neoplasms including brain-stem 
gliomas. Seminars in Oncology. 1994;21(2):260-72. 
61. Glauser TA, Packer RJ. Cognitive deficits in long-term survivors of 
childhood brain tumors. Childs Nervous System. 1991;7(1):2-12. 
62. Robinson KE, Kuttesch JF, Champion JE, Andreotti CF, Hipp DW, 
Bettis A, et al. A quantitative meta-analysis of neurocognitive sequelae in 
survivors of pediatric brain tumors. Pediatric Blood & Cancer. 
2010;55(3):525-31. 
63. Bielack S, Carrle D, Casali PG, Group EGW. Osteosarcoma: ESMO 
clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 
2009;20 Suppl 4:137-9. 
64. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, 
Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of 
the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284-91. 
65. Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, 
Coebergh JWW. Cancer in children and adolescents in Europe: 
developments over 20 years and future challenges. European Journal of 
Cancer. 2006;42(13):2183-90. 
66. Fern LA, Campbell C, Eden TO, Grant R, Lewis I, Macleod U, et al. 
How frequently do young people with potential cancer symptoms present in 
primary care?.[Erratum appears in Br J Gen Pract. 2011 Jun;61(587):382]. 
Br J Gen Pract. 2011;61(586):e223-30. 
67. Stiller CA, Desandes E, Danon SE, Izarzugaza I, Ratiu A, Vassileva-
Valerianova Z, et al. Cancer incidence and survival in European adolescents 
(1978–1997). Report from the Automated Childhood Cancer Information 
System project. European Journal of Cancer. 2006;42(13):2006-18. 
68. Bragonier R, Kenyon C. Two-week urgent referrals for suspected 
childhood cancer: experience within a large tertiary centre. Archives of 
Disease in Childhood. 2012;97(7):674. 
69. Mant J, Nanduri V. Role of the 2-week urgent referral pathway in 
childhood cancer. Archives of Disease in Childhood. 2012;97(3):233-5. 
- 189 - 
 
 
70. Cheung CRLH, Gray JAM. Unwarranted variation in health care for 
children and young people. Archives of Disease in Childhood. 
2013;98(1):60-5. 
71. NCIN. Routes to Diagnosis 2006-2008: Technical Document. London: 
National Cancer Intelligence Network; 2010. 
72. Dommett RM, Redaniel MT, Stevens MCG, Hamilton W, Martin RM. 
Features of childhood cancer in primary care: A population-based nested 
case-control study. Br J Cancer. 2012;106(5):982-7. 
73. Neal RD. Do diagnostic delays in cancer matter? Br J Cancer. 
2009;101(Supl 2):S9-S12. 
74. Macleod U, Mitchell ED, Burgess C, Macdonald S, Ramirez AJ. Risk 
factors for delayed presentation and referral of symptomatic cancer: 
evidence for common cancers. Br J Cancer. 2009;101 Suppl 2:S92-S101. 
75. Mitchell E, Macdonald S, Campbell NC, Weller D, Macleod U. 
Influences on pre-hospital delay in the diagnosis of colorectal cancer: A 
systematic review. Br J Cancer. 2008;98(1):60-70. 
76. Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, 
Richards MA. Factors predicting delayed presentation of symptomatic breast 
cancer: a systematic review. Lancet. 1999;353(9159):1127-31. 
77. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. 
Influence of delay on survival in patients with breast cancer: a systematic 
review. Lancet. 1999;353(9159):1119-26. 
78. Dang-Tan T, Franco EL. Diagnosis delays in childhood cancer: A 
review. Cancer. 2007;110(4):703-13. 
79. Brasme J-F, Morfouace M, Grill J, Martinot A, Amalberti R, Bons-
Letouzey C, et al. Delays in diagnosis of paediatric cancers: a systematic 
review and comparison with expert testimony in lawsuits. Lancet Oncology. 
2012;13(10):e445-59. 
80. Wilne S, Collier J, Kennedy C, Koller K, Grundy R, Walker D. 
Presentation of childhood CNS tumours: a systematic review and meta-
analysis. Lancet Oncology. 2007;8(8):685-95. 
81. Macdonald S, Macleod U, Campbell NC, Weller D, Mitchell E. 
Systematic review of factors influencing patient and practitioner delay in 
diagnosis of upper gastrointestinal cancer. [Review] [36 refs]. Br J Cancer. 
2006;94(9):1272-80. 
- 190 - 
 
 
82. Ferrari A, Miceli R, Casanova M, Meazza C, Favini F, Luksch R, et al. 
The symptom interval in children and adolescents with soft tissue sarcomas. 
Cancer. 2010;116(1):177-83. 
83. Goyal S, Roscoe J, Ryder WDJ, Gattamaneni HR, Eden TOB. 
Symptom interval in young people with bone cancer. Eur J Cancer. 
2004;40(15):2280-6. 
84. Halperin EC, Watson DM, George SL. Duration of symptoms prior to 
diagnosis is related inversely to presenting disease stage in children with 
medulloblastoma. Cancer. 2001;91(8):1444-50. 
85. Kukal K, Dobrovoljac M, Boltshauser E, Ammann RA, Grotzer MA. 
Does diagnostic delay result in decreased survival in paediatric brain 
tumours? Eur J Pediatr. 2009;168(3):303-10. 
86. Saha V, Love S, Eden T, Micallef-Eynaud P, MacKinlay G. 
Determinants of symptom interval in childhood cancer. Arch Dis Child. 
1993;68(6):771-4. 
87. Dang-Tan T, Trottier H, Mery LS, Morrison HI, Barr RD, Greenberg 
ML, et al. Delays in diagnosis and treatment among children and 
adolescents with cancer in Canada. Pediatr Blood Cancer. 2008;51(4):468-
74. 
88. Shay V, Fattal-Valevski A, Beni-Adani L, Constantini S. Diagnostic 
delay of pediatric brain tumors in Israel: A retrospective risk factor analysis. 
Child's Nervous System. 2011;28(1):93-100. 
89. Bai S, Ren R, Li B, Xu X, Zhao B, Gao F, et al. Delay in the diagnosis 
of retinoblastoma in China. Acta Ophthalmol. 2011;89(1):e72-e4. 
90. Haimi M, Perez-Nahum M, Stein N, Ben Arush MW. The role of the 
doctor and the medical system in the diagnostic delay in pediatric 
malignancies. Cancer Epidemiology. 2011;35(1):83-9. 
91. James BO, Ajayi SO, Ogun OA, Oladokun RE. Factors influencing 
time to diagnosis of childhood cancer in Ibadan, Nigeria. African Health 
Sciences. 2009;9(4):247-53. 
92. Rodrigues KES, Latorre MDRDO, De Camargo B. Delayed diagnosis 
in retinoblastoma. Jornal de Pediatria. 2004;80(6):511-6. 
93. Cecen E, Gunes D, Mutafoglu K, Sarialioglu F, Olgun N. The time to 
diagnosis in childhood lymphomas and other solid tumors. Pediatr Blood 
Cancer. 2011;57(3):392-7. 
- 191 - 
 
 
94. Edgeworth J, Bullock P, Bailey A, Gallagher A, Crouchman M. Why 
are brain tumours still being missed? Arch Dis Child. 1996;74(2):148-51. 
95. Stefan DC, Siemonsma F. Delay and causes of delay in the diagnosis 
of childhood cancer in Africa. Pediatr Blood Cancer. 2011;56(1):80-5. 
96. Loh AHP, Aung L, Ha C, Tan AM, Quah TC, Chui CH. Diagnostic 
delay in pediatric solid tumors: A population based study on determinants 
and impact on outcomes. Pediatr Blood Cancer. 2012;58(4):561-5. 
97. Brasme JF, Chalumeau M, Doz F, Lacour B, Valteau-Couanet D, 
Gaillard S, et al. Interval between onset of symptoms and diagnosis of 
medulloblastoma in children: Distribution and determinants in a population-
based study. Eur J Pediatr. 2012;171(1):25-32. 
98. Hayashi N, Kidokoro H, Miyajima Y, Fukazawa T, Natsume J, Kubota 
T, et al. How do the clinical features of brain tumours in childhood progress 
before diagnosis? Brain Dev. 2010;32(8):636-41. 
99. Klitbo DM, Nielsen R, Illum NO, Wehner PS, Carlsen N. Symptoms 
and time to diagnosis in children with brain tumours. Danish Medical Bulletin. 
2011;58(7):1-5. 
100. Goddard AG, Kingston JE, Hungerford JL. Delay in diagnosis of 
retinoblastoma: Risk factors and treatment outcome. Br J Ophthalmol. 
1999;83(12):1320-3. 
101. Thulesius H, Pola J, Hakansson A. Diagnostic delay in pediatric 
malignancies: A population-based study. Acta Oncol. 2000;39(7):873-6. 
102. Chotel F, Unnithan A, Chandrasekar CR, Parot R, Jeys L, Grimer RJ. 
Variability in the presentation of synovial sarcoma in children: A plea for 
greater awareness. J Bone Joint Surg Br. 2008;90(8):1090-6. 
103. Yang JYK, Cheng FWT, Wong KC, Lee V, Leung WK, Shing MMK, et 
al. Initial presentation and management of osteosarcoma, and its impact on 
disease outcome. Hong Kong Med. 2009;15(6):434-9. 
104. Crawford JR, Santi MR, Vezina G, Myseros JS, Keating RF, LaFond 
DA, et al. CNS germ cell tumor (CNSGCT) of childhood: Presentation and 
delayed diagnosis. Neurology. 2007;68(20):1668-73. 
105. Flores LE, Williams DL, Bell BA, O'Brien M, Ragab AH. Delay in the 
diagnosis of pediatric brain tumors. Am J Dis Child. 1986;140(7):684-6. 
106. Mehta V, Chapman A, McNeely PD, Walling S, Howes WJ, Sutton 
LN, et al. Latency between symptom onset and diagnosis of pediatric brain 
- 192 - 
 
 
tumors: An Eastern Canadian geographic study. Neurosurgery. 
2002;51(2):365-73. 
107. Reulecke BC, Erker CG, Fiedler BJ, Niederstadt TU, Kurlemann G. 
Brain tumors in children: Initial symptoms and their influence on the time 
span between symptom onset and diagnosis. J Child Neurol. 
2008;23(2):178-83. 
108. Wilne S CJ, Kennedy C, Jenkins A, Grout J, Mackie S, Koller K, 
Grundy R, Walker D. Progression from first symptom to diagnosis in 
childhood brain tumours. Eur J Pediatr. 2011;171(1):87-93. 
109. Wallach M, Balmer A, Munier F, Houghton S, Pampallona S, Von Der 
Weid N, et al. Shorter time to diagnosis and improved stage at presentation 
in Swiss patients with retinoblastoma treated from 1963 to 2004. Pediatrics. 
2006;118(5):e1493-e8. 
110. Wirix M, Parys-Vanginderdeuren R, Casteels I, Uyttebrouck A. 
Delayed diagnosis of retinoblastoma. Bull Soc Belge Ophtalmol. 
2000(278):37-41. 
111. LaQuaglia MP, Heller G, Filippa DA, Karasakalides A, Vlamis V, 
Wollner N, et al. Prognostic factors and outcome in patients 21 years and 
under with colorectal carcinoma. J Pediatr Surg. 1992;27(8):1085-90. 
112. Schnurr C, Pippan M, Stuetzer H, Delank KS, Michael JWP, Eysel P. 
Treatment delay of bone tumours, compilation of a sociodemographic risk 
profile: A retrospective study. BMC Cancer. 2008;8(22):1-10. 
113. OECD. OECD Better Policies for Better Lives. 2013 [1st July 2013]; 
Available from: http://www.oecd.org/about/membersandpartners/. 
114. Dang-Tan T, Trottier H, Mery LS, Morrison HI, Barr RD, Greenberg 
ML, et al. Determinants of delays in treatment initiation in children and 
adolescents diagnosed with leukemia or lymphoma in Canada. International 
Journal of Cancer. 2010;126(8):1936-43. 
115. Feltbower RG, Lewis IJ, Picton S, Richards M, Glaser AW, Kinsey 
SE, et al. Diagnosing childhood cancer in primary care--a realistic 
expectation? Br J Cancer. 2004;90(10):1882-4. 
116. Wilne S, Liu J, Clough L, Dudley J, Lakhanpaul M, Kennedy C, et al. 
P01 A Service Evaluation of Implementation of RCPCH Brain Pathways 
Clinical Guideline Linked to HeadSmart – Be Brain Tumour Aware 
(HeadSmart). A Health Foundation, Closing the Gap Project. Archives of 
Disease in Childhood. 2013;98(Suppl 1):A1. 
- 193 - 
 
 
117. Dommett RM, Redaniel MT, Stevens MCG, Hamilton W, Martin RM. 
Features of cancer in teenagers and young adults in primary care: a 
population-based nested case-control study. Br J Cancer. 
2013;108(11):2329-33. 
118. Torring ML, Frydenberg M, Hansen RP, Olesen F, Hamilton W, 
Vedsted P. Time to diagnosis and mortality in colorectal cancer: a cohort 
study in primary care.[Erratum appears in Br J Cancer. 2011 Jun 
7;104(12):1930]. Br J Cancer. 2011;104(6):934-40. 
119. National Patient Safety Agency. Delayed diagnosis of cancer: 
Thematic review. National Health Service; 2010. 
120. Webb P, Bain C. Essential Epidemiology: An Introduction for Students 
and Health Professionals 2nd ed: Cambridge University Press; 2011. 
121. National Health Service, The Information Centre for Health and Social 
Care. HES online - About HES - Background. 2012; Available from: 
http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categ
oryID=457. 
122. DEPARTMENT OF HEALTH 2011. Payment by results - Background. 
2010; Available from: 
http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Managingyou
rorganisation/NHSFinancialReforms/DH_077259. 
123. United Kingdom Association of Cancer Registries (UKACR). Release 
of potentially identifiable patient information. 2013; Available from: 
http://www.ukcancassoc.ismysite.co.uk/content/release-potentially-
identifiable-patient-
information?phpMyAdmin=628c0920c0ef2bb3163c7b56b06f3b9c. 
124. National Cancer Action Team. National Cancer Action Team part of 
the National Cancer Programme - Ensuring Better Treatment - Cancer 
Waiting Times. 2013 [1st July 2013]; Available from: http://ncat.nhs.uk/our-
work/ensuring-better-treatment/cancer-waiting-times#. 
125. National Institute for Health and Clinical Excellence (NICE). Referral 
guidelines for suspected cancer. 2005. 
126. MacMillan Cancer Support. Types of children's cancers 2013; 
Available from: 
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Childrenscanc
ers/Typesofchildrenscancers/Typesofchildrenscancers.aspx. 
- 194 - 
 
 
127. Bone Cancer Research Trust. BCRT Be Aware. 2010 [1st July 2013]; 
Available from: http://www.bcrt.org.uk/bci_be_symptom_aware.php. 
128. StataCorp. Stata Statistical Software: Release 12. College Station, 
TX, USA: Stata Corp LP; 2011. 
129. Thomson CS, Forman D. Cancer survival in England and the 
influence of early diagnosis: what can we learn from recent EUROCARE 
results? Br J Cancer. 2009;101 Suppl 2:S102-9. 
130. Bland M. An Introduction to medical statistics. Third ed: Oxford 
University Press; 2000. 
131. Andersohn F, Konzen C, Garbe E. Systematic review: 
agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 
2007;146(9):657-65. 
132. Ahrensberg JM, Fenger-Gron M, Vedsted P. Use of Primary Care 
during the Year before Childhood Cancer Diagnosis: A Nationwide 
Population-Based Matched Comparative Study. PLoS ONE. 
2013;8(3):e59098. 
133. Stiller C, Kroll M, Eatock E. 5 Survival from Childhood Cancer. In: 
Stiller C, editor. Childhood Cancer in Britain: Incidence, Survival, Mortality, 
Volume 1: Oxford University Press; 2007. 
134. Fern L, Davies S, Eden T, Feltbower R, Grant R, Hawkins M, et al. 
Rates of inclusion of teenagers and young adults in England into National 
Cancer Research Network clinical trials: report from the National Cancer 
Research Institute (NCRI) Teenage and Young Adult Clinical Studies 
Development Group. 2008. 
135. Goulden N, editor. UKALL 2011 Trial - United Kingdom National 
Randomised Trial For Children and Young Adults with Acute Lymphoblastic 
Leukaemia and Lymphoma 2011: Cancer Research UK Clinical Trials Unit; 
2011. 
136. Cancer Research UK. Our campaign to encourage earlier diagnosis 
of cancer. 2013; Available from: 
http://scienceblog.cancerresearchuk.org/2013/07/02/our-campaign-to-
encourage-earlier-diagnosis-of-cancer/. 
137. UK Clinical Trials Research Network. UKALL 2013. 2013; Available 
from: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=11319. 
 
- 195 - 
 
Appendix 1 - NICE Guideline for suspected cancer in children and young adults (125) 
General 
1 CYA presenting with symptoms and signs of cancer should be referred to a paediatrician or a specialist children‟s cancer service 
2 CYA presenting several times with the same problems, but with no clear diagnosis, urgent referral should be made 
3 The parent is the best observer of the CYA‟s symptoms, as such parental insight should be taken into consideration when considering urgent referral 
4 Persistent parental anxiety should be a sufficient reason for referral 
5 Persistent back pain in CYA should prompt urgent examination, investigation with FBC, film and consider referral 
6 
Associations such as Down‟s and leukaemia, NF and CNS tumours and other rare syndromes and some cancers should alert to a potential diagnosis in 
CYA patients with unexplained symptoms 
7 Primary HC prof should convey info to parents and CYA about reason for specialist referral 
8 Primary HC prof should develop good communication with parents and CYA to provide a supportive care relationship 
Leukaemia 
9 
 
Has a relatively short history in weeks rather than months. 
Presence of >=1 symp & sign should prompt 
FBC & film 
Pallor 
Fatigue 
Unexplained irritability 
Unexplained fever 
Persistent or recurrent URTI 
Generalised lymphadenopathy 
Persitent or unexplained bone pain 
Unexplained Bruising 
10 
Immediate referral in the presence of either of 
the following 
Unexplained petechiae 
Hepatomegaly 
Lymphoma 
11 
 
Typically present with non-tender cervical +/or suprclavicular lymphadenopathy. 
The natural history is long except in NHL 
NHL may present with lymphadenopathy, breathlessness, SVC obst, abdo distension 
Lymphadenopathy in the presence of no 
evidence of local infection 
LN are non-tender, firm ot hard 
LN >2cm 
LN progressively enlarging 
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Other features of general ill health, fever or weight-loss 
Axillary nodes (in theabsence of local infection or dermatitis) 
Supraclavicular nodes 
12 The presence of hepatosplenomegaly requires immediate referral 
13 SOB can indicate chest involvement and if assoc with above symp should prompt urgent referral 
14 CYA with mediastinal or hilar mass on CXR should be referred immediateley 
CNS >=2 
15 Persistent headache in CYA requires primary HC prof to conduct urgent exam and unable to undertake adequate exam they should refer 
16 Headache and vomiting that occur at or lead to early morning waking require immediate referral 
17 
The presence of the following neuro symp 
and signs should prompt urgent referral 
New-onset seizures 
Cranial nerve abnormalities 
Visual disturbance 
Gait abnormalities 
Motor or sensory 
Unexplained deterioration in school performance of developmental milestones 
Unexplained behaviour +/or mood changes 
18 CYA with reduced level of consciousness requires immediate referral 
CNS <2 
19 
 
Symp & signs 
prompting referral 
Immediate 
New-onset seizures 
Bulging fontanelles 
Extensor attacks 
Persistent vomiting 
Urgent 
Abnormal increase in head-size 
Arrest or regression of motor development 
Altered behaviour 
Abnormal eye movements 
Lack of visual following 
Poor feeding/FTT 
Urgent contingent on 
other factors 
Squint 
Neuroblastoma 
20 Most CYA with neuroblastoma have symptoms of metastatic disease at presentation, symp & signs similar to 9 should prompt FBC & film 
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21 Other symp which should raise concern 
Proptosis 
Unexplained back pain 
Leg weakness 
Unexplained urinary retention 
22 If symp suggest neuroblastoma an abdo exam, CXR and FBC should be considered 
23 Immediate referral in children <1 with localized abdo or thoracic masses, some babies have skin lesions 
Wilms’ Tumours 
24 Commonly present with painless masses, urgent referral in the presence of persistent or progressive distension 
25 Haematuria in CYA, although a rarer presentation should prompt urgent referral 
Soft Tissue Sarcoma 
26 
CYA with an unexplained mass at any site 
with one or more of the following 
Deep to fascia 
Non-tender 
Progressively enlarging 
Associated with a regional LN that is enlarging 
>2cm in diameter 
27 Unusual Location 
Head & Neck 
Proptosis 
Persistent unexplained unilateral nasal obstruction +/- discharge +/or bleeding 
Aural polyps/discharge 
Genitourinary 
Urinary retention 
Scrotal swelling 
Bloodstained vaginal discharge 
Bone Sarcoma 
28 
Limbs are most common site, especially knees in the case of osteosarcoma, persistent localized pain +/or swelling requires and X-ray and if 
tumour suspected an urgent referral 
29 History of an injury should not exclude the possibility of a bone tumour 
30 Rest pain, back pain or unexplained limp may all point to a bone tumour 
Retinoblastoma 
31 Leukocoria spotted by parent, in photo or on exam should prompt urgent referral 
32 A new squint or change in visual acuity should be referred, if cancer suspected urgently 
33 
A family history of retinoblastoma in a child presenting with eye signs should prompt the primary HC prof to ? retinoblastoma. Offspring of an 
affected parent or siblings to affected child should be screened from birth 
Table adapted from the National Institute for Health and Clinical Excellence (NICE). Referral guidelines for suspected cancer. 2005 
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Appendix 2 – Broad alert codes 
D689 Coagulation defect, unspecified 
G952 Cord compression, unspecified 
I871 Compression of vein 
K590 Constipation 
K625 Haemorrhage of anus and rectum 
K920 Haematemesis 
K921 Melaena 
M254 Effusion of joint 
M255 Pain in joint 
M436 Torticollis 
M542 Cervicalgia 
M545 Low back pain 
M549 Dorsalgia, unspecified 
M796 Pain of limb 
M844 Pathological fracture, Not elsewhere classified 
N62X Hypertrophy of breast 
Q850 Neurofibromatosis (nonmalignant) 
R040 Epistaxis 
R042 Haemoptysis 
R05X Cough 
R060 Dyspnoea 
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R065 Abnormalities of breathing - mouth breathing (snoring) 
R068 Other and unspecified abnormalities of breathing 
R073 Other chest pain 
R074 Chest pain, unspecified 
R101 Pain localized to upper abdomen 
R103 Pain localized to other parts of lower abdomen 
R104 Abdominal & pelvic pain - Other & UN 
R11X Nausea and vomiting 
R190 Intra-abdominal & pelvic swelling, mass & lump 
R220 Localized swelling, mass and lump, head 
R221 Localized swelling, mass and lump, neck 
R222 Localized swelling, mass and lump, trunk 
R227 Localized swelling, mass and lump, multiple sites 
R229 Localized swelling, mass and lump, unspecified 
R233 Spontaneous ecchymoses 
R31X Unspecified haematuria 
R509 Fever, PUO 
R51X Headache 
R521 Chronic intractable pain 
R53X Malaise and fatigue 
R590 Localized enlarged lymph nodes 
R591 Enlarged lymph nodes - Generalised 
R633 Feeding difficulties and mismanagement 
R634 Abnormal weight loss 
R69X Unknown & unspecified causes of morbidity 
- 200 - 
 
R900 Abnormality of diagnostic imaging - Intracranial SOL 
Y431 Antineoplastic antimetabolites 
Y433 Other antineoplastic drugs 
Z031 Observation for suspected malignant neoplasm 
Z112 Special screening examination for neoplasm of respiratory organs 
Z115 Special screening examination for neoplasm of prostate 
Z128 Special screening examination for neoplasms of other sites 
Z129 Special screening examination neoplasm, UN 
Z510 Radiotherapy session 
Z511 Chemotherapy session for neoplasm 
Z800 Family history of malignant neoplasm of digestive organs 
Z801 Family history of malignant neoplasm of trachea, bronchus and lung 
Z803 Family history of malignant neoplasm of breast 
Z806 Family history of leukaemia 
Z807 Family history of other malignant neoplasms of lymphoid, haematopoietic and related tissues 
Z808 Family history of malignant neoplasm of other organs or systems 
Z834 Family history of other endocrine, nutritional and metabolic diseases 
Z856 Personal history of leukaemia 
Z858 Personal history of malignant neoplasms of other organs and systems 
Z877 Personal history of congenital malformations, deformations and chromosomal abnormalities 
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Appendix 3 – Specific alert codes by International Classification of Childhood Cancer group 
Leukaemia 
 D471 Refractory anaemia with excess of blasts 
D610 Constitutional aplastic anaemia 
D619 Aplastic anaemia, unspecified 
D630 Anaemia in neoplastic disease  
D649 Anaemia, unspecified 
D696 Thrombocytopenia, unspecified 
D699 Haemorrhagic condition, unspecified 
D70X Agranulocytosis 
D721 Eosinophilia 
J351 Hypertrophy of tonsils 
J353 Hypertrophy of tonsils with adeniods 
K921 Melaena 
K922 Gastrointestinal haemorrhage, unspecified 
M255 Pain in joint 
M545 Low back pain 
M549 Dorsalgia, unspecified 
M796 Pain of limb 
Q909 Down's syndrome, unspecified 
R160 Hepatomegaly, not elsewhere classified 
R161 Splenomegaly, not elsewhere classified 
R162 Hepatomegaly with splenomegaly, not elsewhere classified 
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R233 Spontaneous ecchymoses 
R53X Malaise and fatigue 
R72X Abnormality of white blood cells, not elsewhere classified 
R91X Abnormal findings on diagnostic imaging of lung 
T810 Haemorrhage and haematoma complicating a procedure, not elsewhere classified 
Y420 Glucocorticoids and synthetic analogues 
Y430 Antiallergic and antiemetic drugs 
Lymphoma 
 D70X Agranulocytosis 
D728 Other specified disorders of white blood cells 
D803 Selective deficiency of immunoglobulin G [IgG] subclasses 
D804 Selective deficiency of immunoglobulin M [IgM] 
D823 Immunodeficiency following hereditary defective response to Epstein-Barr virus 
D831 Common variable immunodeficiency with predominant immunoregulatory T-cell disorders 
D839 Common variable immunodeficiency, unspecified 
D849 Immunodeficiency, unspecified 
I871 Compression of vein 
J929 Pleural plaque without asbestos 
J985 Diseases of mediastinum, not elsewhere classified 
R060 Dyspnoea 
R061 Stridor 
R160 Hepatomegaly, not elsewhere classified 
R161 Splenomegaly, not elsewhere classified 
R162 Hepatomegaly with splenomegaly, not elsewhere classified 
R190 Intra-abdominal & pelvic swelling, mass & lump 
R221 Localized swelling, mass and lump, neck 
R222 Localized swelling, mass and lump, trunk 
R224 Localized swelling, mass and lump, lower limb 
R229 Localized swelling, mass and lump, unspecified 
R630 Anorexia 
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R634 Abnormal weight loss 
R91X Abnormal findings on diagnostic imaging of lung 
R932 Abnormal findings on diagnostic imaging of liver and biliary tract 
R933 Abnormal findings on diagnostic imaging of other parts of digestive tract 
R938 Abnormal findings on diagnostic imaging of other specified body structures - Skin, Subcut, mediastinal shift  
  CNS tumours 
 E230 Hypopituitarism 
E232 Diabetes insipidus 
E309 Disorder of puberty, unspecified 
G400 Localization-related (focal)(partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset 
G401 Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures 
G403 Generalized idiopathic epilepsy and epileptic syndromes 
G409 Epilepsy UN 
G431 Migraine with aura [classical migraine] 
G439 Migraine, unspecified 
G442 Tension-type headache 
G500 Trigeminal neuralgia 
G510 Bell's palsy 
G810 Flaccid hemiplegia 
G819 Hemiplegia, unspecified 
G823 Flaccid tetraplegia 
G941 Hydrocephalus in neoplastic disease  
H471 Papilloedema, unspecified 
H490 Third [oculomotor] nerve palsy 
H492 Paralytic strabismus - 6th N palsy 
H501 Divergent concomitant strabismus 
H509 Strabismus, unspecified 
H532 Diplopia 
H534 Visual field defects 
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H538 Other visual disturbances 
H540 Blindness, binocular 
H547 Visual impairment including blindness (binocular or monocular) 
H55X Nystagmus and other irregular eye movements 
L813 Café au lait spots 
M415 Other secondary scoliosis 
M625 Muscle wasting and atrophy, not elsewhere classified 
N319 Neuromuscular dysfunction of bladder, unspecified 
Q753 Macrocephaly 
Q850 Neurofibromatosis (nonmalignant) 
Q851 Tuberous sclerosis 
Q878 Other specified congenital malformation syndromes, not elsewhere classified 
Q998 Other specified chromosome abnormalities 
R202 Paraesthesia of skin 
R208 Other and unspecified disturbances of skin sensation 
R251 Tremor, unspecified 
R253 Fasciculation 
R258 Other and unspecified abnormal involuntary movements 
R268 Abnormalities of gait & mobility - Unsteadiness on feet 
R270 Ataxia, unspecified 
R278 Other and unspecified lack of coordination 
R401 Stupor 
R410 Disorientation, unspecified 
R42X Dizziness and giddiness 
R470 Dysphasia and aphasia 
R51X Headache 
R55X Syncope and collapse 
R568 Convulsion, UN 
R628 Other lack of expected normal physiological development 
R629 Lack of expected normal physiological development, unspecified 
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R633 Feeding difficulties and mismanagement 
R900 Abnormality of diagnostic imaging - Intracranial SOL 
R930 Abnormal findings on diagnostic imaging of skull and head, not elsewhere classified 
R933 Abnormal findings on diagnostic imaging of skull and head, not elsewhere classified 
Neuroblastoma 
 G253 Myoclonus 
H052 Exophthalmic conditions 
H492 Paralytic strabismus - 6th N palsy 
H500 Convergent concomitant strabismus 
H509 Strabismus, unspecified 
K590 Constipation 
R061 Stridor 
R13X Dysphagia 
R18X Ascites 
R190 Intra-abdominal & pelvic swelling, mass & lump 
R229 Localized swelling, mass and lump, unspecified 
R53X Malaise and fatigue 
R681 Nonspecific symptoms peculiar to infancy 
R91X Abnormal findings on diagnostic imaging of lung 
R934 Abnormal findings on diagnostic imaging of urinary organs 
R935 Abnormal findings on diagnostic imaging of other abdominal regions, including retroperitoneum 
R937 Abnormal findings on diagnostic imaging of other parts of MSK 
Retinoblastoma 
 H102 Other acute conjunctivitis 
H118 Other specified disorders of conjunctiva 
H409 Glaucoma, unspecified 
H509 Strabismus, unspecified 
Renal tumours 
 I10X Essential (primary) hypertension 
I120 Hypertensive renal disease with renal failure 
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M545 Low back pain 
R103 Pain localized to other parts of lower abdomen 
R104 Abdominal & pelvic pain - Other & UN 
R190 Intra-abdominal & pelvic swelling, mass & lump 
R222 Localized swelling, mass and lump, trunk 
R31X Unspecified haematuria 
Z805 Family history of malignant neoplasm of urinary tract 
Hepatic tumours 
 R160 Hepatomegaly, not elsewhere classified 
R161 Splenomegaly, not elsewhere classified 
R18X Ascites 
Malignant bone tumours 
 M255 Pain in joint 
M545 Low back pain 
M796 Pain of limb 
M844 Pathological fracture, Not elsewhere classified 
M895 Osteolysis 
M899 Disorder of bone UN 
M907 Fracture of bone in neoplastic disease 
R268 Abnormalities of gait & mobility - Unsteadiness on feet 
R509 Fever, PUO 
R936 Abnormal diagnostic imaging of limbs 
R937 Abnormal findings on diagnostic imaging of other parts of MSK 
R938 Abnormal findings on diagnostic imaging of other specified body structures - Skin, Subcut, mediastinal shift  
S568 Injury to other & unspecified muscles & tendons of forearm level  
S724 Fractures of lower end of femur 
W008 Fall on same level invloving ice or snow 
W100 Fall on & from stairs & steps 
W192 Unspecified Fall 
W213 Striking against or struck by sports equipment  
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Z016 Radiological examination, not elsewhere classified - Routine CXR, mammogram 
Soft-tissue sarcoma 
 G510 Bell's palsy 
H024 Ptosis of eyelid 
H653 Chronic muciod otitis media 
H744 Polyp of middle ear 
N328 Other specified disorders of bladder 
N508 Other specified disorders of male genital organs 
N509 Disorder of male genital organs, unspecified 
N938 Other specified abnormal uterine and vaginal bleeding 
N939 Abnormal uterine and vaginal bleeding, unspecified 
R190 Intra-abdominal & pelvic swelling, mass & lump 
R220 Localized swelling, mass and lump, head 
R222 Localized swelling, mass and lump, trunk 
R33X Retention of urine 
R599 Enlarged lymph nodes, unspecified 
R934 Abnormal findings on diagnostic imaging of urinary organs 
Germ-cell tumours 
 H474 Disorders of optic chiasm 
H539 Visual disturbance, unspecified 
H545 Severe visual impairment, monocular 
N44X Torsion of testis 
N508 Other specified disorders of male genital organs 
N832 Other and unspecified ovarian cysts 
N939 Abnormal uterine and vaginal bleeding, unspecified 
R190 Intra-abdominal & pelvic swelling, mass & lump 
R31X Unspecified haematuria 
Carcinoma 
 H653 Chronic muciod otitis media 
H919 Hearing Loss UN 
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H921 Otorrhoea 
J352 Hypertrophy of adenoids 
L040 Acute lymphadenitis of face, head and neck 
R221 Localized swelling, mass and lump, neck 
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Appendix 4 – Stata do files 
 
****** INCLUSION OF CASES BY YEAR OF DIAGNOSIS ******  
 
gen Inclusion=1 if (( d_diag1>=td(01Jan2004)) & ( d_diag1<td(31Dec 2009)))  
keep if Inclusion==1  
 
****** INCLUSION BY AGE ****** 
 
gen Age= ((d_diag1 - dob_yctr)/365.25) 
keep if Age <=25 
gen Age_group=0 if Age<15 
replace  Age_group=1 if  Age>=15 
gen age_ranges=5 if Age>=20 
replace age_range=4 if Age<20 
replace age_range=3 if Age<15 
replace age_range=2 if Age<10 
replace age_range=1 if Age<5 
 
****** GENERATING ICCC GROUPS ****** 
 
gen icccgroup=1 if iccc_1<20 
replace icccgroup=2 if iccc_1<30 & iccc_1>19 
replace icccgroup=3 if iccc_1<40 & iccc_1>29 
replace icccgroup=4 if iccc_1<50 & iccc_1>39 
replace icccgroup=5 if iccc_1<60 & iccc_1>49 
replace icccgroup=6 if iccc_1<70 & iccc_1>59 
replace icccgroup=7 if iccc_1<80 & iccc_1>69 
replace icccgroup=8 if iccc_1<90 & iccc_1>79 
replace icccgroup=9 if iccc_1<100 & iccc_1>89 
replace icccgroup=10 if iccc_1<110 & iccc_1>99 
replace icccgroup=11 if iccc_1<120 & iccc_1>109 
replace icccgroup=12 if iccc_1<130 & iccc_1>119 
 
****** IDENTIFYING THE FIRST EPISODE ****** 
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gen duration=(epistart-d_diag1) 
sort yctr_id epistart 
by yctr_id: gen epiindex=_n if duration<=0 
gen first_epi=1 if epiindex==1  
gen first_epi_date=epistart if first_epi==1 
format  first_epi_date %td 
by yctr_id: egen first_epi_date_pt=total(first_epi_date) 
format first_epi_date_pt %td 
replace first_epi_date_pt=. if first_epi_date_pt==0 
by yctr_id:  egen total_epis1=count( first_epi_date_pt ) 
 
****** LABELLING EPISODES WITH A CANCER DIAGNOSIS CODE ****** 
 
gen Diag_Cancer = strpos( diag_01, "C")  | strpos( diag_02, "C") | strpos( diag_03, "C") | strpos( diag_04, 
"C")  
| strpos( diag_05, "C") | strpos(diag_06, "C") | strpos( diag_07, "C") | strpos( diag_08, "C") | strpos( 
diag_09, "C")  
| strpos( diag_10, "C") | strpos( diag_11, "C") | strpos( diag_12, "C") | strpos( diag_11, "C") | strpos( 
diag_13, "C")  
| strpos( diag_14, "C") | strpos( diag_15, "C") | strpos( diag_16, "C") | strpos( diag_17, "C") | strpos( 
diag_18, "C")  
| strpos( diag_19, "C") | strpos( diag_20, "C") 
 
****** IDENTIFYING THE FIRST CANCER CODE EPISODE ****** 
 
sort yctr_id  Diag_Cancer epistart 
bysort yctr_id Diag_Cancer: gen index=_n if duration<=0 
gen first_cancer_epi=1 if index==1 &  Diag_Cancer==1 
gen first_cancer_epi_date=epistart if first_cancer_epi==1 
format first_cancer_epi_date %td 
by yctr_id: egen first_cancer_epi_date_pt=total(first_cancer_epi_date) 
format first_cancer_epi_date_pt %td 
replace first_cancer_epi_date_pt=. if first_cancer_epi_date_pt==0 
by yctr_id:  egen total_cancer_epis=total(Diag_Cancer) 
 
****** LABELLING ADMISSION CODES ****** 
 
gen AdmiCode="L" if admimeth==11 | admimeth==12 | admimeth==13 
replace AdmiCode="EA" if admimeth==21 
replace AdmiCode="EG" if admimeth==22 
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replace AdmiCode="EO" if admimeth==24 
replace AdmiCode="Eot" if admimeth==28 | admimeth==23 
replace AdmiCode="M" if admimeth==31 | admimeth==32 
replace AdmiCode="T" if admimeth==81 
replace AdmiCode="B" if admimeth==82 | admimeth==83  
replace AdmiCode="O" if admimeth==84 | admimeth==89  
replace AdmiCode="N" if admimeth==98 | admimeth==99 
gen Tag=1 if AdmiCode!="X" 
 
****** IDENTIFYING ALERT CODES: ICCC GROUP 4 (EXAMPLE DO FILES, 1 OF 11 SPECIFIC AND 1 BROAD 
ALERT CODE DO FILE) ****** 
 
forvalues i=1(1)9{ 
rename diag_0`i' diag_`i' 
} 
forvalues i=1(1)20{ 
gen diag_`i'_4=substr(diag_`i',1,4) 
} 
gen A_diag_binary=0  
foreach x of varlist diag_1_4 diag_2_4 diag_3_4 diag_4_4 diag_5_4 diag_6_4 diag_7_4 diag_8_4  
diag_9_4 diag_10_4 diag_11_4 diag_12_4 diag_13_4 diag_14_4 diag_15_4 diag_16_4 diag_17_4 
diag_18_4 diag_19_4 diag_20_4 { 
#delimit ; 
replace A_diag_binary=1 if (`x'=="G253" | `x'=="H052" | `x'=="H492" | `x'=="H500" | `x'=="H509" | 
`x'=="K590"  
| `x'=="R061" | `x'=="R13X" | `x'=="R18X" | `x'=="R190" | `x'=="R229" | `x'=="R53X" | `x'=="R681"  
| `x'=="R91X" | `x'=="R934" | `x'=="R935" | `x'=="R937" ); 
#delimit cr 
} 
 
****** THE PROCESS OF COUNTING THE NUMBER OF ALERT CODES PER CASE ****** 
 
forvalues i = 1(1)20{  
       generate x`i' = "" 
    foreach x of varlist diag_`i'_4 { 
#delimit ; 
    replace x`i'=`x' if (A_diag_binary==1 |  A_diag_binary==2) & 
(`x'=="G253" | `x'=="H052" | `x'=="H492"  
| `x'=="H500" | `x'=="H509" | `x'=="K590" | `x'=="R061" | `x'=="R13X" | `x'=="R18X" | 
`x'=="R190" | `x'=="R229" | `x'=="R53X"  
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| `x'=="R681" | `x'=="R91X" | `x'=="R934" | `x'=="R935" | `x'=="R937" ); 
#delimit cr 
} 
foreach x of newlist G253 H052 H492 H500 H509 K590 R061 R13X R18X R190 R229 R53X R681 R91X 
R934 R935 R937{ 
gen `x'=0 
} 
foreach x of varlist G253 H052 H492 H500 H509 K590 R061 R13X R18X R190 R229 R53X R681 R91X 
R934 R935 R937{ 
forvalues i = 1(1)20{ 
replace `x'=1 if x`i'=="`x'" 
} 
foreach x of varlist G253 H052 H492 H500 H509 K590 R061 R13X R18X R190 R229 R53X R681 R91X 
R934 R935 R937{ 
bysort yctr_id: egen `x'_tot= total(`x') 
} 
egen total_A_diags=rsum(G253_tot H052_tot H492_tot H500_tot H509_tot K590_tot R061_tot R13X_tot 
R18X_tot R190_tot R229_tot R53X_tot R681_tot R91X_tot R934_tot R935_tot R937_tot) 
egen total_distinct_A_diags = anycount(G253_tot H052_tot H492_tot H500_tot H509_tot K590_tot 
R061_tot R13X_tot  
R18X_tot R190_tot R229_tot R53X_tot R681_tot R91X_tot R934_tot R935_tot R937_tot), values(1(1)100) 
 
****** GENERATING A TIME TO DIAGNOSIS FOR EACH CODE & A MINIMUM TIME FOR EACH CASE ******  
foreach x of newlist x1_time x2_time x3_time x4_time x5_time x6_time x7_time x8_time x9_time 
x10_time x11_time x12_time x13_time x14_time x15_time x16_time x17_time x18_time x19_time 
x20_time{ 
gen `x'=. 
} 
forvalues i=1(1)20{ 
foreach x of varlist x`i'_time { 
replace `x'=(epistart-d_diag1)/365.25 if x`i'!="" & icccgroup==4 
}  
foreach x of varlist G253 H052 H492 H500 H509 K590 R061 R13X R18X R190 R229 R53X R681 R91X 
R934 R935 R937{ 
by yctr_id: gen `x'_time=x1_time if `x'_tot!=0 & x1=="`x'" & icccgroup==4 
forvalues i=2(1)20{ 
replace `x'_time=x`i'_time if `x'_tot!=0 & x`i'=="`x'" & `x'_time>x`i'_time & icccgroup==4 
} 
foreach x of varlist G253 H052 H492 H500 H509 K590 R061 R13X R18X R190 R229 R53X R681 R91X 
R934 R935 R937{ 
by yctr_id: egen `x'_min=min(`x'_time) 
} 
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****** GENERATING CIPS FOR ADMISSION ROUTE ANALYSIS ****** 
 
gen transit = 0 
replace transit = 1 if ((admisorc<51 | admisorc>53) & admimeth!=81) & (disdest>=51 & disdest<=53) 
replace transit = 3 if ((admisorc>=51 & admisorc<=53) | admimeth==81) & (disdest<51 | disdest>53) 
replace transit = 2 if ((admisorc>=51 & admisorc<=53) | admimeth==81) & (disdest>=51 & 
disdest<=53) 
gen procode3 = substr(procode, 1,3) 
sort hesid epistart epiorder epiend transit epikey 
gen admidisdate = admidate-disdate[_n-1] if hesid==hesid[_n-1] 
tab adm_cfl 
replace adm_cfl=2 if admidate==. 
replace adm_cfl=2 if admidate>disdate 
replace adm_cfl=0 if adm_cfl==. 
rename adm_cfl adm_cfl 
gen dis_cfl=0 
replace dis_cfl=2 if disdate<admidate 
replace dis_cfl=2 if disdate<dob_yctr 
gen long cips =_n 
replace cips= cips[_n-1] if (epiorder!=1 & dismeth[_n-1]>5 & hesid==hesid[_n-1]) | 
((admidate==admidate[_n-1] & adm_cfl==0 & adm_cfl[_n-1]==0) & hesid==hesid[_n-1] & 
admidisdate<0) 
 | (hesid==hesid[_n-1] & epiorder==1 & adm_cfl==0 & dis_cfl[_n-1]==0 & admidisdate<=2 & 
((disdest[_n-1]>=51 & disdest[_n-1]<=53) | (admisorc>=51 & admisorc<=53) | admimeth==81)) 
gen long spell =_n 
replace spell = spell[_n-1] if (((epiorder != 1 & dismeth[_n-1]>5 & hesid==hesid[_n-1]) | 
(admidate==admidate[_n-1] & adm_cfl==0 & adm_cfl[_n-1]==0 & hesid==hesid[_n-1] & 
admidisdate<0))  
 & (procode3==procode3[_n-1])) 
codebook cips spell 
count if cips!=cips[_n-1] & cips!=cips[_n+1] 
 
****** COUNTING EPISODES & CIPS ****** 
 
bysort yctr_id: egen number_episodes=count(epiorder) 
sort cips 
gen c=0 
replace c=1 if cips!=cips[_n-1] 
bysort yctr_id: egen number_cips= total(c) 
sort spell 
gen s=0 
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replace s=1 if spell!=spell[_n-1] 
bysort yctr_id: egen number_spells = total(s) 
 
****** GENERATING DATE FOR FIRST CIPS & FIRST ALERT CODE CONTAINING CIPS ****** 
 
gen cipstart=epistart if c==1 
by yctr_id cips: egen cipstartdate=max(cipstart)  
format %td cipstartdate 
sort yctr_id cipstartdate 
by yctr_id: gen index_cips=_n 
gen first_cipS_date= cipstartdate if  index_cips==1 
format %td first_cipS_date    
gen first_cips_admi=admimeth if  first_cipS_date!=.  
gen first_cipS_duration_pt= first_cips_pt- d_diag1  
sort yctr_id cips epistart epiorder 
by yctr_id cips: egen AB_diag_binary_cips=max(AB_diag_binary) 
sort yctr_id cips  AB_diag_binary_cips 
gen alert_cips_date= cipstartdate if  AB_diag_binary_cips==1 
sort yctr_id  alert_cips_date 
by yctr_id: gen index_cipsAB=_n if  AB_diag_binary_cips==1 
gen first_AB_cips_date= alert_cips_date if  index_cipsAB==1 
format %td first_AB_cips_date 
by yctr_id: egen  first_AB_cips_date_pt=max( first_AB_cips_date) 
format %td  first_AB_cips_date_pt 
 
****** GENERATING TIME TO DIAGNOSIS VARIABLE ****** 
 
sort yctr_id  A_diag_binary epistart 
by yctr_id  A_diag_binary: gen AlertAindex=_n 
gen first_alertA_epi=1 if AlertAindex==1 &  A_diag_binary>0 
gen first_alertA_date=epistart if first_alertA_epi==1 
format  first_alertA_date %td 
by yctr_id: egen first_alertA_date_pt=total(first_alertA_date) 
format first_alertA_date_pt %td 
replace first_alertA_date_pt=. if first_alertA_date_pt==0 
sort yctr_id  B_diag_binary epistart 
by yctr_id  B_diag_binary: gen AlertBindex=_n 
gen first_alertB_epi=1 if AlertBindex==1 &  B_diag_binary>0 
gen first_alertB_date=epistart if first_alertB_epi==1 
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format  first_alertB_date %td 
by yctr_id: egen first_alertB_date_pt=total(first_alertB_date) 
format first_alertB_date_pt %td 
replace first_alertB_date_pt=. if first_alertB_date_pt==0 
gen AB_diag_binary=0 
replace  AB_diag_binary=1 if  A_diag_binary>0 
replace  AB_diag_binary=1 if  B_diag_binary>0 
sort yctr_id  AB_diag_binary epistart 
by yctr_id  AB_diag_binary: gen AlertABindex=_n 
gen first_alertAB_epi=1 if AlertABindex==1 &  AB_diag_binary>0 
gen first_alertAB_date=epistart if first_alertAB_epi==1 
format  first_alertAB_date %td 
by yctr_id: egen first_alertAB_date_pt=total(first_alertAB_date) 
format first_alertAB_date_pt %td 
replace first_alertAB_date_pt=. if first_alertAB_date_pt==0 
by yctr_id:  egen total_alertAB=count(first_alertAB_date) 
gen First_Epi_Duration=  first_epi_date_pt-d_diag1 
gen first_ab_Duration= first_alertAB_date_pt- d_diag1 
gen TTD=0 if  first_ab_duration==. 
replace TTD=1 if  first_ab_duration>-31 & TTD!=0 
replace TTD=2 if  first_ab_duration<=-31 
 
****** GENERATING SURVIVAL TIME DATA SET ****** 
 
gen dead=1 if  d_death!= . 
replace  dead=0 if  d_death==. 
gen survtime=( d_death- d_diag1)/365.25 
replace  survtime=(td(31Dec2012)- d_diag1)/365.25 if dead==0 
replace survtime=survtime+0.0027 
 
****** Final Models ****** 
 
/*Model 1*/ 
 
stcox i.lab0 i.age_group2 i.sex_yctr i.icccgroup Year_Dx 
  
/*Model 2*/ 
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stcox i.lab0##i.age_group2 i.sex_yctr i.icccgroup Year_Dx  
lincom 0.age_group2 + 0.lab0 + 0.age_group2#0.lab0, hr 
lincom 0.age_group2 + 1.lab0 + 0.age_group2#1.lab0, hr 
lincom 0.age_group2 + 2.lab0 + 0.age_group2#2.lab0, hr 
lincom 1.age_group2 + 0.lab0 + 1.age_group2#0.lab0, hr 
lincom 1.age_group2 + 1.lab0 + 1.age_group2#1.lab0, hr 
lincom 1.age_group2 + 2.lab0 + 1.age_group2#2.lab0, hr 
  
 /*Likelihood Ratio Test*/ 
   
stcox i.lab0 i.age_group2 i.sex_yctr i.icccgroup Year_Dx 
estimates store model1 
stcox i.lab0 i.age_group2 i.sex_yctr i.icccgroup Year_Dx i.Year_Dx 
estimates store model2 
 
lrtest model1 model2 
 
 
